,ticker,content
0,BDX,becton dickinson bdx see welcome improvement relative strength rs rating thursday rise look best stock buy watch factor watch closely be relative price strength ibd unique rating track price movement worst best score grade show stock price performance last week compare other stock database history show market biggest winner typically have better rs rating begin largest climb see becton dickinson continue show renew price strength hit benchmark look winning stock try simple routinebecton dickinson be build consolidation entry see clear price volume least average company see earning sale growth rise last quarter earning share increase revenue rise company earn rank peer medical supply industry group west pharmaceutical service wst halyard health hyh be also group highest rate stock get newsletter deliver inbox more info product service privacy policy term also stock be show improve price performance use ibd relative strength rating relative strength line help judge stock
1,BDX,becton dickinson bdx have relative strength rs rating upgrade tuesday welcome improvement still shy better score prefer see try find best stock buy watch keep close eye relative price strength proprietary rating measure market leadership show stock price movement last week compare other stock database history show market biggest winner often have higher rs rating early stage move see becton dickinson continue rebound hit benchmark look best stock buy watch start herebecton dickinson be work consolidation buy point see break volume least higher normal earning grow last quarter prior report revenue also increase company earn rank peer medical supply industry group halyard health hyh henry schein hsic be also group highest rate stock get newsletter deliver inbox more info product service privacy policy term also stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
2,BDX,relative strength rs rating becton dickinson bdx moved new percentile friday get lift look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily identify market leadership worst best score grade show stock price movement last week hold other stock database decade market research show stock go make biggest gain often have rs rating early stage move see becton dickinson continue rebound hit benchmark see ibd help make more money stocksbecton dickinson be not currently show potential buy point see stock go build promising consolidation kick new climb earning growth drop most recent report revenue moved higher becton dickinson earn rank peer medical supply industry group west pharmaceutical service wst halyard health hyh be also group highest rate stock related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
3,BDX,monday becton dickinson bdx receive upgrade relative strength rs rating ibd proprietary rating track share price movement worst best score rating show stock price movement trail week hold other stock database year market history reveal best stock often have rs rating north launch biggest run see becton dickinson continue show renew price strength clear threshold look best stock buy watch start herebecton dickinson break earlier be now prior entry flat base scenario stock break then fall more entry price consider fail happen best new pattern form also keep mind most recent pattern be later stage base make riskier establish new position add share exist earning growth fall prior quarter revenue rise prior report becton dickinson hold rank peer medical supply industry group halyard health hyh west pharmaceutical service wst be also group highest rate stock related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
4,BDX,wednesday halyard health hyh clear noteworthy technical benchmark see relative strength rs rating jump percentile improvement day look best stock buy watch factor watch closely be relative price strength proprietary rating measure technical performance used worst best score indicate stock price performance trail week match rest market year market history reveal best stock often have rs rating north launch biggest climb look winning stock try simple routinehalyard health be build flat base buy point see break heavy trade earning growth rise company latest report revenue fall company earn rank peer medical supply industry group becton dickinson bdx be top rank stock group get newsletter deliver inbox more info product service privacy policy term also ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
5,BDX,key stock index fund rise thursday fang stock other big cap techs power big gain tech heavy powershare qqq trust powershare qqq trust qqq lead upside gain spdr spy spdr dow jone industrial average dium add respective small cap lag slightly ishare russell iwm ishare core small cap ijr climb respectively fang stock boost techs facebook fb gap soar almost retake day move average first time week close wednesday social network report result top view top bottom line amazon netflix pop stock regain day line alphabet googl advanced reclaim day line intel intc microsoft msft rise more dow stock be time high apple aapl add be tough week so far iphone maker share trade day line analyst expect apple earn share revenue report tuesday chip technology biotechs be biggest sector fund gainer stock market today vaneck vector semiconductor smh gap rise retake day line advanced micro device amd surge regain day line earning sale beat late wednesday well higher revenue outlook real estate homebuilder financial underperform stock fund be ailing volatility market health care play hold medtronic mdt abbott laboratory be find healthy support ishare medical device ihi continue consolidate mark record high late january tumble day move average stock market slump early february etf find support have be trading day line then climb back high market environment improve potential buy point be fund track dow jone select medical equipment index turn year old next month health care equipment represent biggest sector weighting tuesday nearly asset life science tool service make health care service rest top holding include medtronic abbott lab thermo fisher scientific tmo becton dickinson bdx dhr account stock portfolio get free access ibd digital april
6,BDX,get premium stock list pass fail stock rating more start herethermo fisher have produce gain wednesday close becton dickinson abbott be medtronic be medtronic have have rough start year share weaken mid february medical device maker suggest first use human hugo surgical robot be delay previously plan start operate patient end fiscal end month fund return year date tuesday accord morningstar inc far ahead loss average annual return past year have also outperformed broader index gain same period be ihi carry expense ratio wednesday pick spdr bank kbe spdr regional bank kre see mixed finish continue work right side respective shallow basis also be interested stock rise boee soar ge sink bitcoin pare lossesai robotic blockchain hot new etf industry trendshere way invest fang stock etf
7,BDX,stock market index fund extend gain monday key dow jone industrial average etf reclaim couldn hold day move average spdr dow jone industrial average dium rally nearly inch day line then retreat gain spdr spy powershare qqq trust qqq also add stock market today foreign market trail ishare msci eafe efa ishare msci emerge market eem edge higher dow stock advanced top blue chip winner include unh merck mrk apple aapl add mark third straight advance iphone maker be work right side shallow base potential buy point raymond james warn apple get hit sell news reaction report expectation be already baked share price utility consumer staple homebuilder be top sector fund gainer spdr homebuilder xhb advanced continue trade day day line aerospace defense also show strength ishare aerospace ita lift build flat base potential buy point defense contractor include raytheon rtn northrop grumman noc dow component unite technology utx rally heel coordinate strike syrium britain france friday raytheon lift clear flat base entry average volume telecom biotech gold miner underperform most biotech health care fund get hurt past month heighten volatility broader market top performer accompany table see healthy year date gain vs wednesday accord morningstar direct first trust nyse arca biotechnology index fund fbt place first year date return even drop past month fund regain day move average thursday be form double bottom base buy point top holding thursday include avexis avxs intrexon xon nektar therapeutic nktr agio pharmaceutical agio intercept pharmaceutical icpt avexis share soar april news novartis nvs buy biotech get newsletter deliver inbox more info product service privacy policy term useark genomic revolution multus sector arkg come second year date return fund invest company involved genomic related field such gene therapy target therapeutic next generation oncology top holding intellium therapeutic ntla edita medicine edit illumina ilmn invitae nvta bluebird bio blue account third stock portfolio fund lose past month have be trading day line late march share be march intraday high third place go ishare medical device ihi gain wednesday fund track dow jone select medical equipment index sit high top holding make stock portfolio be medtronic mdt abbott laboratory thermo fisher scientific tmo becton dickinson bdx dhr alp medical breakthrough sbio spdr biotech xbi round top etfs respective year date gain also be interested stock lower big bank weigh dow apple buck declinestock market rally intel apple boost dow bitcoin biotechs drugmaker fare senate tax bill
8,BDX,welcome move halyard health hyh see relative strength rating rise monday look best stock buy watch factor watch closely be relative price strength ibd proprietary rating track market leadership worst best score grade show stock price movement trail week hold other stock database history show best perform stock typically have rs rating north early stage move see halyard health continue show renew price strength clear threshold see ibd help make more money stockshalyard health be build flat base buy point see break heavy trading halyard health post ep growth latest quarterly report sale rise next quarterly result be expect halyard health earn rank peer medical supply industry group becton dickinson bdx be rank stock group get newsletter deliver inbox more info product service privacy policy term also stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
9,BDX,important metric look stock be higher relative strength rating halyard health hyh now clear threshold jump wednesday ibd unique rs rating identify technical performance used worst best score identify stock price performance last week match rest market history reveal top perform stock often have rs rating least launch biggest climb look best stock buy watch start herehalyard health be build cup handle buy point see stock clear price volume least higher normal company see earning sale growth rise last quarter earning share increase revenue rise company hold rank peer medical supply industry group becton dickinson bdx be rank stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
10,BDX,wednesday becton dickinson bdx receive positive adjustment relative strength rs rating ibd unique rating identify market leadership worst best score grade show stock price performance trail week hold other stock database year market history reveal top perform stock often have rs rating north early stage move see becton dickinson continue rebound clear threshold see ibd help make more money stock be not proper entry right now see manage form break proper chart pattern earning growth decrease last quarter top line grow previous report company earn rank peer medical supply industry group west pharmaceutical service wst halyard health hyh be also group highest rate stock related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
11,BDX,relative strength rs rating becton dickinson bdx moved higher percentile thursday get lift unique rating track technical performance used worst best score show stock price performance last week stack other stock database history reveal market biggest winner often have rs rating north begin largest price move see becton dickinson continue show renew price strength hit benchmark look best stock buy watch start herebecton dickinson break earlier be now trading prior entry flat base stock re tracking clear buy point then retreat more original entry price consider fail base stock set new base buy point also understand latest consolidation be later stage base involve more risk earning growth drop company most recently report quarter revenue rise previous report company hold rank peer medical supply industry group west pharmaceutical service wst halyard health hyh be also group highest rate stock related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
12,BDX,relative strength rs rating halyard health hyh jump higher percentile friday get lift try find best stock buy watch be sure pay attention relative price strength ibd proprietary rs rating measure technical performance used worst best score indicate stock price action last week stack other stock database history show stock go make biggest gain often have higher rs rating launch biggest climb see halyard health continue rebound hit benchmark look best stock buy watch start herehalyard health be build flat base entry see break heavy volume halyard health show earning growth most recent report sale growth come company hold rank peer medical supply industry group becton dickinson bdx be rank stock group get newsletter deliver inbox more info product service privacy policy term also stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
13,BDX,build watch list focus stock higher rs rating halyard health hyh be stock just reach mark now earn score exclusive rating investor business daily measure share price performance worst best score score show stock price performance last week compare other stock database history show market biggest winner tend have rs rating launch biggest climb look winning stock try simple routinehalyard health be buy zone climb buy point flat base once stock move higher initial entry consider proper buy zone top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase company earn rank peer medical supply industry group becton dickinson bdx be top rank stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
14,BDX,important metric look stock be higher relative strength rating west pharmaceutical service wst just hit mark jump friday exclusive rating investor business daily track price action worst best score rating show stock price performance last week stack other stock database history reveal stock go make biggest gain typically have rs rating north early stage move see ibd help make more stockswest pharmaceutical service be still buy range breaking past entry cup handle proper buy range extend initial entry once stock move range best hold investing set buy opportunity top bottom line growth moved higher last quarter earning be compare prior report revenue increase company earn rank peer medical supply industry group becton dickinson bdx be rank stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
15,BDX,number high profile medical technology firm include like boston scientific bsx abbott laboratory medtronic mdt be unlikely stand way dutch firm philips bid heart device maker spectranetic spnc analyst say wednesday xon stock market today spectranetic stock rocket record close high philips announce plan acquire spectranetic cash share deal value spectranetic euro needham analyst mike matson say bidding likely stop boston scientific abbott medtronic aren expect bid company spectranetic make drug coat balloon call stellarex treatment disease artery leg stomach arm head narrow rival bard bcr boston scientific medtronic already make drug coat balloon matson write note client further becton dickinson bdx be acquire bard leave major firm sector lack drug coat balloon abbott cardinal health cah terumo suspect abbott be too preoccupy st jude medical alere alr acquisition pursue large deal say similarly cardinal be process acquire medtronic medical supply business ibd take heart valve sector heated last year boston scientific make acquisition bring closer compete medtronic edward lifescience head sector leader look battle be shape matson be unsure terumo acquisition strategy similarly doesn expect philips acquisition get catch regulatory issue philips spectranetic only overlap atherectomy process harden narrow artery be remove body philips get area earlier acquisition believe market share be very low think regulatory issue be unlikely say philips say wednesday expect deal close third quarter dutch firm expect see revenue growth profit accretion matson keep buy rating spectranetic stock boost price target reflect acquisition cost related medtronic edward rivale unit outgrow broader market boston heart valve win face trial rival medtronicedward rocket month high strong heart valve sale
16,BDX,medical sector bury slumping drugmaker still have few big capitalization stock have be shine biotechs be more year ethical drug maker be more generic drug company nearly worry pricing power have contribute bad sentiment pharmaceutical other segment medical sector be fare much
17,BDX,head wednesday ibd medical sector rank sector rank ibd sector be big comprise sub group various drugmaker long term care provider be lag group hold own include system equipment maker supplier manage care provider steris ste provide infection prevention contamination control surgical critical care
18,BDX,index outperformed dividend stock mutual fund average past year index dividend group be actually neck neck much decade wasn second quarter charge lead decisively earlier dividend fund have outperformed then much include financial crisis fuel market meltdown period investor seek relative safe haven fund hold stock paid dividend overall past year averaged yearly gain dividend fund averaged annually difference add have invest march decade later money have grow have invest same amount cross section dividend fund have grow decade now jpmorgan equity income fund hliex be best perform dividend stock mutual fund post average annual gain manage clare hart simon fund have shareholder money stock dec bulk balance be cash financial service be fund biggest sector weighting health care be next weighting industrial be third biggest sector share price gain medical supply company becton dickinson bdx have help make equity income top perform dividend fund past decade share be so far year earning share grow past quarters little more year company acquire carefusion debt financing company have paid term loan takeover firm continue dish dividend have suspend share repurchase meet debt reduction goal dividend yield be company have composite rating ibd composite rating combine ibd performance rating include ep relative strength rating verizon communication vz be recent contributor fund share be so far year telecom carrier earning share grow past quarters stock have very strong comp rating dividend yield be altrium group mo have be third contributor share be year tobacco firm have comp rating dividend yield be ep growth be slow be past quarters
19,BDX,medical device supply maker have outperformed recently stock industry group make stock spotlight screen tuesday issue heart valve maker edward lifescience ew part ibd leaderboard feb medical supply developer becton dickinson bdx be extend respective buy point boston scientific bsx remain well buy range ahead
20,BDX,halyard health hyh see positive improvement relative strength rs rating friday increase look best stock buy watch factor watch closely be relative price strength exclusive rating investor business daily track market leadership worst best score rating show stock price behavior trail week hold other stock database year market history show best stock often have rs rating least begin largest climb see halyard health continue rebound clear threshold look winning stock try simple routinehalyard health be build flat base buy point see break volume least higher normal halyard health report earning growth last quarter sale growth come halyard health hold rank peer medical supply industry group becton dickinson bdx be rank stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
21,BDX,relative strength rs rating halyard health hyh jump new percentile friday get lift exclusive rating investor business daily track price action worst best score score show stock price movement trail week compare other stock database history reveal best perform stock tend have rs rating early stage move see halyard health continue rebound clear threshold see ibd help make more money stockshalyard health be try complete cup handle entry see stock break heavy trade earning grow last quarter prior report revenue also increase company hold rank peer medical supply industry group becton dickinson bdx be rank stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
22,BDX,becton dickinson bdx see positive improvement relative strength rs rating friday rise ibd unique rs rating measure technical performance used worst best score identify stock price performance last week match rest market decade market research show stock go make biggest gain typically have rs rating least launch biggest climb look best stock buy watch start herebecton dickinson have moved more past entry first stage flat base meaning now proper buy range look stock create new buy opportunity week tight pullback day week move average earning grow last quarter prior report revenue also increase becton dickinson earn rank peer medical supply industry group west pharmaceutical service wst vwr be also group highest rate stock related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
23,BDX,many stock mutual fund manager be bask warm glow hot performance number broad market index rise december lift fourth quarter gain cap year dow jone industrial surge year way top first time ever thursday be already so far year dow be diversify stock mutual fund edge average december extend gain accord lipper inc world equity fund power part weaker dollar turn gain december last year general domestic taxable bond fund averaged gain top december move finished year fund manager investment strategist have also turn eye many expect more modest gain overall list mutual fund month leaderstop mutual fund mutual fund category performancewhy buffalo discovery fund keep stock be top fund manager buy fund manager strategist expect rely more foreign stock value equity gain still fund manager certainly have not abandon equity totally have bet stock first solar fslr part amazon amzn key piece nasdaq composite boee ba best perform dow jone industrial average stock reason fund manager strategist expect search further afield overall big return history have rally more annually year time do follow year broad market gain averaged just more reason expect rotation more foreign stock value equity cheaper valuation many foreign equity give more room run forecast faster economic growth abroad re synchronous growth pattern say bob doll chief equity strategist asset management manager co manager stock mutual fund combine asset rare have growth well key market abroad sort economic environment value stock overall beat growth stock stock also continue get tailwind federal reserve slow tempo interest rate hike slow pace be reassure investor say allen bond manager jensen quality growth fund jensx outperformed well past year just fall short past year key reason doll expect value outperform be corporate earning have be roll remain way indicative rise economic tide lift stock stripe include modestly price value oriented one doll say further strengthen economy lift earning type stock investor be likely flock value stock be more attractively price growth stock inflation interest rate have be behave let earning growth go bottom line add doll add tax reform boost corporate earning also corporate ceo consumer confidence be demand be strong many good service especially technology health care certain consumer area ibd take see tax reform impact individual check ibd report much consumer area have be do capital spending improve tax bill enactment accentuate capital spending doll say be good industrial many tech stock tech space doll like software company credit card company use software facilitate digital payment transaction visa mastercard be top holding doll largest portfolio large cap core nlcix nov health care stock highlight diversify biotech company manage care provider say less interested pharmaceutical equipment company prefer diversify biotech pharma have faster growth similar valuation characteristic large cap core also hold cloud compute service provider red hat rht red hat enable client noncloud enterprise software jibe cloud infrastructure amazon aw microsoft azure manage care provider unitedhealth group unh be third hold unitedhealth benefit membership growth drive rise employment increase use manage care government control cost firm also benefit use datum analytic additional holding include first solar amazon boee solar energy company first solar be new fund november post result oct crushed analyst expectation quarters decline earning share ep grow past stanzas hot solar flare stock gain trading first solar be extend have very strong ibd composite rating ibd composite rating be score scale stock poise move higher often have comp rating higher ibd smr rating be mean top stock term sale growth profit margin return equity ratio base ibd proprietary formula amazon soar nearly last year commerce leader slide dec report president trump have call amazon also leader cloud service pay postal service higher fee package delivery separately faang stock say ship more item prime program customer pay year amazon be buy point share break thursday close just flat base buy point now stock be back proper entry aerospace defense titan boee gap more dec say raise dividend share give share dividend yield boee also increase stock buyback program dow component boee be tech sector jensen bond like stock benefit ongoing transition cloud compute like company help make switch make money help other shift cloud microsoft msft be dual beneficiary say oracle orcl enable customer use premise enterprise software shift cloud compute be go database software provider company extremely sensitive information have thing go wrong bond say also like alphabet googl googl be more player cloud infrastructure space say customer need access cloud structure sell most business be core advertising model result ubiquitous position online search online ad buy bond also like specific theme health care such theme be grow affluence emerge market enable patient be able afford better health care health care system start grow develop emerge market needle syringe be first thing need make work say result like becton dickinson co bdx lead maker needle syringe company acquire carefusion maker infusion pump deliver medical liquid time last month becton dickinson say bard have agree divest product line regulatory approval merger bard make catheter biopsy device bond also like stryker syk orthopedic implant surgical tool medical device enable capitalize age population europe japan kinetic internet fund wwwfx be top perform diversify stock mutual fund post gain accord morningstar direct fund have holding include stake bitcoin investment trust gbtc cryptocurrency be volatile rise last year re not afraid be wrong say co manager peter doyle lot person win participate upside consensus money cryptocurrency need outside reinforcement don say cryptocurrency fail control risk control size position doyle say fund stake be much higher have formally disclose due appreciation investment opportunity general fund be look many popular large cap enjoy large run up other recent year high valuation leave insufficient room post additional gain say co manager james davolos thing fund hold stock company note investor liberty global lbtyk chairman john malone hold large block share include liberty medium lsxmk liberty lbrdk liberty global ve trust john malone own share company year almost exception ve do well doyle say kinetic internet also like live nation entertainment lyv company help popular music performer earn live live performance concession sale corporate sponsorship advertising doyle say fund manager also copart cprt conduct salvage vehicle auction company keep gain market share provide value buyer seller vehicle provide price transparency lower transaction cost davolos say index fund lead diversify category average gain tack december world equity fund trail diversify stock fund average advance december return india region fund pace foreign stock fund category soar help december romp global natural resource fund beat other major sector post gain aid december geyser give return year commodity base metal fund do even better gain december year consumer service fund add december lift gain loan participation fund be top general domestic taxable bond category rise december gain be world income fund emerge market hard currency fund enjoy best gain shade better december return municipal bond fund averaged gain return december related stock watch join apple bofa list new buy top do mutual fund perform need much retirement saving age income
24,BDX,relative strength rs rating becton dickinson bdx moved higher percentile tuesday get lift ibd proprietary rating track share price movement worst best score grade show stock price performance trail week compare other stock database decade market research show market biggest winner typically have rs rating north begin largest climb see becton dickinson continue show renew price strength hit benchmark look winning stock try simple routinebecton dickinson be trading buy zone climb entry flat base once stock move higher initial entry consider proper buy area becton dickinson post earning growth last quarter revenue rise company be expect report latest number nov company hold rank peer medical supply industry group becton dickinson bdx be rank stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
25,BDX,welcome move west pharmaceutical service wst see relative strength rating improve thursday exclusive rating investor business daily track market leadership worst best score grade show stock price performance last week compare other stock database year market history reveal best stock typically have rs rating launch largest run see west pharmaceutical service continue rebound hit benchmark look winning stock try simple routinewest pharmaceutical service be buy range move past buy point cup handle once stock move higher original entry consider extend buy range top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase company hold rank peer medical supply industry group becton dickinson bdx be top rank stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
26,BDX,be street wear dark sunglass make thing look darker be be sky truly turn threaten analyst expect earning drop revenue inch accord report bloomberg news bull be hope low expectation lead significant beat prompt market
27,BDX,something everyone vast universe sector fund consumer staple health care technology sector be favor fund rack big return also be prone bigger decline re more concentrated specific area diversify fund ibd run screen actively manage fund least asset have beaten benchmark past year sector be clear winner best sector fund rank year performance focus biotech health science see full list best sector mutual fund highlight best mutual fund top perform sector best best list ibd best mutual fund award winner include top fund sector click here view table top perform mutual fund select biotechnology portfolio fbiox come top year average annual return well ahead fund hold net asset feb expense ratio be rajiv kaul have manage fund october most sector biotech have see fair share volatility not necessarily negative next year go be renaissance industry term golden age innovation kaul tell ibd not go be straight line biotech be volatile investor amazing opportunity happen jan biotech stock make portfolio pharmaceutical fidelity select biotech hold stock top holding end include alexion pharmaceutical alxn regeneron pharmaceutical regn vertex pharmaceutical vrtx gilead science gild celgene celg stock ibd biotech industry group surge more november low july peak turnover fund tend run fairly low be high barrier entry biotech field include expertise capital regulatory hurdle kaul point do get major breakthrough medication really improve person life help save cost health care system do kaul pick stock fund have understand management be track record success say have kind historical understand depth understand industry individual player equally important be ability company access capital low cost want company be self reliant top biotech fund own big cap biotech soliris maker alexion recently report quarters fund also hold biotechs celgene gilead focus cancer hepatitis respectively generic drug maker track ibd soar more march july ethical drug stock rally nearly march august rowe price health science prhsx take second place biotech fund year return fund have net asset have be close new retail investor june feb portfolio hold stock service account asset follow biotech pharmaceutical product device life science top holding include aetna aet alexion pharmaceutical allergan agn becton dickinson bdx cigna ci focus innovative medicine diagnostic device business model have be core driver success taymour tamaddon have manage fund february say mail past year strength have be broad base biotech likely have highest level performance fund expense ratio be prudential jennison health science phlax return past year have be close new investor end june fund have total net asset expense ratio david michael del balso debra netschert manage fund biotech make biggest weighting jan asset pharmaceutical account health care provider service be health care equipment supply be life science tool service be biggest holding stock portfolio include celgene biomarin pharmaceutical bmrn bristol myer squibb bmy shire shpg allergan remain focuse longer term outlook fund believe continue be very positive base range industry trend health care reform advent oncology active immune therapy manager say jan fund commentary realization company value encounter intermittent setback believe market recognize reward longer term franklin biotechnology discovery fbdix total net asset feb have year return biotech stock make portfolio follow pharmaceutical nearly life science tool service focus biotechnology generally have limit exposure other area health care evan mcculloch senior vice president lead portfolio manager fund say avoid more traditional large cap pharmaceutical company have less favorable growth prospect do not show same level innovation see biotechnology celgene gilead science biogen biib amgen amgn regeneron pharmaceutical be top position stock fund fund close new investor july have expense ratio overall believe be strong fundamental underlie biotechnology sector recent growth have also help fund mcculloch say innovation remain very strong promising new treatment area immuno oncology gene therapy alzheimer disease gi disorder central nervous system disease other rydex biotechnology ryoax round top sector fund year return expense ratio be biotech account net asset feb pharmaceutical life science tool service top holding march include gilead amgen celgene biogen regeneron health care clearly dominate sector fund past decade other fund lead respective category rowe price global technology prgtx net asset end february lead tech sector fund year average annual return medium semiconductor software make biggest weighting stock fund top holding include alphabet googl amazon com amzn jd com jd have expense ratio lead consumer cyclical sector be fidelity select retail portfolio fsrpx asset feb year average annual return expense ratio be internet retail home improvement retail apparel retail account top subindustry end january amazon home depot hd netflix nflx be top holding rowe price medium prmtx top communication sector average annual return fund have net asset feb expense ratio be medium telecom service software be biggest investment area alphabet amazon american tower amt stock portfolio recent top holding rydex consumer product rycix average annual return expense ratio lead consumer defensive sector food product beverage household product account more half net asset procter gamble pg coca cola ko philip morris international pm be recent top holding burnham financial service burkx hold asset head financial sector average annual return yadkin financial ydkn bnc bancorp bncn atlantic capital bancshare acbi be fund top holding jan fund gross expense ratio be net expense ratio be
28,BDX,major stock index be higher early afternoon trading thursday trading session high thank midday burst nasdaq be add dow jone industrial average have come new test day move average be trend downward move line give chart reader assurance current uptrend small cap have be perform well week russell show advance volume be tracking sharply lower winning stock lead loser more ratio nyse nasdaq few high rate stock clear buy point today market session motorola solution msi break choppy pattern leap past buy point heavy trading communication equipment maker have be tear report earning late monday beat expectation sale lag estimate company full year outlook top consensus analyst estimate sturm ruger rgr break cup handle base heavy trading jump past buy point firearm manufacturer beat profit expectation late wednesday earning exclude special item cent share sale increase utility remain favor american electric power aep climb buy point long cup handle base volume be tracking less half normal pace suggest few institutional investor be involved becton dickinson bdx be try break double bottom base share edge buy point volume also be lackluster run third smaller normal medical supply company
29,BDX,stock further perked late tuesday be track end session slide major index have already re-cover monday loss then
30,BDX,help mining energy stock surge dow jone industrial average rally nasdaq gain volume be run higher board stock market today
31,BDX,masco mas gap day line surge company top view earlier stock market today share clear buy point flat base masco make behr paint delta faucet showerhead well denova countertop
32,BDX,jazz pharmaceutical jazz rally nearly new high stock take buy point flat base jazz have clear several basis september have not produce big gain
33,BDX,becton dickinson bdx rise fast trade month high share pass buy point cup handle base maker medical supply device report fiscal earning aug analyst poll thomson reuter see profit rise share snap quarters single digit growth march becton dickinson complete buyout carefusion
34,BDX,leader volume be few ellie mae elli have trim loss stock find support day line nearly return buy point flat base intraday
35,BDX,akamai technology akam buffalo wild wing bwld citrix system ctxs edward lifescience ew gilead science gild macom mtsi panera bread pnra sturm ruger rgr sunpower spwr twitter twtr yelp yelp be notable company report earning close stock further perked late tuesday be track end session slide major index have already re-cover monday loss then help mining energy stock surge dow jone industrial average rally nasdaq gain volume be run higher board stock market today masco mas gap day line surge company top view earlier stock market today share clear buy point flat base masco make behr paint delta faucet showerhead well denova countertop jazz pharmaceutical jazz rally nearly new high stock take buy point flat base jazz have clear several basis september have not produce big gain becton dickinson bdx rise fast trade month high share pass buy point cup handle base maker medical supply device report fiscal earning aug analyst poll thomson reuter see profit rise share snap quarters single digit growth march becton dickinson complete buyout carefusion leader volume be few ellie mae elli have trim loss stock find support day line nearly return buy point flat base intraday akamai technology akam buffalo wild wing bwld citrix system ctxs edward lifescience ew gilead science gild macom mtsi panera bread pnra sturm ruger rgr sunpower spwr twitter twtr yelp yelp be notable company report earning close
36,BDX,ibd industry group biggest mover lately be medical system equipment group currently rank sit low month group have get lift few different front range boost hospital admission expect affordable care act obamacare positive impact
37,BDX,ibd industry group biggest mover lately be medical system equipment group currently rank sit low month group have get lift few different front range boost hospital admission expect affordable care act obamacare positive impact
38,BDX,momentum shift quickly wall street single trend event send stock industry tumble other get shot arm race higher
39,BDX,stock group fall latter category share price have spiked considerably recent week feature diverse mix company range time warner twx walt disney fedex fdx becton dickinson bdx whirlpool whr
40,BDX,follow be stock group have make big move past few week
41,BDX,freight shipper improve economy combine fall oil price have create positive operate environment company deliver freight package live ibd transport air freight group rank industry track week recently week
42,BDX,fedex unite parcel service up be far away biggest player group boast ibd composite rating respectively possible
43,BDX,couple other stock also have pretty high rating air airt composite rating atla air worldwide aaww composite rating composite rating factor thing earning growth stock price gain
44,BDX,medium conglomerate recently week ibd medium diversify group languish way industry ranking place then group have steadily moved higher currently rank
45,BDX,addition disney time warner group include medium entertainment heavyweight st century fox foxa viacom cbs cbs
46,BDX,stock group have benefit move expand internet offering build bigger audience basis
47,BDX,example time warner hbo premium channel recently say offer stream only hbo go consumer cable subscription next year help compete netflix nflx similarly cbs recently say offer showtime premium channel online subscription service cbs news advertising support online channel
48,BDX,medical supply medium diversify group ibd medical supply group have make big move past few month week group rank have vault group share touch record high monday have rise begin october
49,BDX,becton dickinson largest stock group market cap see share spike october announce plan buy carefusion cfn share have moved even higher becton have ibd composite rating
50,BDX,other highly rate stock group include patterson pdco have composite rating west pharmaceutical service wst composite rating
51,BDX,household appliance improve housing market economy have help ibd household appliance ware group move industry ranking place week
52,BDX,whirlpool be biggest stock group boast composite rating be trading multiyear high highly rate middleby midd composite rating well newell rubbermaid nwl electrolux eluxy momentum shift quickly wall street single trend event send stock industry tumble other get shot arm race higher stock group fall latter category share price have spiked considerably recent week feature diverse mix company range time warner twx walt disney fedex fdx becton dickinson bdx whirlpool whr follow be stock group have make big move past few week freight shipper improve economy combine fall oil price have create positive operate environment company deliver freight package live ibd transport air freight group rank industry track week recently week fedex unite parcel service up be far away biggest player group boast ibd composite rating respectively possible couple other stock also have pretty high rating air airt composite rating atla air worldwide aaww composite rating composite rating factor thing earning growth stock price gain medium conglomerate recently week ibd medium diversify group languish way industry ranking place then group have steadily moved higher currently rank addition disney time warner group include medium entertainment heavyweight st century fox foxa viacom cbs cbs stock group have benefit move expand internet offering build bigger audience basis example time warner hbo premium channel recently say offer stream only hbo go consumer cable subscription next year help compete netflix nflx similarly cbs recently say offer showtime premium channel online subscription service cbs news advertising support online channel medical supply medium diversify group ibd medical supply group have make big move past few month week group rank have vault group share touch record high monday have rise begin october becton dickinson largest stock group market cap see share spike october announce plan buy carefusion cfn share have moved even higher becton have ibd composite rating other highly rate stock group include patterson pdco have composite rating west pharmaceutical service wst composite rating household appliance improve housing market economy have help ibd household appliance ware group move industry ranking place week whirlpool be biggest stock group boast composite rating be trading multiyear high highly rate middleby midd composite rating well newell rubbermaid nwl electrolux eluxy
53,BDX,list stock hit new high monday be short market remain correction medical equipment maker becton dickinson bdx soar nearly announce late sunday be buy carefusion cfn volume be huge stock gap clear long flat base
54,BDX,stock try third straight gain monday fail hit key resistance nasdaq fall be much early session turn tail hit wall day move average monday low nasdaq be much biotech software solar stock be
55,BDX,stock future hold steady healthy gain ahead monday open market look short week preholiday trade dow future be level trading point fair market value
56,BDX,nasdaq future future be also steady point respectively
57,BDX,stock market today have work cut christmas week trade generally tend be light young uptrend run heavy distribution friday raise question long last
58,BDX,economic news isn likely have much impact chicago federal reserve national activity index most prominent piece economic news prior open show slip november accelerate october contraction be not economist consensus have expect increase
59,BDX,international market also appear have negligible effect stock europe trade modestly higher midday china market rise include jump shanghai composite tokyo nikkei japan slip
60,BDX,dollar rise bond edge oil price slip west texas intermediate bob barrel brent crude just most metal trade higher big gain
61,BDX,be star war effect early trade walt disney be stock lead dow better gain premarket trade goldman sachs gs apple aapl also gain more
62,BDX,disney star war force awaken gross estimate canada weekend be expectation beating prior record holder jurassic world gross premier june avenger pull premier
63,BDX,disney share briefly clear buy point cup handle base november then drop undercut buy point more trigger sell rule
64,BDX,huge screen savvy imax imax jump new star war film reportedly premier imax screen weekend pull set imax record top open weekend take jurassic world accord box office figure deadline hollywood imax ibd stock end friday buy point cup handle base
65,BDX,also ibd list arm armh perked ahead open share cambridge england base chip designer tumble last week end stock converge week line support stock future hold steady healthy gain ahead monday open market look short week preholiday trade dow future be level trading point fair market value nasdaq future future be also steady point respectively stock market today have work cut christmas week trade generally tend be light young uptrend run heavy distribution friday raise question long last economic news isn likely have much impact chicago federal reserve national activity index most prominent piece economic news prior open show slip november accelerate october contraction be not economist consensus have expect increase international market also appear have negligible effect stock europe trade modestly higher midday china market rise include jump shanghai composite tokyo nikkei japan slip dollar rise bond edge oil price slip west texas intermediate bob barrel brent crude just most metal trade higher big gain be star war effect early trade walt disney be stock lead dow better gain premarket trade goldman sachs gs apple aapl also gain more disney star war force awaken gross estimate canada weekend be expectation beating prior record holder jurassic world gross premier june avenger pull premier disney share briefly clear buy point cup handle base november then drop undercut buy point more trigger sell rule huge screen savvy imax imax jump new star war film reportedly premier imax screen weekend pull set imax record top open weekend take jurassic world accord box office figure deadline hollywood imax ibd stock end friday buy point cup handle base also ibd list arm armh perked ahead open share cambridge england base chip designer tumble last week end stock converge week line support
66,BDX,normal market common see more stock hit new high give day only dozen scale new peak tuesday market correction deepen many hit new high only reverse lower best perform stock come health care utility sector investor seek
67,BDX,medical equipment maker becton dickinson bdx carefusion hit new high stock market today buyout deal be announce sunday evening
68,BDX,conference call analyst monday morning company leader say firm complement other technologically geographically carefusion cfn sell mostly bd sell mostly outside combine portfolio product service offer full suite medication management industry say
69,BDX,also fielded question bd be make such large buyout do not fit recent history tuck deal response cite consolidation customer base need cut cost necessity global presence most growth industry be come emerge market
70,BDX,such factor have be drive consolidation medtech market medtronic mdt buyout covidien cov zimmer zmh acquisition biomet already work
71,BDX,third big medtech deal be announce year transaction likely be view yet indication scale be take increase level importance management team plan future position company write leerink analyst richard newitter research note add pressure company strong balance sheet often talk likely acquirer stryker syk abbott put capital work sooner rather later potentially larger size transaction
72,BDX,rbc capital market analyst glenn novarro echo point note add acquisition smaller cap medtech company continue be push large cap medtech company digest recent sizeable acquisition
73,BDX,becton dickinson stock hit new high monday late morning be just carefusion also hit new high late morning be
74,BDX,follow amy reeve twitter ibd_areeve medical equipment maker becton dickinson bdx carefusion hit new high stock market today buyout deal be announce sunday evening conference call analyst monday morning company leader say firm complement other technologically geographically carefusion cfn sell mostly bd sell mostly outside combine portfolio product service offer full suite medication management industry say also fielded question bd be make such large buyout do not fit recent history tuck deal response cite consolidation customer base need cut cost necessity global presence most growth industry be come emerge market such factor have be drive consolidation medtech market medtronic mdt buyout covidien cov zimmer zmh acquisition biomet already work third big medtech deal be announce year transaction likely be view yet indication scale be take increase level importance management team plan future position company write leerink analyst richard newitter research note add pressure company strong balance sheet often talk likely acquirer stryker syk abbott put capital work sooner rather later potentially larger size transaction rbc capital market analyst glenn novarro echo point note add acquisition smaller cap medtech company continue be push large cap medtech company digest recent sizeable acquisition becton dickinson stock hit new high monday late morning be just carefusion also hit new high late morning be follow amy reeve twitter ibd_areeve
75,BDX,halyard health hyh see welcome improvement relative strength rs rating thursday increase unique rating measure market leadership show stock price action last week compare other stock database history reveal market biggest winner typically have rs rating early stage move look winning stock try simple routinehalyard health be buy zone breaking past entry flat base proper buy range be initial entry once stock move range best hold investing set buy opportunity top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase company hold rank peer medical supply industry group becton dickinson bdx be top rank stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
76,BDX,halyard health hyh see welcome improvement relative strength rs rating thursday increase unique rating measure market leadership show stock price action last week compare other stock database history reveal market biggest winner typically have rs rating early stage move look winning stock try simple routinehalyard health be buy zone breaking past entry flat base proper buy range be initial entry once stock move range best hold investing set buy opportunity top bottom line growth moved higher company most recent quarter earning be compare prior report revenue increase company hold rank peer medical supply industry group becton dickinson bdx be top rank stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
77,BDX,welcome move dentsply sirona xray see relative strength rating rise monday unique rating track market leadership used worst best score identify stock price action trail week compare rest market decade market research show best stock tend have rs rating north launch largest run see dentsply sirona continue rebound hit benchmark look best stock buy watch start heredentsply sirona be buy range clear entry consolidation proper buy range extend initial entry once stock move range best set buy opportunity top bottom line growth moved higher last quarter earning be compare prior report revenue increase dentsply sirona hold rank peer medical supply industry group becton dickinson bdx west pharmaceutical service wst vwr be top highly rate stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
78,BDX,relative strength rs rating becton dickinson bdx jump new percentile wednesday get lift proprietary rating identify technical performance used worst best score identify stock price performance last week compare rest market year market history show best stock tend have rs rating north early stage move see becton dickinson continue show renew price strength hit benchmark stock be build flat base buy point see stock break volume least higher normal company show ep growth most recent report sale growth come becton dickinson earn rank peer medical supply industry group vwr be rank stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
79,BDX,becton dickinson bdx see positive improvement relative strength rs rating thursday rise exclusive rating investor business daily measure share price action worst best score grade show stock price performance trail week compare other stock database history reveal best perform stock tend have rs rating north begin largest run see becton dickinson continue rebound clear threshold becton dickinson be now consider extend buy range clear buy point second stage flat base see stock form new pattern follow buy opportunity week tight pullback day week line becton dickinson post ep growth last quarter sale growth come becton dickinson hold rank peer medical supply industry group vwr be top rank stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
80,BDX,welcome move halyard health hyh see relative strength rating improve thursday ibd unique rating identify share price movement worst best score rating show stock price performance last week hold other stock database decade market research reveal market biggest winner typically have better rs rating early stage move see halyard health continue rebound hit benchmark halyard health have moved more past entry first stage double bottom meaning now proper buy zone look stock create new chance get week tight pullback day week move average term fundamental health company have post rise ep growth last quarters revenue gain have be different story come last quarter halyard health earn rank peer medical supply industry group becton dickinson bdx be rank stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
81,BDX,relative strength rs rating henry schein hsic moved higher percentile tuesday get lift ibd unique rs rating identify technical performance show stock price movement last week compare other stock database year market history show best stock tend have rs rating north early stage move see henry schein continue rebound hit benchmark henry schein be try complete flat base entry see clear price heavy trade revenue growth fall last quarter ep grow prior report look next report aug company earn rank peer medical supply industry group becton dickinson bdx be top rank stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
82,BDX,important metric look stock be higher relative strength rating west pharmaceutical service wst clear benchmark tuesday jump tuesday unique rating identify technical performance used worst best score identify stock price performance last week match other stock decade market research reveal best stock often have rs rating early stage move west pharmaceutical service be build flat base entry see break heavy trade earning growth drop company most recent quarterly report sale rise prior report next quarterly result be expect jul west pharmaceutical service hold rank peer medical supply industry group becton dickinson bdx be rank stock group related ibd stock rating upgrade rise relative strengthwhy use ibd relative strength rating relative strength line help judge stock
83,BDX,large cap fund be set potential breakout stock market remain time high xfirst be ishare edge msci min vol usa usmv be just shy flat base buy point briefly clear prior flat base entry late april pull back buy point bounce day move average en route gain fund track msci usa minimum volatility index comprise domestic stock tend be less volatile broader equity market carry expense ratio usmv biggest sector weighting be health care july just asset information technology follow nearly consumer staple financial health care name account half top becton dickinson bdx johnson johnson jnj stryker syk unitedhealth group unh intuitive surgical isrg fund top name make less total asset usmv also help limit volatility keep hold less have relatively low annual turnover year date gain july be line accord morningstar inc etf outpaced benchmark index past year vs slightly underperform past year vs have dividend yield flexshare quality dividend index fund qdf track northern trust quality dividend index be buy point flat base fund launch december target stock sustainable yield lead profitable company have ability keep pay dividend top holding july include procter gamble pg boee ba pfizer pfe apple aapl merck mrk top stock account asset annual turnover be qdf have lag year past year annualize yield be well benchmark index average yield expense ratio be tuesday be good day many foreign etfs include international equity fund dwm ishare msci hong kong ewh dwm be still buy range entry ewh flat base buy point stock market pare early gain wednesday leave only dow jone industrial average positive territory earning fuel jump apple aapl spdr dow jone industrial average dium hold only gain spdr spy slip powershare qqq trust qqq edge lower stock sell board telecom retail real estate lead decline spdr telecom xtl fall slip day line first time week vaneck vector oil service oih reversed advance west texas intermediate crude price early reversed higher barrel few sector buck decline industrial select sector spdr xli rise utility select sector spdr xlu climb vaneck vector gold miner gdx be vaneck vector junior gold miner gdxj give powershare db gold fund dgl spdr gold trust gld ishare gold trust iau hold small gain related dow keep streak alive foreign play breaking dow hit new high techs give gain apple focusdow mark record high check solid play buy pointsfind happen stock market today
84,BDX,xfuture dow jone industrial average index nasdaq jump first round french presidential election global multinational particularly benefit dow component microsoft msft boee ba well alphabet googl trade buy point centrist emmanuel macron come first face nationalist marine le pen runoff le pen favor major break european union euro poll have suggest macron have backed economic reform defend eu easily defeat populist le pen head head contest dow jone industrial future open more point fair value early monday morning pull back point future index nasdaq be euro shot month high ibd take french presidential election be just start action packed week investor investing action plan give rundown big earning report economic datum tap microsoft rise friday stock market trading retake buy point flat base microsoft report earning thursday window office software giant be become cloud compute giant boee have find support week line own flat base aerospace defense giant report wednesday close friday have potential buy point google parent alphabet rise last week regain day move average alphabet rise be move reclaim buy point alphabet report late thursday separately bd bdx agree buy medical tech firm bard bcr company say sunday even investor cheer france election result also recalibrate odd tax reform home major market average rally thursday treasury secretary steven mnuchin talk tax cut market come friday lows trump say massive tax cut plan be announce come week sunday white house official say wednesday announcement mostly be broad principle indication propose tax rate asian market be mixed monday japan nikkei hong kong hang seng china shanghai composite related tech industrial giant report euro rally investing action plandow boee near buy point ahead result revenue dropbd buy medical tech firm bard
85,BDX,xmedical supply giant bd bdx becton dickinson acquire medical product firm bard bcr company announce sunday becton dickinson pay share cash share bd bard share premium bard close price friday bard share shot close stock market today bd fall combination create highly differentiate medical technology company uniquely position improve process care treatment disease patient healthcare provider transaction build bd leadership position medication management infection prevention expand offer solution care continuum bd say statement additionally bard strong product portfolio innovation pipeline increase bd opportunity fast grow clinical area combination enhance growth opportunity combine company market bard add vascular urology oncology surgical specialty product bd bd say deal be immediately accretive earning mid single digit gain fiscal bard release first quarter result sunday well diluted earning share rise revenue
86,BDX,xa powerful rebound monday left nasdaq new high heft dow industrial back day move average first time april be only start action nasdaq vault dow jone industrial average rise small cap slightly outpaced general action russell notch gain next be hour report session earning report whirlpool whr barrick gold abx range resource rrc set tone week jam economic political news more dozen dow list stock be set report earning alcoa aa be extend trading follow result express script esrx also announce result be unchanged first round presidential vote france sunday set second round far right wing candidate marine le pen centrist challenger emmanuel macron schedule macron victory strength poll ahead second round vote ease investor concern france be head exit european union move threaten union stock also receive boost white house news report say president trump have call tax plan wednesday prioritize trimming corporate tax rate hold deficit treasury secretary steven mnuchin national economic council director gary cohn be schedule meet key gop congressional leader discuss plan tuesday accord wall street journal combine result send steel maker bank miner soar jpmorgan jpm lead dow jone industrial average nearly gain goldman sachs gs jump caterpillar cat climb nearly fiber optic telecom stock also outpaced general market lead infinera infn apply optoelectronic aaoi stock be not valid buy point bard bcr easily top spiking report first quarter earning news break company be acquire becton dickinson bdx deal value becton slump hurt downgrade credit watch negative due financial risk associate bard deal standard poor hasbro have thrash gain follow strong first quarter result seize new high narrowly top buy point flat base share remain buy range dell technology dvmt pop strong trade enough take new high clear flat base buy point ibd leaderboard swing trader stock be cup handle base november oil gold drop almost session miner energy stock fared reasonably well nasdaq stock biomarin pharmaceutical bmrn xylinx xlnx lead more xylinx end just double bottom base buy point micron technology mu take nasdaq hardest hit bit less strong trade memory chip maker end late march high be still hold support week move average related top stock buy zone ahead result investing action planthese stock break nasdaq near new high
87,BDX,xu stock shot open monday global market respond favorably france presidential vote sunday dow jone industrial average jump nasdaq add success centrist candidate emmanuel macron first round france presidential election provide powerful challenge marine le pen leader national front party raise odd france remain member european union market standpoint suggest stability stability always earn premium market uncertainty send cac paris sailing higher afternoon trade frankfurt dax blaze higher ftse london rally le pen macron face second round election schedule asia market tokyo nikkei japan grab gain china shanghai composite fall hang seng composite hong kong add monday session launch massive week earning report nearly company more third dow industrial due report bank be leader early action monday buoy election result france jpmorgan chase jpm goldman sachs gs rise dow caterpillar cat be also european bank be fire overseas premarket session deutsche bank db ub group ub barclay bcs ahead credit suisse cs open earning front kimberly clark kmb drop report first quarter earning miss halliburton hal add squeaking past first quarter earning expectation lennox international lii tumble break day line big volume follow first quarter report alcoa aa whirlpool whr barrick gold abx due session close hasbro have buzz more report gain earning revenue increase far analyst first quarter target stock break past buy point flat base koninklijke philips phg brighten open report stronger expect result first quarter share be extend new high breaking past cup base buy point start march fortune be mixed china base name premarket action new oriental education technology edu rise open school tutor chain report strong fiscal third quarter clear expectation issue line revenue guidance fourth quarter stock be past buy point profit investor lock least profit dive sohu com sohu fall report quarter result medical product maker bard bcr spiked medical supply leader becton dickinson bdx announce take control bard deal value becton project deal add high single digit accretion earning share year close becton dickinson share slump open standard poor place company credit watch negative due financial impact acquisition week budget battle congress promise heat ahead friday expiration temporary bill funding government spending pledge white house present tax reform plan week potentially stir market activity expectation specific play appear remain generally low commerce department wrapped week economic calendar friday initial estimate first quarter gdp growth today dalla federal reserve report april manufacturing survey et minneapoli federal reserve bank president neel kashkari speak et related tech industrial giant report euro rally investing action plandow boee near buy point ahead result revenue dropbd buy medical tech firm bard
88,BDX,investor toast third quarter strongest year september alone be exciting bottle bubbly go flat third quarter rise lift diversify stock mutual fund average broad market advanced barely breaking even september nose upward modest stock fund edge ahead mere last month raise stock fund gain year date stock market start stop motion third quarter have prompt many fund manager plan ahead sticking name drive strong trend such shift cloud compute company seem capable grind growth matter blah growth be broader economy click here see list ibd mutual fund quarterly leader first half year see more defensive lead rally say lew piantedosi manager eaton vance fund total asset reversed cyclical tech industrial do better click here see list mutual fund month leadersworld equity fund advanced outperform diversify stock fund last month world equity fund rise china regional fund gain lead world equity market september rac return cyclical sector stay hot then stock tie transportation industrial good commodity continue third quarter gain piantedosi hold norfolk southern nsc gain third quarter focuse growth opportunity class eifgx july tax manage growth eitmx hold union pacific unp rolled gain most cyclical lose head steam piantedosi prefer long view focus big picture growth trend be sustainable shift macro noise say facebook fb amazon amzn alphabet googl be sustainable grower benefit great secular tailwind say name have do well especially amazon still runway ibd take ibd brian deagon analyze tailwind drive amazon buy sell column julie mak point lead mutual fund have be selling alphabet amazon tech sector be acquisition seem be pick say click here see list mutual fund category say investor brace volatility election democratic white house senate house republican hand mean continue gridlock say still impression be support tax reform be grow party be huge positive say health care wary many drugmaker due political call price regulation still like celgene celg vertex vrtx biogen biib biotechs feel little safer biotech drugmaker say be do wonderful thing cure big disease combine positive reward risk re beaten trading valuation attractive valuation retail like few name area watch head holiday especially more apparel oriented stock piantedosi say be short term theme macy have go markdown have discount last year overstock say mild winter dampen consumer demand warm clothe competition be stiff amazon company have do great job manage inventory go holiday year piantedosi say expectation be low ve be monetize real estate selling close unneeded location continue home improvement giant lowe low home depot hd housing be still strong say interest rate be still low consumer be stock price have come little fear housing slowdown jeff rottinghaus rowe price manager growth income prgix large cap core trulx say stock price general seem fairly price like name health care price have be push call becton dickinson bdx medtronic mdt unitedhealth group unh quiet none be political pressure drug pricing becton develop medical supply medtronic develop implantable cardiac device other product unitedhealth be industry biggest manage care provider yet rottinghaus be shopping biotechs price be so beaten be underweight tech sector like company benefit secular trend cloud compute growth include alphabet microsoft msft also like sustainable secular growth visa facebook rottinghaus also like nextera energy nee have dividend yield largest renewable energy generator say dividend yield be roughly wouldn own low double digit earning growth expect growth oriented sector lead stock fund third quarter charge science technology fund zoom ahead quarter top september gain health biotechnology fund be also strong manufacturing gain quarter small cap growth fund gain average lead diversify stock fund category left year september gain be related stock fund manager seek scarce profit durable growth stocksmarket tread water august investor shift growth stock
89,BDX,ishare medical device etf ihi be year top etf leader ride best part mixed health care sector year medical sector have diverged industry fare much better other biotechs other drugmaker be roughly ibd medical product equipment industry group be only diversify medical company be do quite well health care much outperformance medical device owe superior result top manufacturer innovation have play key role ignite industry leader stock etf medtronic mdt be largest hold more portfolio share have climb much buy point april stock have perform decently fact earning have be basically flat quarters outlook be improve analyst expect profit rise fiscal year end april next year investor day june medtronic forecast mid single digit revenue growth develop product pipeline draw diversify market edward lifescience ew be stock have shoulder etf advance share be time high main move year be april company announce sapien transcatheter aortic valve replacement be show reduce death heart attack patient moderate risk open heart surgery share soar news medtronic corevalve compete edward heart valve replacement patient not able have open heart surgery analyst canaccord genuity remain bullish stock follow earning report say dominate market transcatheter aortic valve replacement show potential market expansion share stryker syk have broadest range orthopedic product peer have climb much year fall sharply july earning report be clear explanation slide other softness emerge market other key contributor ishare medical device be thermo fisher scientific tmo make equipment medical research zimmer biomet zbh just post strongest quarter sale growth nearly decade becton dickinson bdx have be trend higher fall sharply thursday cut full year sale forecast cite currency headwind etf be extend april pullback day move average june remain buy point week tight pattern form july ibd etf leader index show performance model portfolio exchange trade fund be lead overall market computer algorithm select etfs base relative strength other objective performance rating periodic adjustment market trend condition universe etfs be select include fund list
90,BDX,have quality system come health care information tech hcit company do come go company disappoint fiscal third quarter earning hazy guidance release close thursday quality system qsii stock gap month low early trading stock market today recover bit close friday
91,BDX,technology name tuesday stock spotlight screen hailed different sector be equally intriguing fundamental technical health integrate device technology idti have emerge big leader semiconductor space year date contrast decline philadelphia semiconductor index investor miss initial idt be near test week move average provide new entry lot new go company newness be often catalyst stock idt largest category be datum center product also make inroad wireless charge samsung partnership wireless charge be still nascent market great potential earlier month growth oriented investment banking firm craig hallum say company acquisition zmdi help drive growth fiscal fiscal year end march analyst be currently modele earning share fiscal craig hallum be look share say ep reach zmdi make analog mixed signal chip product automotive industrial medical consumer market latest report quarter idt report increase quarterly profit fourth straight quarter sale growth health care space becton dickinson bdx be try clear cup handle buy point volume be only average stock clear entry dec price action have be volatile recent day strong revenue growth past quarters be result becton dickinson acquisition carefusion combine company provide full range medical product hospital
92,BDX,nothing prospect winning corporate combo bolster investor enthusiasm find look further medical technology giant becton dickinson bdx purchase earlier year rival carefusion becton dickinson bd have see stock rise more intraday high close roughly
93,BDX,supplier medical device be climb ibd industry rank quickly thank part acquisition improve earning stock industry have jump place past week wednesday ibd group have rise year outperform
94,BDX,becton dickinson bdx big cap supplier catheter other equipment lead group composite rating
95,BDX,becton have post straight quarters strong double digit sale growth follow march acquisition carefusion device help reduce medication error prevent infection prior acquisition big cap firm have post long string mostly low mid single digit sale gain
96,BDX,profit growth have also rebound jump share latest quarter just cent same period year earlier
97,BDX,addition carefusion becton be transform company be able comfortably hit double digit ep growth next year jp morgan say nov rate stock outperform
98,BDX,becton initially clear buy point dec volume be unimpressive stock have waver
99,BDX,dentsply international xray sell wide range dental product be slightly extend clear flat base entry late october stock be year
100,BDX,dentsply announce buy sirona dental siro create world biggest provider dental supply product range anesthetic other consumable dental chair deal be expect be approve first quarter next year
101,BDX,combine company be likely achieve significant cost revenue synergy back expand product portfolio bigger customer base better infrastructure zack equity research say dec zack have buy rating stock
102,BDX,profit rise cent share decline sale efficiency improvement higher margin outweighed currency headwind
103,BDX,henry schein hsic provider dental supply be third major stock group composite rating
104,BDX,stock be year be buy range clear buy point october henry schein earning share rating be tie becton best industry henry schein accumulation distribution rating also lead group indicate strong demand
105,BDX,melville ny base company announce nov profit rise share biggest increase quarters ahead wall street estimate
106,BDX,sale rise
107,BDX,fidelity contrafund rate ibd be institution increase holding latest quarter supplier medical device be climb ibd industry rank quickly thank part acquisition improve earning stock industry have jump place past week wednesday ibd group have rise year outperform becton dickinson bdx big cap supplier catheter other equipment lead group composite rating becton have post straight quarters strong double digit sale growth follow march acquisition carefusion device help reduce medication error prevent infection prior acquisition big cap firm have post long string mostly low mid single digit sale gain profit growth have also rebound jump share latest quarter just cent same period year earlier addition carefusion becton be transform company be able comfortably hit double digit ep growth next year jp morgan say nov rate stock outperform becton initially clear buy point dec volume be unimpressive stock have waver dentsply international xray sell wide range dental product be slightly extend clear flat base entry late october stock be year dentsply announce buy sirona dental siro create world biggest provider dental supply product range anesthetic other consumable dental chair deal be expect be approve first quarter next year combine company be likely achieve significant cost revenue synergy back expand product portfolio bigger customer base better infrastructure zack equity research say dec zack have buy rating stock profit rise cent share decline sale efficiency improvement higher margin outweighed currency headwind henry schein hsic provider dental supply be third major stock group composite rating stock be year be buy range clear buy point october henry schein earning share rating be tie becton best industry henry schein accumulation distribution rating also lead group indicate strong demand melville ny base company announce nov profit rise share biggest increase quarters ahead wall street estimate sale rise fidelity contrafund rate ibd be institution increase holding latest quarter
108,BDX,little bit everything week big cap screen lead large cap growth stock stock be extend still be buy range couple other be set possible upside move
109,BDX,even index be high still not easy environment growth investor stock be breaking heavy volume just many not more have be pass buy point sluggish trade latter isn surprising volatile market high distribution day count nasdaq be make challenge environment
110,BDX,medical technology firm becton dickinson bdx get pull broad market monday clear cup handle buy point friday
111,BDX,volume be slightly average increase typical proper breakout still current base have plenty positive attribute include sign accumulation tight trading handle area
112,BDX,sale growth have ramp becton dickinson past quarters due acquisition carefusion provide technology help reduce medication error prevent health care associate infection
113,BDX,fiscal sale becton dickinson jump year earlier period sale report early november rise
114,BDX,meanwhile northrop grumman noc be form flat base buy point base be second part base base pattern
115,BDX,defense stock continue be good source leadership market head monday ibd aerospace defense industry group rank group rank month price performance
116,BDX,other big cap member be still trading buy point include palo alto network panw linkedin lnkd volume have dry palo alto trade entry seller have be linkedin recently handle area be still intact buy point
117,BDX,airline stock take flight again monday sharp drop oil price lower oil price have find way pump be good news consumer other worry oil precipitous drop be signale more sluggish economic growth ahead
118,BDX,low volume buy point volume have finally start come southwest airline luv share jump friday early monday stock give back early gain monday modest gain put slightly buy range
119,BDX,early november company report strong october traffic passenger traffic nearly year earlier period little bit everything week big cap screen lead large cap growth stock stock be extend still be buy range couple other be set possible upside move even index be high still not easy environment growth investor stock be breaking heavy volume just many not more have be pass buy point sluggish trade latter isn surprising volatile market high distribution day count nasdaq be make challenge environment medical technology firm becton dickinson bdx get pull broad market monday clear cup handle buy point friday volume be slightly average increase typical proper breakout still current base have plenty positive attribute include sign accumulation tight trading handle area sale growth have ramp becton dickinson past quarters due acquisition carefusion provide technology help reduce medication error prevent health care associate infection fiscal sale becton dickinson jump year earlier period sale report early november rise meanwhile northrop grumman noc be form flat base buy point base be second part base base pattern defense stock continue be good source leadership market head monday ibd aerospace defense industry group rank group rank month price performance other big cap member be still trading buy point include palo alto network panw linkedin lnkd volume have dry palo alto trade entry seller have be linkedin recently handle area be still intact buy point airline stock take flight again monday sharp drop oil price lower oil price have find way pump be good news consumer other worry oil precipitous drop be signale more sluggish economic growth ahead low volume buy point volume have finally start come southwest airline luv share jump friday early monday stock give back early gain monday modest gain put slightly buy range early november company report strong october traffic passenger traffic nearly year earlier period
120,BDX,stock index strengthen late afternoon trading friday strong november job report pretty much slam door rate hike december fed meeting
121,BDX,dow jone industrial average nasdaq rise small cap lag russell volume nyse nasdaq be tracking close thursday level
122,BDX,economic news employer add job november lead big gain construction retail economist expect growth unemployment rate hold steady
123,BDX,year treasury yield fall basis point soar basis point thursday
124,BDX,stock market today ulta beauty ulta gap choppy week consolidation report strong earning late thursday share jump nearly
125,BDX,airline also outperformed lower oil price ibd airline group gain almost lead alaska air alk share rise still buy range flat base buy point caveat be late stage base southwest airline luv add approach high end buy range buy point
126,BDX,wti crude oil future be barrel opec decide leave output change meeting today vienna
127,BDX,becton dickinson bdx add still buy range buy point fundamental be solid large cap medical supplier latest report quarter sale jump help recent acquisition carefusion
128,BDX,follow ken shreve twitter ibd_kshreve facebookstock index strengthen late afternoon trading friday strong november job report pretty much slam door rate hike december fed meeting dow jone industrial average nasdaq rise small cap lag russell volume nyse nasdaq be tracking close thursday level economic news employer add job november lead big gain construction retail economist expect growth unemployment rate hold steady year treasury yield fall basis point soar basis point thursday stock market today ulta beauty ulta gap choppy week consolidation report strong earning late thursday share jump nearly airline also outperformed lower oil price ibd airline group gain almost lead alaska air alk share rise still buy range flat base buy point caveat be late stage base southwest airline luv add approach high end buy range buy point wti crude oil future be barrel opec decide leave output change meeting today vienna becton dickinson bdx add still buy range buy point fundamental be solid large cap medical supplier latest report quarter sale jump help recent acquisition carefusion follow ken shreve twitter ibd_kshreve facebook
129,BDX,stock market autumn rally be well progress several big capitalization leader be still launch pad potential breakout unusual find lead stock still basis nearly month follow normally most leader have amassed gain be extend now be big cap
130,BDX,seller be back market tuesday nasdaq close high session erase good portion early loss nasdaq give fall much lose close top half intraday range add distribution day count bring
131,BDX,medical supply giant becton dickinson bdx lift earning guidance related buyout carefusion cfn tuesday send stock new high stock market today sec filing tuesday bd say determine need incur only debt acquisition previous
132,BDX,myriad genetic mygn be hit multiple analyst downgrade monday plunge stock market today center medicare medicaid service confirm weekend cut reimbursement myriad genetic test breast cancer vulnerability myriad be morning trading monday week low late friday cms say start
133,BDX,becton dickinson company bdx free report also know bd recently complete acquisition texas base tva medical financial term deal have be keep wrapped post announcement share bd inched management transaction be not expect be accretive bd financial result fiscal past year company share have rally compare industry rise stock carry zack rank hold come back news tva medical develop minimally invasive vascular access solution patient chronic kidney disease require hemodialysis recent integration be likely boost bd core medical segment additionally buyout enable bd provide tva flagship everlinq endoavf system everlinq endoavf receive marketing clearance fda be used hemodialysis rely open surgery acquisition allow bd serve physician patient provide minimally invasive procedure patient chronic kidney disease market opine be more patient end stage renal disease esrd depend hemodialysis unite state moreover research market minimally invasive surgical device be project reach cagr benefit minimally invasive surgery compare traditional open surgeriesa well asreduction healthcare cost growth market hence bd latest move be timely strategic medtech minimally invasive invasive surgery involve fewer incision reduce trauma patient late medtech space have be witness increase usage surgical procedure bd be major global medtech player have be rake huge profit minimally invasive procedure company flagship mueller snowden pencer laparoscopic instrument be most advanced surgical instrument available market intuitive surgical isrg free report coveted da vinci platform deserve special mention here system be power robotic technology enable surgeonsto make smaller precise movement also stryker corporation syk free report robotic arm assist mako surgery platform facilitate advanced joint replacement surgery solution want more industry better rank stock medical dental supply space be henry schein inc hsic free report henry schein gain unite state well overseas raise optimism stock carry zack rank buy see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
134,BDX,abiom abmd free report first quarter fiscal earning be schedule release jul market open believe company be set gain flagship impella product line impressive guidance fiscal recent upgrade coveted benchmark be other tailwind last report quarter abiom post adjust earning share cent beat zack consensus estimate earning also sky-rocket year quarter figure quarter be report zack consensus estimate revenue be peg reflect year year rise zack consensus estimate adjust earning share be peg cent indicate significant climb abiom inc price ep surprise abiom inc price ep surprise abiom inc quotesolid impella product line likely drive impella be world smallest heart pump abiom flagship product line have continue be growth driver company recently impella heart pump receive ce mark approval europe notably first patient be successfully treat university heart center hamburg germany latest acceptance further enhance abiom product portfolio read more abiom impella receive ce mark europe management await approval impella unite state be expect help abiom significantly advance field heart recovery moreover company impella cp heart pump smartassist also receive fda pre market approval pma additionally abiom have already receive ce mark approval european union market impella cp smartassist last report quarter company witness strong adoption impella product line unite state germany japan management anticipate patient adopt product line germany japan respectively other factor playview fiscal company expect total revenue reflect increase prior fiscal notably zack consensus estimate revenue be peg lie project range massachusett base developer medical product replace wyndham worldwide corp join distinguish index portfolio lead company have approximately coverage available market capitalization index be important metric equity hence abiom recent development be proof company solid prospect read more abiom replace wyndham benchmark cutthroat treatment provider heart related disease be intense abiom product compete temporary cardiac assist device throat company also face stiff competition organization develop permanent heart assist product thoratec teleflex heartware jarvik heart microme technology model predictsour quantitative model do not predict earning beat abiom quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate have be illustrated earning esp abiom have earning esp uncover best stock buy sell re report earning esp filter zack rank abiom currently carry zack rank stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter varian medical var free report have earning esp currently stock carry zack rank see complete list today zack rank stock here mckesson corporation mck free report have earning esp stock presently carry zack rank becton dickinson company bdx free report have earning esp stock currently carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
135,BDX,wall street close sharply lower wednesday end day winning streak major stock index close red president donald trump decision impose second round tariff worth chinese good halter day market rally investor remain confused strong expectation second quarter earning support fundamentally robust economy prolong trader tension unite state china dow jone industrial average dji close decline point index inx decrease close nasdaq composite index ixic close shedding total share be trade wednesday lower last session average share decliner outnumber advancer nyse ratio nasdaq decliner have edge advancer ratio cboe vix increase close do benchmark perform dow be once again enter negative territory year date notably stock blue chip index close red trade green remain unchanged slump lead drop energy select sector spdr xle decline material select sector spdr xlb fall industrial select sector spdr xli partially offset gain utility select sector spdr xlu notably sector benchmark index end negative territory likewise tech heavy nasdaq composite lose primarily due poor performance chipmaker have large business stake china china trade war escalate ongoing trade conflict unite state china be show sign abate march trump administration announce first phase tariff worth first part tariff worth be implement jul remain tariff be implement next week jul government release list tariff chinese good worth new tariff undergo month review hire final decision be take last week president trump have threaten china administration consider possibility impose new tariff worth china retaliate tariff however china have retaliate tariff impose export energy stock plunge energy stock plunge wednesday trade war concern positive news supply side development overshadowed government report reveal week end jul crude oil inventory drop significantly barrel previous week investor fear full flag global trade war slow economic growth reduce oil demand worldwide moreover supply concern ease opec report saudi arabia enhance oil production june highest level end further libyan oil port have return normalcy tripoli base national oil corp noc lift ban impose february additionally secretary state mike pompeo state tuesday trump administration consider request country be exempt sanction unite state impose iran november jul wti crude drop settle barrel new york mercantile exchange brent crude fall end session barrel london base ice future europe exchange consequently share price energy behemoth chevron corp cvx free report exxon mobil corp xom free report halliburton co hal free report be respectively chevron sport zack rank strong buy see complete list today zack rank stock here economic labor department report producer price index ppi final demand increase june surpass consensus estimate june ppi jump year year biggest gain november core ppi exclude food energy trade service also rise june beating consensus estimate stock make headlinesbd buy tva medical provide minimally invasive procedurebecton dickinson co bdx free report recently complete acquisition texas base tva medical financial term deal have be keep wrapped read more hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
136,BDX,baxter international inc bax free report be schedule report second quarter earning jul market open expect company see steady growth back international venture majorly drive second quarter result raise guidance strategic collaboration be other tailwind last report quarter baxter post adjust earning share cent beat zack consensus estimate improve year quarter cent quarter be report zack consensus estimate revenue be peg reflect year year rise zack consensus estimate adjust earning share be peg cent indicate increase baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quotestrong international presence likely drive resultsbaxter have strong presence foreign market help company gain traction last report quarter company international sale account impressive total revenue baxter advanced surgery team recently launch tisseel prima europe furthermore japan company renal care team launch kaguya peritoneal dialysis technology last report quarter baxter see higher volume shipment iv solution mexico unite state company look forward reallocate additional iv solution select south america manufacturing facility management help revamp production process manufacturing facility unite state puerto rico other factor playrais guidancebaxter have raise guidance company expect sale growth constant currency cc project adjust earning share continue operation range full year zack consensus estimate be peg guide range second quarter company expect sale growth approximately cc baxter expect adjust earning continue operation cent zack consensus estimate be pin cent high end guide range strategic buyoutsbaxter have be banking strategic acquisition collaboration enhance exist product portfolio recently baxter complete acquisition preveleak mallinckrodt view boost surgical portfolio hemostat sealant notably company buy thrombin topical preveleak surgical sealant product line mallinckrodt buyout do not prove accretive last report quarter management expect deal be modestly reward acquisition claris injectable limit baxter expect revenue worth lately baxter announce partnership international society nephrology isn spread awareness chronic kidney disease awareness therapy emerge market reflect baxter focus specialize renal care be part baxter hospital product segment have be underperform last year baxter expect sale previous guidance however guide figure be much lower model predictsour quantitative model do not predict earning beat baxter quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate have be illustrated earning esp baxter have earning esp uncover best stock buy sell re report earning esp filter zack rank baxter carry zack rank stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter varian medical var free report have earning esp stock carry zack rank see complete list today zack rank stock here mckesson corporation mck free report have earning esp stock carry zack rank becton dickinson company bdx free report have earning esp stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
137,BDX,becton dickinson company bdx free report have top estimate trail quarters company currently have market capitalization approximately currently company face product recall issue foreign exchange headwind zack rank hold stock have rally outperform industry growth year time here take quick look major factor have be plague becton dickinson discuss factor ensure term recovery probable recall issuebecton dickinson also know bd recently recall product notably bd vacutainer edta lavender bd vacutainer lithium heparin green top tube be withdraw device be used collect blood sample vein product be suspect serious health hazard patient laboratory personnel moreover diabetes care business bd have temporarily pause shipment insulin infusion set be due moderately higher anticipate rate complaint associate insertion occur pilot launch product foreign exchange headwindsbd have strong international presence company generate high share revenue international operation get affected fluctuation foreign currency exchange rate strengthen dollar mar bd prospect regard dent such headwind zack consensus estimate bd current quarter earning share fall last day becton dickinson company price consensus becton dickinson company price consensus becton dickinson company quotewhat favore stock view upbeatbd raise fiscal guidance company expect adjust earning share represent growth approximately fiscal zack consensus estimate be peg lie guide range company raise revenue growth guidance fiscal be also high end previous guidance strong fundamentalsbd solid product portfolio strong international presence have help company garner strong revenue earning year notably company revenue have see cagr moreover earning see cagr share such upbeat performance continue provide cushion company stock bottom lineunhinder persistent issue analyst be optimistic bd current quarter revenue zack consensus estimate be peg reflect year year rise key picksa few better rank stock broader medical space be genomic health ghdx free report abiom abmd free report stryker corporation syk free report genomic health have expect earning growth rate current quarter stock sport zack rank strong buy see complete list today zack rank stock here abiom have project long term earning growth rate stock sport zack rank stryker have project long term earning growth rate stock carry zack rank buy hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
138,BDX,global medical device industry have demonstrated strong sustainable growth recent past banking age population increase incidence chronic lifestyle disease increase adoption artificial intelligence ai big datum application upbeat consumer sentiment increase business investment sector appear be pink health go kpmg datum medical device industry global annual sale be forecast rise more year reach nearly cision report say unite state be largest medical device market world present rake more revenue several socio political hazard economic dip medical device company have be ride high innovation increase consolidation emerge market expansion tax cut undoubtedly have be very profitable investment space late here be few major development abolition medtech tax bipartisan year suspension medical device tax impose excise tax medtech manufacturer mark temporary relief be again put effect jan repeal be expect boost hire investment america base medical device manufacturer thus instilling investor optimism ratification tax repeal amendment have encourage massive investment sector uptrend continuesapart tax relief medtech fraternity have also be ride high ongoing merger acquisition trend space fact various report suggest have be key catalyst drive healthcare space late datum provide biospectrum asia activity medtech space surge increase value aggregate more major acquisition recent past include becton dickinson company bdx free report acquisition bard johnson johnson jnj free report buyout actelion pbm health insurer health insurer have be look collaborate pharmacy benefit manager medtech space streamline cost drug supply chain buoy continue capital inflow strategic policy key medical device player have expand customer basis moderate leverage enhance cash flow have also alleviate pricing pressure competition medtech space regard latest buyout announcement express script cigna ci free report come just month drug chain pharmacy giant cvs health corp cvs free report announcement acquire nation third largest health insurer aetna be important digital revolution medtechlatest trend robotic surgery big datum analytic bio printing printing electronic health record ehr predictive analytic real time alert revenue cycle management service medtech space be gain prominence various report suggest strategic application ai sphere healthcare provide impetus productivity company adopt ai technology have witness reduction healthcare cost have also experience improve patient outcome more rise minimally invasive surgery higher demand liquid biopsy test use quick improve patient care shift payment system value base model have be drive profit medical device company late trade war fear grip medtechthe sector have be identify trump imposition higher tariff be now investor radar healthcare include medical equipment be sector likely bear brunt trade dispute go datum provide article christian jone mondaq medtech firm unite state currently sell annually china nation import china total medical device export medical device last year totale create worldwide trade surplus needless say medical device lobby be extremely apprehensive propose tariff chinese product significantly affect international trade zack industry rankwithin zack industry classification medical device be broadly group medical sector zack sector further sub divide industry expand level medical instrument medical product medical dental supply medical info system rank industry zack sector base earning outlook fundamental strength constituent company zack industry rank be top zack classify industry medical info system top medical dental supply top medical instrument bottom medical product backtesting show top zack rank industry outperform bottom factor more analyze zack industry rank different medical device segment be say apart certain medical product stock term outlook aforementioned medical device subsector be overall positive price price performance major zack categorize sub industry be follow past day have gain med instrument space have rise stock space have be trading be varian medical system inc var free report steris plc ste free report edward lifescience corp ew free report medical product subsector industry rank indicated bearish tone sector have increase period player space be haemonetic corp hae free report baxter international inc bax free report boston scientific bsx free report zack ipo watch listbefore look stock mentioned want get head start potential tech ipos be pop zack radar imagine be first wave investor jump company almost unlimited growth potential special report give current scoop go public time have drive valuation year other be little less obvious already show jaw drop growth download ipo watch list today free
139,BDX,bid strengthen medical management solution mms segment becton dickinson company bdx free report popularly know bd recently collaborate indiana base helmer scientific introduce refrigerate solution used bd new pyxis es refrigerator notably solution be first kind have be integrate automate dispense system post announcement new jersey base medical technology company share price drop marginal however past month bd rally impressive significantly outperform industry decline believe such favorable development provide cushion stock notably helmer scientific offer secure medical grade refrigerator freezer blood bank storage clinic lab pharmacy hospital research center university stock currently carry zack rank hold mms pyxis es system be significant contributor mms platform provide automate medication dispense system support decentralize medication management revenue last report quarter grow mms unit management upside be drive strong pyxis es adoption unite state well international growth come back news notification bd pyxis es be see bd healthsight viewer platform unique combination connective technology analytic expert service helmer access technology new bd pyxis es refrigerator provide storage refrigerate medication require temperature monitoring mms prospectsper research global medication management system market be expect reach value be poise see cagr period hence be conclude bd move have be timely strategic key picksa few better rank stock broader medical space be abiom inc abmd free report varian medical var free report intuitive surgical inc isrg free report abiom have expect long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate stock sport zack rank varian medical have project long term earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
140,BDX,have be month last earning report becton dickinson company bdx free report share have lose time frame recent negative trend continue lead next earning release be bdx due dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst recent earningsbecton dickinson post second quarter fiscal earning beat zack consensus estimate earning also improve year year cc bd post revenue surpass zack consensus estimate revenue rise cc year year basis revenue surge buoy synergy acquisition bard segment detailsbd medicalthe segment post worldwide revenue cc management strong result be drive medication delivery solution diabetes care pharmaceutical system unit bd life revenue segment come reflect increase cc revenue growth reflect strong performance diagnostic system bioscience unit however growth preanalytical system unit be negatively impact production issue product line be resolve quarter segment growth be aid flu related revenue diagnostic system unit result stronger flu season comparison prior year bd report quarter segment post worldwide revenue cc segment result reflect strong performance peripheral intervention urology critical care unit solid growth surgery unit geographic resultsussale unite state come cc second quarter bd medical segment account revenue unite state bd life science account revenue bd interventional record unite state outside unite state come cc upside be drive strong performance bd medical bd life science bd interventional segment internationally bd medical post revenue worth bd life science rake international revenue bd interventional contribute margin analysisin report quarter gross profit totale year year bd post operate income guidancebuoy solid fiscal second quarter performance bd raise fiscal guidance company expect adjust earning share increase estimate benefit foreign currency represent growth approximately fiscal company raise revenue growth guidance fiscal be also high end previous guidance have estimate be move then past month investor have witness downward trend fresh estimate have be revision higher current quarter compare lower becton dickinson company price consensus becton dickinson company price consensus becton dickinson company quotevgm scoresat time bdx have average growth score however momentum be do lot better stock be allocate grade value side putt top investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be primarily suitable momentum investor also be suitable look value lesser degree growth outlookestimate have be broadly trend downward stock magnitude revision indicate downward shift interestingly bdx have zack rank hold expect line return stock next few month
141,BDX,president donald trump call summit north korean leader kim jong last thursday be quite shocker abandonement summit plan dealt blow underpenetrated emerge market asia be solid source revenue more base multinational company effect political mayhem cause msci broadest index asia pacific share outside japan south korea kospi japan nikkei plummet major wall street index dow jone industrial average lose ground well consider trend downward movement white house decide conduct meeting unite state announce plan send pre advance team singapore prepare trump kim summit jun medtech appear be very few sector shelter investor political tension shrug current volatility medical product industry have return call fall fact analyst believe medtech sector be able strengthen foothold faster rate meeting go plan be be number base medtech company operate asia post success summit company be able spread network north korea augment overall production research statista medtech market asia pacific region be estimate reach worth buoy encourage projection rather be interesting see medical product company be place political turmoil medtech stock gainmeanwhile medical product company have already be gain organic growth innovation higher consolidation tax abolition well focus emerge market include japan south korea china vietnam india philippine more fact stakeholder medical universe have be eyee market last couple year company be bullish grow medical awareness economic prosperity age population increase wealth government focus healthcare infrastructure expansion medical insurance coverage apac space take look lead medtech player be gain prospect apac market becton dickinson company bdx free report popularly know bd particularly focus broader emerge market india china brazil turkey economic healthcare sector be grow rapidly particular safety engineer product continue drive growth emerge market believe exposure market boost top line turn accelerate ep growth zack rank hold company share have return year significantly higher index gain baxter international bax free report solid presence asia precisely india be worth mention company have research hub japan china recently baxter complete acquisition india base claris injectable global generic injectable pharmaceutical company almost zack rank buy stock have outperformed index year time stock have return intuitive surgical inc isrg free report grow interest emerge market specifically apac region bode well past year company procedure performance asia project consistent strength company register solid growth china japan korea zack rank strong buy company share have return year see complete list today zack rank stock here boston scientific corporation bsx free report growth strategy comprise pursuit development opportunity outside unite station strengthen global presence inclusive emerge market backdrop flatten decline sale growth develop market unite state europe boston scientific be fortify foothold emerge market brazil russia india china bric first quarter business emerge market register growth business china be once again remarkable year year company be currently project improvement performance china banking recent approval synergy zack rank stock have return year thing remember thing be not so easy appear be american never forget former president george bush refer north korea axis evil sponsored terrorism have solid access nuclear weapon further north korea multiple trial nuclear warhead have dampen country relationship analyst believe unforeseen summit not solve age old problem further guarantee kim jong tremendous anger open hostility not offend trump anymore do last week however trump team be expect reach agreement settle north korean nuclear other issue meeting today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
142,BDX,becton dickinson company bdx free report post second quarter fiscal earning beat zack consensus estimate earning also improve constant currency cc becton dickinson also know bd post revenue worth surpass zack consensus estimate revenue rise cc year year basis revenue surge acquisition bard meanwhile bd share have gain compare industry bd currently carry zack rank hold becton dickinson company price consensus ep surprise becton dickinson company price consensus ep surprise becton dickinson company quotesegment detailsbd medicalthe segment post worldwide revenue cc management strong result be drive strength medication delivery solution diabetes care pharmaceutical system unit bd life revenue segment come reflect increase cc revenue growth reflect strong performance diagnostic system bioscience unit however growth preanalytical system unit be negatively impact production issue product line be resolve quarter segment growth be aid flu related revenue diagnostic system unit result stronger flu season comparison prior year bd report quarter segment post worldwide revenue cc segment result reflect strong performance peripheral intervention urology critical care unit solid growth surgery unit geographic resultsussale unite state come cc second quarter bd medical segment account revenue unite state bd life science account revenue bd interventional record unite state outside unite state come cc upside be drive strong performance bd medical bd life science bd interventional segment internationally bd medical post revenue worth bd life science rake international revenue bd interventional contribute margin analysisin report quarter gross profit totale year year bd post operate income year year basis guidancebuoy solid fiscal second quarter performance bd raise fiscal guidance company expect adjust earning share increase estimate benefit foreign currency represent growth approximately fiscal notably zack consensus estimate earning share lie range company raise revenue growth guidance fiscal be also high end previous guidance takebecton dickinson end fiscal second quarter promising note strong growth bd medical be primarily drive medication delivery solution diabetes care pharmaceutical system unit meanwhile acquisition bard have proven accretive fiscal second quarter result internationally bd post strong revenue have maintain global foothold however decline margin raise concern recent product recall foreign exchange volatility be also likely mar company prospect key picksa few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past zack consensus estimate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
143,BDX,ecolab inc ecl free report report fourth quarter adjust earning share miss zack consensus estimate penny earning improve year quarter ecolab carry zack rank hold include net discrete tax benefit tax reform cent share ecolab register earning report basis adjust quarterly net sale be year quarter also net sale miss zack consensus estimate ecolab inc price consensus ep surprise ecolab inc price consensus ep surprise ecolab inc quotesegmental analysisglobal industrial segmentsale segment grow year year almost upside be drive major gain water food beverage life science unit europe north america latin america lead global industrial regional growth acquisition adjust fix currency operate income improve year year basis global institutional segmentsale increase lead strong growth specialty business line segment witness solid growth north america asia pacific acquisition adjust fix currency operate income remain flat year year global energy segmentsale rise owing strong growth well stimulation business modest gain downstream business acquisition adjust fix currency operate income increase year year other segmentsale decline year year sale segment witness robust growth north america margin analysisas percentage revenue ecolab register adjust gross margin fourth quarter basis point bps year year basis adjust operate margin fourth quarter contract bps net revenue outlookecolab expect full year adjust earning range share year year percentage revenue adjust gross margin be expect range first quarter ecolab expect adjust earning range cent share previous range cent current outlook reflect increase year year adjust gross margin first quarter be expect be net revenue takeecolab end fourth quarter unfavorable note miss zack consensus estimate count strength pest elimination business other segment decline year year report basis ecolab operate highly competitive market mar prospect long haul believe volatility foreign currency exchange rate remain significant headwind company ecolab face pricing pressure energy segment be likely hurt profit brighter side strong guidance instill optimism stock further europe north america latin america lead global industrial regional growth quarter strength global institutional segment lead growth specialty healthcare business line be also positive robust product portfolio expand customer base be likely drive organic sale long haul key picksa few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal adjust earning share cent prior year quarter revenue rise perkinelmer post fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter fiscal adjust earning share constant currency revenue totale constant currency hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
144,BDX,henry schein inc hsic free report report adjust earning share ep cent fourth quarter year year adjust ep remain line zack consensus estimate year year upside earning be drive strong revenue growth business segment adjust ep year be improvement year period also remain line zack consensus estimate revenue detailhenry schein report net sale fourth quarter year year marginally zack consensus estimate year year improvement come back internal sale growth local currency increase owing foreign currency exchange acquisition growth be quarter net sale full year be improvement year number top line also exceed zack consensus estimate henry schein inc price consensus ep surprise henry schein inc price consensus ep surprise henry schein inc quotein fourth quarter company record sale north american market year year sale totale international market year year segment analysis henry schein derive revenue operate segment dental medical animal health technology value add service fourth quarter company derive revenue global dental sale year year include growth local currency contribution foreign currency exchange local currency internally generate sale increase acquisition growth be quarterly result also have negative impact additional week year period internal growth local currency include growth north america rise internationally company global animal health segment witness rise revenue include growth local currency increase foreign currency exchange local currency internally generate sale increase acquisition growth be extra week have negative impact quarterly sale performance internal growth local currency include rise north america improvement internationally worldwide medical revenue rise year year growth local currency be increase owing favorable foreign exchange revenue global technology value add service grow include growth local currency rise related foreign currency exchange acquisition contribute quarter review margin trend gross profit increase report quarter however gross margin contract basis point bps year quarter due rise cost sale higher revenue growth rate rise selling general administrative expense adjust operate income improve year year however adjust operate margin decline bps year year report quarter financial positionhenry schein exit year cash cash equivalent compare end full year net cash provide operate activity be compare year period quarter review company buy back approximately share almost close fourth quarter company have authorize repurchase common stock guidancehenry schein raise ep guidance reflect impact tax reform legislation include estimate cent impact associate certain time cash bonus company currently expect ep range reflect growth report ep figure previous ep guidance range be zack consensus estimate adjust ep be guide range takehenry schein exit fourth quarter mixed note company operate segment record strong year year growth henry schein strong share gain north american overseas market solid revenue raise optimism better expect revenue performance be disappoint year year deterioration henry schein gross operate margin due higher cost sale expense increase ep guidance buoy optimism zack rank key pickshenry schein have zack rank hold better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
145,BDX,idexx laboratory inc idxx free report have be gain investor confidence consistently positive result stock have rally last year ahead gain broader industry rise moreover lead manufacturer product service primarily companion animal veterinary livestock poultry have market cap company year historical growth rate be also favorable compare industry solid prospect zack rank buy stock be attractive pick investor moment company estimate revision trend current year have be positive last day analyst revise estimate upward movement opposite direction estimate revision earning increase share same time frame style score idexx laboratory sport growth score be reflective company strong prospect research show stock growth style score combine zack rank strong buy offer best upside potential regard idexx laboratory have favorable net margin net income sale industry negative company sale asset ratio versus industry signify be solid growth pick let find recent positive trend be sustainable idexx exit fourth quarter promising note strong year year growth organic revenue be encourage stellar performance be drive strong sale cag business fourth quarter cag organic revenue rise low double digit strong cag diagnostic recur organic revenue growth vetlab consumable organic revenue growth be upbeat company expand premium instrument base unite state international market include growth competitive instrument placement increase utilization continue customer retention regard be optimistic gain commercial launch catalyst sdma test north america january company point care customer be able add sdma essential element routine chemistry panel continue slew development january idexx enter global agreement diagnostic company apply biocode agreement idexx bring reference laboratory customer digital multiplex platform build apply biocode management aim commercial launch technology companion animal market fundamental remain solid tremendous global runway growth management innovation base multus modality global strategy accelerate recur cag diagnostic revenue growth report quarter moreover strong top line growth quarter be drive considerable contribution rest business segment furthermore raise guidance earning share instill confidence stock be also upbeat company witness double digit organic revenue growth international business reflect continue consumable revenue gain support catalyst instrument base average testing utilization additionally company have strong cash balance allow carry share repurchase meanwhile idexx high reliance third party distributor be concern moreover competitive landscape domestic overseas market weigh company other key picksother top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
146,BDX,medtronic plc mdt free report report third quarter fiscal adjust earning share ep beating zack consensus estimate penny earning rise year year adjustment quarter primarily include impact restructure charge intangible asset amortization divestiture related item acquisition related item adjust unfavorable foreign exchange impact penny adjust ep be adjustment company report net loss share compare cent previous year include net tax expense related tax reform total revenue report quarter gross constant exchange rate cer basis report basis top line surpass zack consensus estimate foreign currency fluctuation favorably impact medtronic third quarter revenue quarter review sale total revenue fall year year cer develop market revenue totale total revenue reflect increase cer report emerge market revenue total revenue amount cer report medtronic plc price consensus ep surprise medtronic plc price consensus ep surprise medtronic plc quote segment company currently generate revenue major group viz cardiac vascular group cvg minimally invasive therapy group mitg restorative therapy group rtg diabetes group cvg comprise cardiac rhythm heart failure crhf coronary structural heart csh aortic peripheral vascular division apv mitg now include surgical innovation si respiratory renal rgr division divestiture patient care deep vein thrombosis compression nutritional insufficiency enteral fee business rtg comprise spine brain therapy specialty therapy pain therapy segment diabetes group incorporate intensive insulin management iim intensive diabetes therapy ndt diabetes service solution dss division cvg revenue improve cer report drive strong balanced growth division crhf sale totale year year cer report come back growth arrhythmia management lead high teen growth atrial fibrillation solution cer amplify penetration micra transcatheter pace system strong uptake tyrx absorbable antibacterial envelope apart strong demand company suite quadripolar cardiac therapy pacemaker crt growth mechanical circulatory support drive heart failure division revenue csh revenue be cer report back low constant currency growth transcatheter aortic valf result strong customer uptake corevalve evolut pro platform expand fda approval include patient intermediate risk moreover continue uptake resolute onyx drug eluting stent unite state japan revive coronary business apv revenue register growth cer report drive continue adoption valiant stent graft system peripheral be drive double digit growth percutaneous transluminal angioplasty drug coat balloon moreover solid contribution venaseal closure system drive high single digit growth endovenous mitg worldwide sale reach mark year year increase cer report basis high single digit growth si low single digit growth rgr cer rtg worldwide revenue be year year cer report low double digit growth brain therapy mid single digit growth specialty therapy high single digit growth pain therapy cer however revenue spine business remain flat cer year year basis moreover revenue diabetes group increase cer report marginsgross margin report quarter expand basis point bps rise gross profit adjust operate margin expand bps year year owing rise research development expense uptick selling general administrative expense other expense report quarter totale compare year quarter reiterate fiscal constant currency revenue ep guidance company maintain full year revenue growth projection range cer however company revise foreign currency fluctuation estimation be now project have positive impact fiscal result compare estimate earlier zack consensus estimate revenue remain fiscal adjust earning share growth be still expect range cer currency translation be likely have adverse impact cent compare earlier expectation negative effect cent zack consensus estimate fiscal earning be peg fourth quarter fiscal medtronic expect currency translation have favorable impact revenue currency translation be expect affect fourth quarter earning share cent takemedtronic exit fiscal third quarter solid note company demonstrated improve segmental performance cer growth business segment however escalate cost continue be concern moreover major business group contribute solid top line growth cer highlighted sustainability group region addition display successful integration achievement synergy target be also encourage company solid growth trend unite state well healthy global acceptance advanced therapy apart product innovation company be focuse geographical diversification business moreover company recent receipt fda approval riptide aspiration system neurovascular unit rtg business buoy optimism add valuable tool company acute ischemic stroke ais product portfolio zack rank peer have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal adjust earning share cent prior year quarter revenue rise perkinelmer post fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter fiscal adjust earning share constant currency revenue totale constant currency hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
147,BDX,base new jersey becton dickinson company bdx free report be medical technology company engage principally development manufacture sale medical device instrument system reagent product be used healthcare institution life science researcher clinical laboratory pharmaceutical industry general public currently becton dickinson have zack rank buy change follow first quarter fiscal earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning becton dickinson adjust earning share beat zack consensus estimate increase constant currency cc basis becton dickinson company price ep surprise becton dickinson company price ep surprise becton dickinson company quoterevenue report revenue amount cc revenue also come zack consensus estimate key stat fiscal revenue include accretion acquisition bard be expect increase approximately cc company also expect adjust diluted earning share be represent growth approximately cc include accretion acquisition bard major factor bd medical generate revenue cc bd life science generate revenue cc stock price share have rise roughly last month broader industry have gain same time frame however follow earning release share price decrease pre market trading session check back later full becton dickinson company earning report more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
148,BDX,base new jersey becton dickinson company bdx free report be medical technology company engage principally development manufacture sale medical device instrument system reagent product be used healthcare institution life science researcher clinical laboratory pharmaceutical industry general public currently becton dickinson popularly know bd have zack rank hold change follow second quarter fiscal earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning bd post fiscal second quarter earning beat zack consensus estimate earning also improve constant currency cc revenue revenue come beating zack consensus estimate revenue also surge year quarter becton dickinson company price ep surprise becton dickinson company price ep surprise becton dickinson company quotekey stat bd medical generate revenue year quarter bd life science generate revenue year year major factor company have raise full fiscal year revenue adjust earning share guidance company have further reaffirm acquisition bard be expect be accretive adjust earning share high single digit basis fiscal year company have raise revenue guidance growth be high end previous guidance range full year adjust earning share be expect be reflect growth fiscal stock price share bd have rise roughly past year industry have gain same time frame however follow earning release share price do not show movement pre market trading session check back later full becton dickinson company earning report medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
149,BDX,first quarter earning season have take center stage member elite index have report financial number so far latest earning preview performance index participant indicate increase total earning higher revenue beat ratio have be impressive well company surpass bottom line expectation beating top line mark medical sector zack sector have put stellar show so far sector be expect rise revenue growth earning season await medical product stock medical product industry have be gain prominence late courtesy increase life expectancy rate age population change market dynamic use technologically superior device fact industry be not dependent just medical advancement solely nowadays rely technological advancement microelectronic instrumentation biotechnology software development industry well view trend investor sentiment have be solid medical product company fact industry have return compare rally year time further bipartisan suspension medical device tax have give significant boost sector first quarter meanwhile medtech bigwig baxter international bax free report ecolab ecl free report have report upbeat first quarter number company have beaten consensus estimate count strong outlook now let take look company be set release result becton dickinson company bdx free report second quarter fiscal result be likely show strong outcome core bd medical segment management steady growth sub segment medication procedural solution pharmaceutical system be expect be growth propeller however improvement other segment lead improve result read more bd medical drive becton dickinson earning zack consensus estimate second quarter earning be peg reflect year year growth bd have earning esp zack rank hold zack quantitative model stock advantageous combination solid zack rank strong buy buy positive earning esp have higher chance beating estimate uncover best stock buy sell re report earning esp filterbecton dickinson company price ep surprise becton dickinson company price ep surprise becton dickinson company quotecardinal health inc cah free report third quarter fiscal result be likely reflect decline core pharmaceutical segment growth other segment be likely make decline partially however raise guidance buoy optimism furthermore medical segment be expect post solid number medical glove unit result witness softness quarter be report read more store cardinal health earning zack consensus estimate third quarter earning be peg reflect decline year year company have earning esp zack rank see complete list today zack rank stock here cardinal health inc price ep surprise cardinal health inc price ep surprise cardinal health inc quoteteleflex incorporate tfx free report first quarter earning be expect be strong back vascular unit north america emea sale be also likely be high zack consensus estimate earning be pin indicate year year growth teleflex have earning esp zack rank teleflex incorporate price ep surprise teleflex incorporate price ep surprise teleflex incorporate quoteabiom inc abmd free report be likely see strong fourth quarter fiscal back flagship product line impella notably last report quarter impella revenue rise internationally impella revenue increase whopping plethora regulatory approval impella impella cp be encourage moreover increase guidance buoy optimism zack consensus estimate earning be cent reflect year year growth company have earning esp zack rank abiom inc price ep surprise abiom inc price ep surprise abiom inc quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
150,BDX,dentsply sirona inc xray free report first quarter result be schedule release market open company cad cam imaging platform be expect boost result quarter be report improvement other unit be tailwind well last report quarter dentsply post adjust earning share ep cent beating zack consensus estimate penny however metric decline year year net sale increase year quarter also figure surpass zack consensus estimate rise constant currency cc exchange rate currently zack consensus estimate earning quarter be report be peg cent share reflect decline year year zack consensus estimate net sale be project show improvement year year let delve major factor influence dentsply performance quarter be report expect dentsply company cad cam unit be likely drive top line first quarter cad cam be dental imaging platform major foundation global dental market last report quarter dentsply announce consistent focus sale force effectiveness be likely boost result present be sale force close person employ globally sale sale support quarter be report prospect innovation be other growth driver recently company announce plan redirect industry lead budget high impact project provide better competitive position dentsply sirona inc price ep surprise dentsply sirona inc price ep surprise dentsply sirona inc quotedentsply confirm have undertake measure reduce interest expense approximately end be likely boost first quarter result overall company have very low cost debt structure ample availability grow business make acquisition mar dentsply announce definitive agreement acquire orametrix lead industry provider innovative technology solution company also offer advanced cad platform develop dental professional deliver consistently predictable orthodontic outcome transaction be expect be complete second quarter dentsply overall growth strategy rest product innovation company solid internal growth challenge macroeconomic headwind be primarily drive innovative new product do model predict solid prospect quantitative model do not show beat dentsply earning season be stock need have positive earning zack rank strong buy buy hold be able beat estimate zack esp earning esp dentsply be uncover best stock buy sell re report earning esp filter zack rank dentsply carry zack rank strong sell notably caution stock zack rank sell go earning announcement especially company be see negative estimate revision stock worth lookhere be few medical stock worth consider have right combination element post beat earning season becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here cardinal health inc cah free report have earning esp zack rank cooper company inc coo free report have earning esp zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
151,BDX,investor be always look stock be poise beat earning season becton dickinson company bdx free report be such company firm have earning come pretty soon event be shape quite nicely report be becton dickinson be see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface bdx report analyst have very recently bump estimate bdx give stock zack earning esp head earning season becton dickinson company price ep surprise becton dickinson company price ep surprise becton dickinson company quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give bdx have zack rank esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead becton dickinson beat be card upcoming report look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
152,BDX,becton dickinson company bdx free report popularly know bd second quarter fiscal result be schedule release market open result be likely show steady growth core bd medical segment rise revenue other segment also act driver first quarter bd report earning share beat zack consensus estimate adjust earning increase constant currency cc year year basis revenue come beating consensus estimate show rise year quarter second quarter zack consensus estimate earning be peg reflect year year growth same revenue be pin indicate growth bd deliver average positive earning surprise trail quarters becton dickinson company price ep surprise becton dickinson company price ep surprise becton dickinson company quotelet delve deeper bd medical key growth driverin last report quarter bd medical account whopping company total revenue revenue segment rise cc year year basis management include headwind approximately basis point bps dispense change furthermore add legacy bard have lead accelerate growth segment be also encourage note second quarter zack consensus estimate segment be sequentially medication procedural solution mps revenue grow first quarter second quarter zack consensus estimate be peg sequentially growth be likely be drive continue strength pre filled flush device infection prevention surgical product diabetes care revenue grow growth pen needle yet zack consensus estimate quarter be pin sequentially pharmaceutical system revenue grow first quarter zack consensus estimate second quarter be show rise sequentially revenue medication management solution mms decline zack consensus estimate be sequentially other factor playview solidbd expect fiscal revenue growth range report basis however revenue be expect grow band company expect adjust earning share range previous range current range indicate growth approximately report basis cc management expect bd medical grow life science segment be expect rise growth new bd interventional segment be anticipate acquisition divestituresbd acquisition drive strategy have be instrumental drive growth recently bd acquire bard management bd be way become biggest medical technology device company world approximately annualize revenue closure takeover lead third new business segment bd interventional bd collaborative move fresenius medical care provide sodium chloride saline customer be also worth mention last year bd announce merit medical system have sign agreement acquire certain asset company bd life sciencesrevenue bd life science totale fiscal first quarter cc year segment performance be backed strong number bioscience diagnostic system preanalytical system unit segment also see solid growth outside unite state recently bd announce pre market approval fda bd onclarity hpv assay management be likely boost bd diagnostic system segment zack consensus estimate second quarter be pin sequentially quantitative model predict earning beat bd quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate zack esp earning esp bd be uncover best stock buy sell re report earning esp filter zack rank bd carry zack rank favorable zack rank increase predictive power esp other stock worth lookhere be few other medical stock worth consider have right combination element post beat earning season stryker corp syk free report have earning esp zack rank see complete list today zack rank stock here hologic inc holx free report have earning esp zack rank edward lifescience ew free report have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
153,BDX,trade war cacophony have spread far wide not spare investment world conflict world biggest economy have lead dow fall more point just day last week be gradually recover market be still fraught possibility other outbreak sector have be identify trump imposition higher tariff be now investor radar healthcare include medical equipment be sector face brunt trade dispute current most economist have initially expect china be fast adopt stance square america advantage point import tariff game response trump propose imposition annual tariff chinese product beij have announce initial reciprocal tariff roughly import unite state be supposedly prepare bolder counter attack wake tariff threat nobel prize winning economist robert shiller have warn impending economic crisis meanwhile bloomberg report state unite state maintain lead trade conflict china be unite state extent be monopsony market large number buyer thus nation stop purchasing chinese product china not be able channelize surplus canada indonesia same price however china not be able adopt tit tat strategy do not import same scale unite state accordingly follow last week crash market be slowly look news nation be likely resolve issue mutually be fuel recovery however talk extinguish possibility trade war completely be yet be see meanwhile investor be catch america first make china web be medical device catch storm state earlier trade representative robert lighthizer have identify healthcare sector be subject tariff more specifically trump have consider biomedicine high performance medical device include china advanced chemical medical equipment respectively needless say have trigger decline sector follow news chance china retaliation loss be widespread medical device sector bigwig take severe blow note sector have gain significantly profit earn number medical device company bric nation go market realist report company medtronic plc mdt free report becton dickinson company bdx free report abbott other see considerable weakness mar talk china trade war start do round stock be gradually revive rise chance nation negotiating certain term investor consider still extremely vulnerable widely expose trade conflict give huge business network mainland china have shortlist stock be face brunt tumultuous market condition zimmer biomet holding inc zbh free report zack rank strong sell lose mar note company have be investing heavily cash chinese reconstructive trauma market strategic investment region past several quarters improve operational sale performance be yielding result fourth quarter company witness improvement asia pacific business solid distributor order china particularly demonstrated strong growth thus form retaliation china impact company zimmer biomet holding inc price zimmer biomet holding inc price zimmer biomet holding inc quotemedtronic last report quarter medtronic business china show strength grow double digit accord company next decade china be expect be biggest health care market needless say zack rank hold company be expending large amount cash strengthen business market company be focuse develop public private partnership well execute channel optimization strategy see complete list today zack rank strong buy stock here medtronic plc price medtronic plc price medtronic plc quoteover last few year abbott free report have be lead emerge market investment trend total sale come region zack rank stock core establish pharmaceutical division epd business operate solely emerge geography lead position chinese pharmaceutical market brand generic last report quarter well china demonstrated double digit growth epd trade war not stock be extremely vulnerable position broad network diversify business base china abbott laboratory price abbott laboratory price abbott laboratory quotebreaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
154,BDX,go latest center disease control prevention report more adult be live diabetes prediabetic condition notably be gradually take shape deadly epidemic diabetes rate unite state have moved furthermore diabetes be seventh lead cause death unite state result approximately medical cost reduce productivity year article state obesity globally scenario be quite intriguing global report diabetes world health organization prevalence diabetes adult rise moreover worldwide expense related diabetes be international diabetes foundation notably projection related disease hint continuation present trend regard number patient age year diagnosed diabetes be expect rise international diabetes foundation go say rise incidence diabetes have open opportunity diabetes device maker market be expect see cagr reach worth report mordor intelligence globally market be expect value cagr transparency market research report thus investor be keen place bet healthcare space long term gain diabetes device market undoubtedly hold immense potential factor drive diabetes device marketrising healthcare expenditure unhealthy lifestyle practice expand treatment option have be drive demand center medicare medicaid service report publish advisory board healthcare spending be project rise represent gdp base assumption affordable care act continue diabetes device market be largely dependent age population census bureau report person age more be likely total almost double estimate population datum also show median age be increase most area country global scenario be pretty similar strengthen emerge market have be contribute largely rise demand diabetes care device report cision put more light report demand insulin delivery blood glucose monitoring device have be rise highly populate country china india accord international diabetes federation china record highest number diabetic patient follow india ai shape diabetes device artificial intelligence ai have be transform way diabetes be manage world tech medical device analytical predictive diagnostic tool be help create customize program support blood glucose management improve medication adherence go report statista worldwide revenue ehealth solution diabetes be expect furthermore market be expect see cagr accord report grow demand increase availability connect medical device home usage apps smartphone aid self management telemedical service service oriented apps have be stimulating growth niche market view mentioned factor number bigwig have be expending lump sum amount continuously innovate develop device improve efficacy side effect instance back medtronic plc mdt free report partner ibm watson utilize latter machine learn algorithms incorporate ai diabetes app minime company jointly launch first artificial pancreas system medtronic have utilize sugar iq cognitive compute capability ibm watson detect important pattern trend diabetes line development diabetes business february abbott laboratory free report announce availability freestyle librelink app europe use smartphone iphone android encouragingly note abbott be plan mobile app solution freestyle libre user outside europe base country regulatory approval moreover boston taipei hong kong bangalore base company have develop diabetes ai provide personalize metric analysis decision make tool physician patient improvise pre diabetes diabetes management stock bet onwe have select company believe tap promising prospect diabetes device market nordisk nvo free report company have strong presence diabetes care market global market share company boast most extensive diabetes portfolio industry encompass new generation insulin full portfolio modern insulin well once daily glp analog once weekly glp analog also company have strong presence total insulin modern new generation insulin market company have be ride high continue uptake long act insulin tresiba nordisk price nordisk price nordisk zack rank buy company have earning growth rate current year estimate revision trend stock have be encourage estimate move upward compare downward movement past month resultantly earning estimate increase share sanofi sny free report company have be commit develop strengthen insulin franchise lantus toujeo soliqua suliqua insulin company have launch soliqua suliqua unite state europe receipt approval insulin lispro biosimilar same region also note company have be gain substantially availability lantus country courtesy solid sale unite state china france germany sanofi price sanofi price sanofi zack rank hold company have earning growth rate current year estimate revision trend stock have be solid estimate move upward compare downward movement past month resultantly earning estimate increase share see complete list today zack rank strong buy stock here becton dickinson company bdx free report company commonly know bd offer portfolio syringe pen needle other product related injection infusion insulin other drug diabetes care business notably company have be consistently try improve performance diabetes care unit bd medical segment bd see diabetes care revenue growth constant exchange rate first quarter fiscal becton dickinson company price becton dickinson company price becton dickinson company quote regard company recently launch bd ultra fine micro pen needle mm use pen injection device needle offer comfortable injection experience enhance customer satisfaction bd have widen needle length option diabetic patient interestingly most insurance plan include medicare part cover bd ultra fine micro mm pen needle zack rank company have earning growth rate current fiscal estimate revision trend stock have be solid estimate move upward compare movement opposite direction past month resultantly earning estimate increase share conclusiona say strike iron be hot be opportune time cash bountiful opportunity rapidly grow diabetes device market hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
155,BDX,integrate medical care pharmacy benefit roof express script hold company esrx free report recently announce be get acquire cigna corporation ci free report global health insurance company acquisition be expect be complete dec post acquisition combine company invest charitable foundation support community operate definitive agreement cigna take express script cash stock transaction worth notably include cigna assumption approximately debt express script express script be largest pharmacy benefit manager express script sport zack rank strong buy see complete list today zack rank stock here express script stock have outperformed industry past year specifically company share have gain compare industry rally term deal cigna pay cash share stock newly combine company closure express script shareholder own approximately combine company transaction result total cost synergy double digit accretion earning first year closure result cigna expect deal increase earning share latest acquisition have be undertake solely enhance customer base improve patient provider alignment express script hold company price express script hold company price express script hold company quoteu healthcare lead gamemerger acquisition have be key driver healthcare space lately glance major acquisition recent past becton dickinson company bdx free report acquisition bard johnson johnson buyout actelion deserve mention fact health insurer be try consolidate pharmacy benefit manager streamline cut cost drug supply chain notably latest buyout express script come just month drug chain pharmacy giant cvs health corp cvs free report agree take nation third largest health insurer aetna come post acquisition impact believe latest development big threat unitedhealth group incorporate unh largest health insurer own pharmacy benefit unit cvs health complete merger aetna move be also expect nullify threat amazon com inc be make huge expansion world pharmacy business recently commerce giant announce joint venture jpmorgan chase co warren buffett berkshire hathaway curb medical cost employee be moody rating express script moody investor service rating service arm moody corporation place baa senior unsecured long term rating express script notably obligation rate baa be subject moderate credit risk however latest rating have be keep review tag direction uncertain moody moody have not rate express script high credit risk solid position lead pharmacy benefit manager moderate leverage strong cash flow however moody be worry express script high customer concentration pricing pressure further company ongoing dispute anthem inc largest customer be concern moody express script experience decline script volume higher typical customer loss other challenge include fewer generic drug introduction softening mail order growth trend client focus cost saving transparency hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
156,BDX,fourth quarter earning season have take center stage member have report number season have turn be favorable so far especially revenue front sturdy revenue momentum be witness season average proportion positive surprise favorable revision trend present upcoming quarters latest earning preview total earning company have report result be year year higher revenue total company beat earning surpass revenue estimate member line release quarterly result week be decidedly bullish equity market be gradually demonstrate sequential improvement medical zack sector be expect fare impressively fourth quarter expect earning growth rate sector be revenue growth let take look major factor be likely influence earning result medical product company broader medical universe factor influence medtech tax benefitsas part tax overhaul corporate tax rate have be slash provide huge relief sector needless say medical device company cheer legislation well further news congress delay medical device tax year be huge boost industry player investor manufacturer appreciate delay be likely favor company activity favorable consumer behaviordespite political issue healthcare space change consumer demand market dynamic lead dramatic transformation entire healthcare system last couple year be evident grow prevalence minimally invasive surgery rise demand liquid biopsy test use ensure quick improve patient care shift payment system value base model let take look major medical product stock slate release quarterly report feb becton dickinson company bdx free report becton dickinson be schedule report first quarter fiscal result open bell notably zack consensus estimate first quarter revenue be peg year year zack consensus estimate first quarter earning be year year basis quarter be expect show sluggishness bd medical major revenue component majorly dampen earning first quarter expect improvement revenue other segment help company generate solid result zack consensus estimate bd medical revenue be peg indicate decline year quarter company innovative product pipeline be key catalyst plethora regulatory approval unite state international market be expand company product portfolio read more store becton dickinson earning quantitative model do not indicate earning beat becton dickinson quarter be stock need have positive earning esp zack rank strong buy buy hold beat estimate becton dickinson earning esp be stock carry zack rank uncover best stock buy sell re report earning esp filter becton dickinson company price consensus becton dickinson company price consensus becton dickinson company quote corporation abc free report be schedule report first quarter fiscal result market open notably zack consensus estimate first quarter revenue be peg year year zack consensus estimate first quarter earning be year year basis quarter be expect show steady growth pharmaceutical distribution segment significant contributor revenue zack consensus estimate pharmaceutical distribution segment be quarter review almost year quarter read more be poise beat earning proven model do not conclusively show earning beat quarter have earning esp stock carry zack rank corporation hold co price consensus ep surprise corporation hold co price consensus ep surprise corporation hold co quote laboratory corporation america holding lh free report laboratory corporation america holding also know labcorp be slate report fourth quarter result market open zack consensus estimate fourth quarter revenue be peg year year zack consensus estimate fourth quarter earning be year year basis several quarters dismal performance covance drug development witness revenue growth third quarter courtesy strong organic growth favorable foreign currency translation chiltern acquisition chiltern have add high complementary capability labcorp offering include scale expansion asia pacific wider reach fast grow emerge mid tier biopharma customer segment expertise oncology drug development factor be likely drive labcorp covance drug development top line yet be report quarter read more covance drug development drive labcorp lh free report earning proven model do not predict earning beat company season thank earning esp zack rank see complete list today zack rank stock here laboratory corporation america holding price consensus ep surprise laboratory corporation america holding price consensus ep surprise laboratory corporation america holding quote cerner corporation cern free report cerner be set report fourth quarter result market close zack consensus estimate fourth quarter revenue be peg year year zack consensus estimate fourth quarter earning be cent share flat year year basis company be expect show steady growth system sale major revenue component be expect drive fourth quarter result expect improvement revenue other segment help company generate solid result zack consensus estimate system sale revenue be peg last quarter growth cerner license software subscription cerner be expect witness strong performance segment read more higher system sale drive cerner earning quantitative model do not predict earning beat cerner fourth quarter stock have zack rank earning esp cerner corporation price consensus ep surprise cerner corporation price consensus ep surprise cerner corporation quote today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
157,BDX,edward lifescience corporation ew free report announce receipt ce mark self expand centera valve valve be used severe symptomatic aortic stenosis patient high risk open heart surgery however centera valve be not approve commercial sale unite state company edward centera valve be repositionable retrievable be deliver low profile french motorize delivery system ce mark be base centera eu trial result be present europcr study enrolled high risk patient center europe australia new outcome trial demonstrated high survival rate low rate disable stroke new permanent pacemaker day regulatory approval be likely boost company transcatheter heart valf thv segment precisely thv focusthv segment include technology design treat heart valve disease used catheter base approach opposed open surgical technique fourth quarter company report thv sale growth prior year quarter double digit procedure growth europe latest development be likely further enhance company prospect europe outside unite state underlie growth rate be contribution region late edward lifescience have witness multiple development thv segment edward lifescience announce receipt fda approval aortic mitral valve valve procedure used sapien transcatheter heart valve june management release positive patient outcome sapien valve include high survival rate low rate stroke paravalvular leak market potentialtaking consideration huge growth potential thv market recent ce mark centera valveis strategic persistence market research report global heart valve repair replacement market be project reach worth cagr share price estimate revision trendedward lifescience have be gain investor confidence consistently positive result last year company share price have outperformed industry stock have gain compare industry current estimate revision trend be favorable current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have rise share zack rank other key picksedward lifescience carry zack rank buy few other top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
158,BDX,medtronic plc mdt free report have present positive datum home pediatric study patient age year notably datum be base minime system be demonstrated advanced technology treatment diabetes international conference vienna austria study result multus center study have enrolled participant year age group trial consist week run phase study phase month participant choose continue used system part continue access program moreover study result demonstrated datum pivotal trial minime system patient age year used study result company have apply expand fda approval include patient range year eligible used minime system same time company be work expand usage product child age year hope be harbore effectiveness system get greater customer adoptability time minime glancepost receipt fda approval medtronic have commercially launch minime system june be hybrid close loop insulin delivery system type diabetic patient age year older minime system feature medtronic latest guardian sensor glucose sensor increase accuracy enhance performance be only fda approve sensor control hybrid close loop system include diagnostic technology continuously check sensor health system also carry medtronic most advanced algorithm know smartguard hcl technology development diabetes witness sluggish growth diabetes business last quarter however company gain strong uptake new sensor augment insulin pump system unite state well international market growth be temporarily offset limit supply continuous glucose monitor cgm sensor moreover strong customer enrollment priority access program briefly affected revenue management diabetes business witness revenue growth third quarter fiscal company have finished shipping pump priority access program also company be move steadily sensor capacity expansion plan schedule be complete fourth quarter fiscal additionally medtronic gear international launch minime launch cgm system guardian connect sugar iq late new professional cgm ipro regard company also announce favorable result support use cgm person type diabetes october apart be upbeat corporation johnson johnson diabetes care company exit insulin pump business medtronic partner support transition patient caregiver healthcare provider notably patient used insulin pump be offer choice switch medtronic pump market potentialan agee population unhealthy lifestyle rise awareness expenditure healthcare be likely drive growth diabetes market report mordor intelligence global market diabetes care device be project reach value cagr give bullish market sentiment believe latest positive study result have come opportune moment share price have be gain investor confidence consistently positive result past month company share price have outperformed broader industry stock have gain comparison broader industry increase zack rank key picksmedtronic carry zack rank hold better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report perkinelmer have long term expect earning growth rate stock carry zack rank buy bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate becton dickinson company be zack rank player company have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
159,BDX,month have go last earning report becton dickinson company bdx free report share have lose time frame recent negative trend continue lead next earning release be bdx due dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst recent earningsbecton dickinson company popularly know bd report first quarter fiscal earning share beat zack consensus estimate adjust earning increase constant currency cc year year basis company report revenue beating zack consensus estimate represent increase prior year quarter cc segmental analysisbd medicalthe bd medical segment generate revenue cc year year basis segment result reflect adverse impact change dispense business model however bd medical witness strong performance medication procedural solution well diabetes care pharmaceutical system unit medication procedural solution register revenue bd medical segment year year cc diabetes care report revenue cc year year basis pharmaceutical system report revenue cc year year basis however medication management solution report revenue cc year year basis bd life bd life science segment generate revenue cc year quarter segment performance indicate strong number bioscience diagnostic system preanalytical system unit preanalytical system record revenue first quarter cc year year basis diagnostic system report revenue year year cc meanwhile bioscience unit register revenue cc geographic resultsunite statesu revenue be roughly year year basis bd medical segment growth medication procedural solution diabetes care unit be offset decline medication management solution pharmaceutical system unit bd life science segment result unite state be primarily drive diagnostic system preanalytical system unit report quarter international revenue rise cc bd medical bd life science segment register strong growth outside unite state bd medical segment growth be drive strength pharmaceutical system unit aid impressive result medication procedural solution diabetes care unit guidanceinclude accretion bard acquisition bd expect fiscal revenue increase range report basis however revenue be expect grow range notably revenue be likely be affected change dispense business model company expect adjust earning share range previous range current range indicate growth approximately report basis approximately cc have estimate be move then past month investor have witness upward trend fresh estimate have be revision higher current quarter compare lower becton dickinson company price consensus becton dickinson company price consensus becton dickinson company quotevgm scoresat time bdx have poor growth score however momentum be do lot better stock be allocate grade value side putt middle investment strategy overall stock have aggregte vgm score aren focuse strategy score be be interested style score indicate stock be more suitable momentum investor value investor outlookestimate have be broadly trend upward stock magnitude revision look promising notably bdx have zack rank hold expect line return stock next few month
160,BDX,chimerix inc cmrx free report report net loss continue operation cent share fourth quarter wider net loss cent year however same be narrower zack consensus estimate loss cent full year net loss come share narrower year revenuesin fourth quarter chimerix report contract revenue year year top line however exceed zack consensus estimate year year decline result fall reimbursable expense related company barda developmental contract full year contract revenue come drop year period level research development expense totale year year report quarter downside be primarily due ongoing advance trial initiation adapt trial general administrative expense amount surge year year primarily increase market education launch readiness chimerix inc price consensus ep surprise chimerix inc price consensus ep surprise chimerix inc quote consequently loss operation come wider prior year quarter operate loss be attribute significantly lower revenue year year escalate cost expense exit cash cash equivalent short term investment compare record end takechimerix exit fourth quarter positive note narrower estimate loss revenue surpass zack consensus estimate however year year decrease top line be concern nonetheless be encourage company progress fourth quarter courtesy advancement lead product candidate brincidofovir company witness impressive enrollment multiple ascend dose study iv bcv quarter review company commence adapt study unite state eu study be design provide comparative datum brincidofovir patient life threaten adenovirus infection company be also progress well ongoing first time human study cmx zack rank key pickschimerix have zack rank hold few better rank stock have already report solid earning result be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal result adjust earning share cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter fiscal adjust earning share constant currency revenue totale constant currency basis wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
161,BDX,bio rad laboratory inc bio free report report fourth quarter earning share year loss cent thus make huge improvement zack consensus estimate be peg earning share notably net income quarter be favorably impact substantial benefit tax cut job act net sale come year year constant exchange rate cer top line closely beat zack consensus estimate year year rise sale be largely drive strong sale life science product include continue sturdy sale droplet digital pcr instrument consumable cell biology product quarter detailon segmental basis life science net sale come year year cer also sale droplet digital pcr ddpcr cell biology product line process medium rise back strong performance cer geographically north america europe asia pacific demonstrated sturdy flourish bio rad laboratory inc price consensus ep surprise bio rad laboratory inc price consensus ep surprise bio rad laboratory inc quote clinical diagnostic company register sale year year cer upside result increase blood typing immunology diabetes quality control product line gross margin report quarter contract basis point bps year year climb gross profit adjust operate margin however expand basis point surge adjust operate profit company exit year cash cash equivalent short term investment compare end full year net cash provide operate activity be compare year guidance bio rad expect currency neutral revenue growth approximately outlook anticipate continue strong sale life science segment increase growth diagnostic zack consensus estimate be peg operate margin constant exchange rate be target revenue bottom linebio rad post strong quarterly performance earning sale show sharp year year improvement sale growth be majorly drive company many life science product line diagnostic instrument placement be solid promising guidance further instill confidence stock however contraction gross margin quarter review be due toescalate warranty service cost largely associate higher instrument placement zack rank key picksbio rad have zack rank hold few better rank medical stock be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm perkinelmer sport zack rank strong buy becton dickinson company carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal result adjust ep cent soar prior year quarter revenue rise perkinelmer report fourth quarter adjust ep cent adjust revenue be approximately year earlier quarter becton dickinson report first quarter adjust ep constant currency revenue totale constant currency basis hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
162,BDX,opko health inc opk free report report loss cent share fourth quarter compare loss cent year zack consensus estimate quarter be peg loss cent company report full year loss cent compare unfavorably year loss cent revenuesin fourth quarter opko health generate total revenue year year report figure also miss zack consensus estimate net revenue totale year number gross profit fourth quarter be year year gross margin contract massive basis point bps year quarter opko health inc price consensus ep surprise opko health inc price consensus ep surprise opko health inc quoteresearch development expense totale year year selling general administrative expense amount consequently loss operation come highlight significant decline operate loss prior year quarter decline be attribute rise operate expense owing company significant investment associate commercial launch rayaldee consistent investment pharmaceutical pipeline financialsopko health exit cash cash equivalent marketable security compare record end takeopko health exit fourth quarter disappointing note nonetheless be encourage ongoing development company business include diagnostic business bio reference laboratory pharmaceutical business be also upbeat opko health grow revenue genedx bio reference genetic testing unit kscore test quarter however rise operate expense continue mar company financial zack rank key picksopko health have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal result adjust earning share cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter fiscal adjust earning share constant currency revenue totale constant currency hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
163,BDX,medtronic plc mdt free report announce fda have approve new arm indication guardian sensor continuous glucose monitor cgm used minime insulin pump notably guardian sensor be company latest most accurate cgm medtronic be only sensor have receive fda nod control automate insulin delivery hybrid close loop system minime be important note medtronic commercially launch minime system june system be hybrid close loop insulin delivery system type diabetic patient age year older minime system feature medtronic guardian sensor glucose sensor increase accuracy enhance performance new arm indication guardian sensor now offer more convenience flexibility patient be available unite state use minime system progress minime have be forge ahead initiative boost performance minime portfolio recently company expand product portfolio unveil minime advance infusion set recent offer diabetes business be commercially available canada hong kong certain country europe fourth quarter fiscal however company plan extensive launch same also company report positive datum home pediatric study patient age year outcome be base minime system be demonstrated advanced technology treatment diabetes international conference vienna austria development diabetes witness rise constant exchange rate diabetes business revenue third quarter fiscal company benefit positive uptake new sensor augment insulin pump system unite state well international market enhance production capacity same notably medtronic expect double digit growth segment fourth quarter fiscal courtesy consistent performance minime system unite state enhance sensor supply capacity additionally medtronic have be gear international introduction minime launch cgm system guardian connect sugar iq late new professional cgm ipro regard company have earlier announce favorable result support use cgm patient type diabetes october market potentialan agee population unhealthy lifestyle rise awareness well expenditure healthcare be likely drive growth diabetes market report mordor intelligence global market diabetes care device be project reach value cagr consider bullish market sentiment believe latest development have arrived opportune moment stock performance estimate revisionover last month share medtronic have underperform industry stock hasdipped industry growth index gain also estimate revision trend current year remain unfavorable estimate move south last month compare couple opposite direction earning estimate inched share same time frame zack rank key picksmedtronic carry zack rank hold few better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report perkinelmer have long term expect earning growth rate stock carry zack rank buy bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate becton dickinson company be zack rank player company have long term expect earning growth rate don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
164,BDX,feb issue update research report myriad genetic inc mygn free report stock carry zack rank hold salt lake city ut base molecular diagnostic provider have be outperform broader industry past month company have rally industry decline myriad genetic exit second quarter fiscal promising note company particularly observed strong growth genesight testing revenue company molecular diagnostic portfolio have be gain prominence medtech space late be particularly upbeat newly launch range product myriad genetic have be record strong volume endopredict genesight test prolaris testing space volume continue grow double digit fiscal second quarter particular myriad genetic be focuse drive revenue commercialize innovative product include vectra da prolaris mypath melanoma myriad genetic companion diagnostic endopredict myplan lung cancer test earlier management expect product generate revenue more fiscal moreover myriad genetic have be consistently gain reimbursement approval report quarter company announce finalization lcd noridian endopredict thereby expand total coverage market also prolaris test be evaluation revise nccn guideline have be cover medicare patient intermediate risk also order gain reimbursement coverage vectra da genesight testing platform company have be undertaking certain measure furthermore raise fy guidance instill confidence be upbeat growth new product volume expand reimbursement new product increase international rna kit revenue meanwhile myriad genetic face competition key bracanalysis market company expect competition intensify owing advancement technology believe competitive headwind reduce price expensive test provide company impede margin improvement well moreover company receive considerable portion revenue pay portion expense foreign currency be risk exchange rate fluctuation foreign currency dollar key pickssome better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
165,BDX,abiom inc abmd free report scale new week high feb eventually close bit lower company share have gain last month compare broader industry gain headquarter danver abiom be engage develop manufacturing marketing medical product design assist replace pump function case heart failure be currently top perform stock medtech space improvement price performance strong fundamental indicate stock bullish run therefore haven take advantage price appreciation yet time add stock portfolio long term expect earning growth rate also hold promise solid stock have market cap abiom year historical growth rate be also favorable compare broader industry company have zack rank hold indicate robust fundamental expectation line performance term company have impressive growth style score growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank strong buy buy offer best investment opportunity factor drive stocklet take look major factor have be boost abiom late strong earning resultsabiom recently exit third quarter fiscal better expect revenue margin quarter company witness breakthrough term record revenue earning growth also expansion margin buoy optimism guidance raisedbase strong third quarter performance company raise fiscal revenue guidance again earlier fourth quarter revenue be estimate year year basis guidance operate margin fiscal have also be raise earlier expectation regulatory approval impella product lineabiom recently announce expand fda pre market approval pma flagship impella impella cp impella impella ld heart pump expand pma heart pump now be used treat heart failure associate cardiomyopathy lead cardiogenic shock include peripartum postpartum cardiomyopathy also abiom recently announce flagship impella impella cp heart pump have receive pma fda expand use product now be used elective urgent high risk percutaneous coronary intervention procedure bcc research global market cardiac medical device be project reach cagr consider prospect niche space expect abiom gain solid market traction year come northward estimate revisionfive estimate current quarter moved north past day southward revision indicate analyst optimism zack consensus estimate adjust earning increase current quarter much cent also year year growth be expect positive trend signify analyst bullish sentiment key pickssome better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson have zack rank company have long term expect earning growth rate breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
166,BDX,investor be always look stock be poise beat earning season becton dickinson company bdx free report be such company firm have earning come pretty soon event be shape quite nicely report be becton dickinsonis see favorable earning estimate revision activity late be generally precursor earning beat analyst raise estimate right earning most date information possible be pretty good indicator favorable trend surface bdx report fact most accurate estimate current quarter be currently share bdx compare broader zack consensus estimate share suggest analyst have very recently bump estimate bdx give stock zack earning esp head earning season becton dickinson company price ep surprise becton dickinson company price ep surprise becton dickinson company quotewhy be important positive read zack earning esp have proven be very powerful produce positive surprise outperform market recent year backtest show stock have positive earning esp zack rank hold better show positive surprise nearly time have return average annual return see more top earning esp stock here give bdx have zack rank buy esp positive territory investor want consider stock ahead earning see complete list today zack rank strong buy stock here clearly recent earning estimate revision suggest good thing be ahead becton dickinson beat be card upcoming report breaking news cryptocurrency now bigger visa total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
167,BDX,dentsply sirona inc xray free report announce preliminary fourth quarter result company report adjust earning share ep cent beating zack consensus estimate penny however preliminary result metric decrease year year preliminary net sale increase year also figure surpass zack consensus estimate rise constant currency cc exchange rate top line be favorably impact approximately result inventory build distribution channel stock carry zack rank sell dentsply sirona inc price ep surprise dentsply sirona inc price ep surprise dentsply sirona inc quotenet sale exclude precious metal impact net sale company precious metal dental alloy product be used third party construct crown bridge material be subject risk fluctuation precious metal price avoid impact fluctuate price dentsply report net sale precious metal content show actual performance independent precious metal price volatility preliminary net sale segment be year year segmental business be organized report segment dental healthcare consumable technology dental healthcare segment comprise preventive restorative instrument endodontic laboratory dental product well consumable medical device product preliminary result sale improve segment cc technology equipment consist dental implant cad cam system imaging system treatment center orthodontic product metric increase segment cc geographic detailsin quarter sale unite state grow year year country cc net sale europe increase cc net sale rest world climb cc margin profit report quarter be year year percentage revenue gross margin expand basis point bps company report preliminary net sale year year consumable segment increase net sale net sale technology equipment segment jump however sale combine business technology equipment slip cc year year company register adjust earning share expect adjust ep range reflect cent adverse impact tax expense related tax reform revenue be project rise cc key picksa few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal adjust earning share cent prior year quarter revenue rise perkinelmer post fourth quarter adjust earning share cent adjust revenue be approximately year becton dickinson report first quarter adjust earning share constant currency revenue totale cc don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
168,BDX,patterson company inc pdco free report report adjust earning cent share third quarter fiscal miss zack consensus estimate cent earning fall year year net sale dip year quarter beat zack consensus estimate adjust effect foreign currency exchange sale decline year year basis decrease sale gross margin compression mar company result report quarter patterson company inc price consensus patterson company inc price consensus patterson company inc quote patterson company have zack rank buy segmental company currently distribute product mainly subsidiary patterson dental patterson animal health dental segment provide virtually complete range consumable dental product equipment software turnkey digital solution value add service dentist dental laboratory north america third quarter dental sale total sale decline cc year year approximately change sale force disruption enterprise resource plan implementation expansion company digital equipment portfolio mar revenue segmentdental consumablesale segment be year year dental equipment softwaresale segment decline year year basis other service segment be primarily compose technical service part labor software support service office supply decrease year year basis animal health segment be lead distributor product service technology production companion animal health market north america come third quarter performance platform total sale sale increase almost cc year year basis global companion animal sale inched production animal sale increase reflect strong performance swine beef cattle segment margin profit report quarter be year year percentage revenue gross margin contract basis point bps quarter operate income third quarter be year year percentage revenue operate margin expand bps quarter share repurchase updatepatterson company repurchase approximately share outstanding common stock report quarter company also paid cash dividend shareholder guidance company expect adjust earning share fiscal range share much lower previously issue range patterson company expect deal amortization expense cent share company estimate integration business restructure expense cent share takelackluster sale earning performance dampen patterson company fourth quarter result however be upbeat company animal health segment have be perform well lately company provide wide range consumable supply equipment software value add service company broad spectrum product cushion economic downturn medtech space believe diversify product portfolio strong veterinary business prospect accretive acquisition strategic partnership be key growth catalyst flip side downbeat guidance indicate loom concern ahead decrease revenue dental segment be headwind recent decline segment be drive decrease sale cerec digital technology product management expect headwind technology base equipment business persist fiscal key picksother top rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank see complete list today zack rank stock here petm report third quarter fiscal adjust earning share cent prior year quarter revenue rise perkinelmer post fourth quarter adjust earning share cent adjust revenue be approximately year becton dickinson report first quarter adjust earning share constant currency revenue totale constant currency don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
169,BDX,dexcom inc dxcm free report report earning share ep cent fourth quarter beating zack consensus estimate also figure improve loss cent year quarter full year loss cent be narrower loss cent year quarter figure be also better zack consensus estimate loss cent total revenue grow year quarter revenue surpass zack consensus estimate full year revenue come beating zack consensus estimate figure also improve year number segmental detailssensor revenue other revenue total revenue grow year year basis transmitter revenue increase prior year quarter receiver revenue grow year year operational detailsdexcom generate gross margin percentage revenue expansion basis point bps year year international business display continue growth quarter generate revenue year year basis notably international business represent total revenue fourth quarter research development expense totale quarter year year selling general administrative expense totale report quarter increase year year financial updatefull year dexcom have cash cash equivalent short term marketable security versus end guidancedexcom reaffirm full year guidance company expect full year revenue range gross profit margin be project band report operate expense exclude investment intensive program be expect increase takedexcom exit fourth quarter solid note year year growth revenue earning be encourage expansion gross margin buoy optimism company be also focuse product innovation peer performancesome medical stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm report third quarter fiscal result adjust ep cent be prior year quarter revenue rise perkinelmer report fourth quarter adjust ep cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust ep constant currency revenue totale constant currency hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
170,BDX,abbott free report have recently enter agreement diagnostic technology player surmodic inc srdx free report term deal former have exclusive worldwide right surmodic surveil drug coat balloon deal remain align abbott focus expand broad line vascular care product notably surveil drug coat balloon surmodic be used treat superficial femoral artery be evaluation pivotal clinical trial significantly new generation device be likely complement extend company vascular device portfolio include stent vessel closure device address peripheral artery disease pad american heart association pad be narrowing artery cause reduce blood flow leg stomach arm head accord abbott condition be often underdiagnosed lead other serious vascular condition regard drug coat balloon have emerge important treatment option treatment pad globally person be affected pad american alone age year be suffering disease undoubtedly market therapy related indication look lucrative abbott surveil drug coat balloon hold greater promise capture market compare traditional device be include proprietary drug excipient formulation durable balloon coating be manufacture used innovative process improve coating uniformity pre clinical datum surveil have show time higher target tissue drug concentration more evenly distribute durable drug effect lower incidence downstream drug particle comparison control drug coat balloon accordingly surmodic deal seem highly strategic abbott point view monopolize huge grow market pad regulate drug coat balloon apart surveil related pact abbott have choice negotiate agreement surmodic knee arteriovenous fistula drug coat balloon product currently pre clinical development datum reportsnreport global market peripheral vascular intervention include lower extremity stent percutaneous transluminal angioplasty pta balloon pta drug eluting balloon carotid stent renal stent be estimate rise cagr major player drug coat balloon market be medtronic inc mdt free report becton dickinson company bdx free report hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
171,BDX,quality system qsii free report report third quarter adjust earning share cent line zack consensus estimate however adjust earning share decline year year basis revenue third quarter fiscal totale marginally beat zack consensus estimate additionally revenue increase year year basis segment detailstotal software hardware related revenue segment decline year year basis amount subscription revenue increase year year support maintenance revenue improve year year basis however figure decline sequentially professional service revenue segment increase year year basis electronic datum interchange revenue segment grow year year revenue cycle management rcm revenue segment increase year year report quarter new rcm deal be sign be entirely new client company whole quality system inc price consensus ep surprise quality system inc price consensus ep surprise quality system inc quotequarter acquisition major quality system acquire eagledream software analytic solution company be incorporate company operation third quarter fiscal quarter company close deal broad product spectrum account specialty geography have also lead swift uptake interest company user base eagledream thus quality system witness deal flow significant interest integration eagledream booking strengthena sequential increase booking majorly drive sale report quarter amount company framework be suitable software exchange make use information management company have more client integrate national care quality framework dec further more client be be add month post upgrade ensure patient datum be transportable not just company database also industry margin profit third quarter totale gross margin be gross margin decline basis point year year basis decline be mainly due general shift lower margin subscription revenue rcm margin be too compress company invest future efficiency witness headwind quarter personnel expense operate expense surge due investment sale marketing well acquisition partially financial company exit third quarter cash equivalent outstanding revolve credit agreement end quarter quality system continue be well position term financial flexibility available total liquidity fy fiscal company reiterate revenue outlook range company reiterate adjust earning share range cent takequality system exit third quarter fiscal lukewarm performance earning revenue beat zack consensus estimate solid revenue growth segmental support buoy optimism revenue benefit eagledream software platform have be enjoy favorable market response integration report quarter flip side decline revenue software hardware related segment be concern operate expense be also high due acquisition drive cost continue acquisition pose integration risk acquire company price performancein past year quality system have underperform respect industry zack rank key picksquality system carry zack rank hold few better rank medical stock broader medical space be becton dickinson company bdx free report bioverativ exelixis exel free report becton dickinson carry zack rank buy bioverativ exelixis sport zack rank strong buy see complete list today zack rank stock here becton dickinson have expect long term growth rate stock have return outperform industry last month bioverativ have impressive project growth rate next year last month stock have gain compare industry rally exelixis have notable long term expect growth rate last month stock have gain surpass industry gain zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
172,BDX,becton dickinson company bdx free report first quarter fiscal result schedule release feb be expect show sluggishness bd medical major revenue component majorly dampen earning first quarter expect improvement revenue other segment help company generate solid result zack consensus estimate bd medical revenue be peg first quarter indicate decline year quarter notably becton dickinson also know bd deliver positive earning surprise past quarters average be previous quarter management expect strong number bioscience diagnostic system preanalytical system unit major factor playdull prospect bd life science zack consensus estimate revenue bd life science segment be peg year year fact bioscience diagnostic segment be expect decline respectively year year basis lower reimbursement medical product service have be impose downward pressure price product further longer sale cycle slower adoption new technology be also expect affect bd top line foreign exchange wo bd generate more half revenue international operation more fiscal be affected fluctuation foreign currency exchange rate notably domestic manufacturer such bd be be hurt strong dollar have benefit more upbeat economic prospect compare rest world currency volatility continue be headwind first quarter fiscal emerge market hold promise emerge market continue be key growth driver bd company momentum china emerge market have be already reflect previously report quarters expect trend continue be report quarter regard bd strategic transformation dispense business model have be successfully implement further company strategy end end medication management be gain prominence northward estimate revision zack consensus estimate revenue first quarter be grow year year further zack consensus estimate earning first quarter be peg improve year year becton dickinson company price consensus becton dickinson company price consensus becton dickinson company quotehowever bd do not have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat here be quantitative model predict zack esp earning esp bd be most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank bd carry zack rank buy however also need positive esp be confident earning beat season stock considerhere be few medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank strong buy see complete list today zack rank stock here luminex lmnx free report have earning esp zack rank cooper company coo free report have earning esp zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
173,BDX,cheme corporation che free report fourth quarter adjust earning share ep be compare year figure figure also surpass zack consensus estimate full year adjust ep come beating zack consensus estimate moreover figure improve year number quarter detailsrevenue quarter increase year year beating zack consensus estimate net revenue totale outpace zack consensus estimate figure also improve year number cheme currently operate wholly own subsidiary namely vita healthcare corporation major provider end life care roto rooter lead commercial residential plumbing drain clean service provider fourth quarter net revenue vita healthcare totale reflect increase year year revenue be drive increase average net medicare reimbursement rate rise average daily census however be partially offset acuity mix shift impact revenue adverse impact revenue due medicare cap cheme corp price consensus ep surprise cheme corp price consensus ep surprise cheme corp quote roto rooter report sale fourth quarter year year accord company revenue water restoration increase year year gross margin expand basis point bps year year adjust operate margin contract nominal bps quarter rise selling general administrative expense cheme exit total cash cash equivalent end company have total debt end compare year dec company have approximately undrawn borrow capacity exist year credit agreement fourth quarter company do not repurchase share dec company have remain share repurchase authorization company project vita healthcare revenue growth range prior medicare cap also admission average daily census be expect increase medicare cap bill limitation be expect roto rooter business be likely grow full year guidance be backed increase job pricing water restoration service growth full year adjust ep be expect grow band compare report takecheme exit fourth quarter solid note also company witness year year growth front moreover be encourage note company subsidiary see year year revenue growth quarter expansion gross margin strong bottom line projection also buoy optimism further reimbursement related issue seasonality business competitive landscape dependence government mandate continue challenge key picksa few top rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal adjust earning share cent prior year quarter revenue rise perkinelmer post fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter fiscal adjust earning share constant currency revenue totale constant currency hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
174,BDX,amedisys inc am free report report adjust earning share ep continue operation cent fourth quarter year year however earning miss zack consensus estimate cent full year adjust ep come miss zack consensus estimate however figure improve year number fourth quarter net service revenue gross year year top line also beat zack consensus estimate net revenue totale line zack consensus estimate figure improve year number quarter company home health division net service revenue totale fourth quarter reflect improvement year year medicare revenue rise year year medicare revenue improve year year hospice division net service revenue gross year year include medicare revenue medicare revenue recently company integrate additional operate segment business personal care corporate personal care net service revenue totale reflect increase year number meanwhile corporate segment do not register revenue end fourth quarter company gross margin contract basis point bps fourth quarter increase gross profit expense salary benefit rise other expense drop adjust operate income report quarter reflect increase year adjust operate margin expand bps year figure amedisys exit cash cash equivalent compare end company long term obligation exclude current portion be net cash provide operate activity be compare year period takeamedisys end fourth quarter mixed note home health hospice division company witness encourage growth medicare medicare revenue amedisys be currently explore opportunity segment be also upbeat company solid performance recently launch personal care segment favorable demographic trend strategic acquisition bode well company however escalate operate expense decline gross margin continue raise concern also intense competitive landscape regulatory concern continue challenge home health hospice industry peer performancesome medical stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm report third quarter fiscal result adjust ep cent be prior year quarter revenue rise perkinelmer report fourth quarter adjust ep cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust ep constant currency revenue totale constant currency hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
175,BDX,becton dickinson company bdx free report popularly know bd recently announce completion enrollment lutonix knee trial trial be prospective multicenter randomize controlled demonstrate superior efficacy lutonix drug coat balloon dcb compare standard angioplasty balloon catheter dcb platform glancedcb be special category balloon angioplasty be used treat coronary peripheral artery disease lutonix dcb platform treat severe claudication critical limb ischemia patient be suffering stenotic occlusive lesion knee artery reason lutonix dcb drive growth lutonix knee trial be only dcb trial knee artery unite state platform have enrolled more patient past year bd plan submit pre market approval application lutonix knee trial late fortify bd international lutonix dcb product have be make commercially available country europe canada australia treatment artery associate cli cli be detrimental arterial disease reduce blood flow lower leg artery estimate person nation have be suffering cli number be estimate grow nearly thus company customer base be expect expand course time lucrative marketsbd consistent focus expand emerge overseas market new product launch acquisition drive strategy be significant growth catalyst also latest development balloon angioplasty market be likely enhance company growth trajectory research report grand view research global angioplasty balloon market be expect reach worth further drug eluting balloon be expect be fastest grow segment forecast period courtesy favorable tiding regulatory front advantage standard normal balloon low cost effectiveness share shinein last year bd have outperformed industry term price performance company share have return compare favorably industry gain just fact current return be relatively higher index rally zack rank other key picksbd have zack rank buy other top rank stock broader medical sector be integer holding corporation itgr free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate integer holding have long term expect earning growth rate stock carry zack rank intuitive surgical have long term expect earning growth rate stock carry zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
176,BDX,share becton dickinson company bdx free report rally new week high jan close tad lower indicate strong year date return approximately better index base franklin lake nj becton dickinson commonly know bd be medical technology company engage principally development manufacture sale medical device instrument system reagent last year bd outperformed industry term share price stock have return compare favorably industry gain just fact current return be relatively higher index rally notably bd have market cap consider stable performance expect bd scale higher come quarters company long term growth look promising becton dickinson company price becton dickinson company price becton dickinson company quote let take look major factor have be boost bd lately favorable tide regulatory frontbd collaboration check point health recently obtain ce mark molecular screening test antibiotic resistant carbapenemase produce organism cpos bd max system development be expect strengthen company foothold molecular diagnostic business globally abundant prospect global molecular diagnostic market be encourage accord research market be project reach cagr read more bd ce mark check point screening test fight cpo acquisition bard strategic acquisition have be key growth catalyst bd recently bd acquire bard management company be well place become biggest medical technology device company world approximately annualize revenue cash stock acquisition be value completion deal bd create third business segment bd interventional notably bard be integrate vertical come strategic advantage post deal closure bd generate high single digit growth adjust earning share fiscal transaction also lead pre tax annual saving fiscal bd be able expand new area bard operated fast grow vascular access segment piccs peripherally insert central catheter midline drug delivery port estimate revision trendmeanwhile company recent earning estimate have be favorable current year have see estimate go higher past day compare movement opposite direction have have significant impact zack consensus estimate earning inched becton dickinson company price consensus becton dickinson company price consensus becton dickinson company quote zack rank key picksbd have zack rank hold few better rank stock broader medical sector be integer holding corporation itgr free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate integer holding have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock carry zack rank zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
177,BDX,integra lifescience holding corporation iart free report report adjust earning share ep cent fourth quarter year figure adjust ep surpass zack consensus estimate cent full year adjust earning come reflect increase year quarter full year adjust ep also surpass zack consensus estimate integra lifescience holding corporation price consensus ep surprise integra lifescience holding corporation price consensus ep surprise integra lifescience holding corporation quote revenue discussiontotal revenue report quarter increase year year surpass zack consensus estimate exclude revenue acquisition discontinue product effect currency exchange rate organic revenue rise year year full year revenue come reflect increase figure also surpass zack consensus estimate solid revenue growth be primarily drive high organic revenue better expect performance recently acquire business johnson johnson codman neurosurgery business derma science come product category revenue company codman specialty surgical segment increase orthopedic tissue technology revenue come fourth quarter year year margin trendadjust gross margin contract basis point bps report quarter selling general administrative expense increase report quarter research development expense rise accordingly adjust operate margin see bps contraction fourth quarter financial positionintegra lifescience exit cash cash equivalent record end full year cash flow operate activity be year period company now expect full year revenue guidance high end range back more favorable foreign currency rate zack consensus estimate full year revenue be high end guide range company expect adjust earning diluted share be high end previously provide range zack consensus estimate adjust earning be peg company guide range full year company reiterate adjust gross margin band first quarter company expect adjust ep range cent represent growth year year zack consensus estimate first quarter adjust ep be peg cent company guide range first quarter company expect total revenue range include organic growth zack consensus estimate be guide range takeintegra lifescience exit fourth quarter solid note strong year year increase revenue back recent acquire business buoy optimism be also encourage note company segment see year year revenue growth quarter nonetheless believe company be try execute growth plan efficient management team moreover increase year year investment research development be encourage company promising guidance also instill confidence stock however significant margin contraction cause escalate cost expense be concern zack rank key picksintegra lifescience have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal result adjust ep cent be prior year quarter revenue rise perkinelmer report fourth quarter adjust ep cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust ep constant currency revenue totale constant currency wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
178,BDX,medtronic plc mdt free report announce fda nod launch resolute onyx mm drug eluting stent de new stent be smallest size market presently resolute onyx de be available use size unite state europe country recognize ce mark stent have be exclusively design help interventional cardiologist treat patient coronary artery disease cad patient have small vessel be often untreatable larger stent technology percutaneous coronary intervention pci management believe introduction resolute onyx mm de enable doctor broaden treatment option patient smaller vessel notably resolute onyx de platform be only de feature core wire technology evolution continuous sinusoid technology be also be note resolute onyx mm clinical study support resolute onyx mm de study be present europcr annual meeting simultaneously publish journal american college cardiology jacc cardiovascular intervention coronary structural heart be consistently try enhance coronary structural heart csh segment be part cardiac vascular group cvg segment csh revenue third quarter fiscal be cer report low constant currency growth transcatheter aortic valf result strong customer uptake corevalve evolut pro platform expand fda approval include patient intermediate risk moreover continue uptake resolute onyx drug eluting stent unite state japan revive business market strategy gain traction csh sub segment seem be align datum provide transparency market research report global coronary stent market be expect see cagr more specifically de market coronary stent market be expand fast be estimate witness cagr period market be likely expand unite state asia pacific europe well rest world stock performance estimate revisionover last month medtronic have underperform industry decline compare industry gain last month also underperform gain market same time frame also estimate revision trend current year remain unfavorable estimate move south last month compare movement opposite direction earning estimate rise share same time frame zack rank key picksmedtronic carry zack rank hold few better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory sport zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company be zack rank player company have long term expect earning growth rate zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
179,BDX,nuvasive inc nuva free report report fourth quarter adjust earning share ep cent reflect rise year quarter figure be par zack consensus estimate solid contribution international business lead year year improvement earning include time item company report fourth quarter net income share cent cent year full year adjust ep come line zack consensus estimate moreover figure improve year number revenue report quarter come marginally flat constant exchange rate cer year figure figure however miss zack consensus estimate net revenue totale line zack consensus estimate figure also improve year number nuvasive inc price consensus ep surprise nuvasive inc price consensus ep surprise nuvasive inc quote notably company announce preliminary result jan quarter company witness robust performance international market however upside be mar decline revenue notably pressure biologic business softness procedural volume spine market follow difficult comparison year figure lead disappointing performance unite state however management be satisfied key volume growth core hardware business notably company face headwind international business hurricane hit puerto rico report quarter company spinal hardware business decline however revenue business be flat adjust year figure magec sale notably rise pricing pressure product mix have offset case volume growth revenue surgical support business decline fourth quarter primarily due weakness biologic portfolio persistent sluggishness service business case volume growth however international business record growth cer report basis fifth consecutive time solid contribution key geography report quarter be increase cost good sell exclude amortization intangible asset expense accordingly gross profit decline moreover company report basis point bps year year contraction gross margin fourth quarter sale marketing administrative expense go research development expense contract nuvasive post adjust operate income report quarter reflect rise year figure adjust operate margin expand bps quarter company exit cash cash equivalent short term investment end outlooknuvasive provide guidance full year well guidance have be adjust recent buyout safepassage full year benefit tax reform suspension medical device tax company expect revenue range reflect organic growth moreover report basis company expect revenue growth range zack consensus estimate lag guide range foreign exchange rate be expect prove favorable nuvasive fact company expect foreign exchange rate have positive impact almost year nuvasive expect full year adjust ep current zack consensus estimate lag guide range additionally adjust operate margin year be expect bps year year basis exit fourth quarter unfavorable note miss zack consensus estimate revenue moreover company see softness business however solid performance international business more growth fifth consecutive quarter buoy optimism company expectation higher adjust operate profit margin least bps show focus operational efficiency house manufacturing facility moreover be upbeat recently complete buyout safepassage nuvasive acquisition strengthen company intraoperative neuromonitoring business line consolidated giant be expect deliver service more customer surgeon zack rank key picksnuvasive have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal result adjust ep cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust ep cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust ep constant currency revenue totale constant currency zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
180,BDX,conm corporation cnmd free report be currently top perform stock medtech space improvement price performance strong fundamental reflect stock bullish run therefore haven take advantage price appreciation yet time add stock portfolio headquarter utica ny conm be major medical product manufacturer specialize surgical instrument device minimally invasive procedure monitoring company perform impressively have potential sustain momentum upcoming period long term expect earning growth rate be positive attractive pick solid resultsconm deliver stellar performance fourth quarter beating earning revenue estimate performance company business segment have be commendable orthopedic surgery rebound quarters decline solid focus innovation continue drive sale gain leverage international market raise guidance shrink debt instill optimism notably company long term debt decline year year basis share price appreciationa glimpse company price trend reveal stock have have impressive run bourse year date conm share have return versus index fall current return be also greater industry gain just northward estimate revisionsfour estimate current year moved north past day versus southward revision indicate analyst optimism company zack consensus estimate adjust earning rise current year positive trend signify analyst bullish sentiment company hold zack rank buy indicate robust fundamental expectation outperformance term zack consensus estimate revenue be peg year year company expect sale growth range constant currency cc adjust earning share be project range fiscal conm corporation price consensus conm corporation price consensus conm corporation quote general surgery consistent surgery consist complete line endo mechanical instrumentation minimally invasive laparoscopic procedure line cardiac monitoring product well electrosurgical generator related instrument constant currency basis general surgery grow fourth quarter post eighth straight quarter positive gain additionally domestic general surgery grow ride solid growth advanced surgical endoscopic technology deliver decent performance fourth quarter well full year base strong performance segment organization be position drive mid single digit revenue growth double digit earning growth organically sustainable basis solid market trendsconm be benefit increase trend used minimally invasive technique large percentage company product be design procedure use minimally invasive surgery lower cost reduce patient trauma recovery time length hospitalization research report market market suggest global minimally invasive surgical instrument market be estimate reach worth multiply cagr such solid market trend be likely fortify conm foothold niche space other key picksa few other top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
181,BDX,corporation abc free report be big mover last session company see share rise more day move come solid volume too far more share change hand normal session reverse recent trend company stock be now past month time frame stock gain report walgreen boot alliance consider purchasing drug wholesaler company have see positive estimate revision past few week zack consensus estimate current quarter have also moved higher past few week suggest more solid trading be ahead so make sure keep eye stock go forward see recent jump turn more strength road currently have zack rank buy earning esp be negative corporation price corporation price corporation quoteanother stock worth consider medical dental supply industry be becton dickinson company bdx free report also carry zack rank see complete list today zack rank strong buy stock here be abc go predict see other think downdon even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
182,BDX,becton dickinson company bdx free report popularly know bd collaboration check point health recently obtain ce mark molecular screening test antibiotic resistant carbapenemase produce organism cpos bd max system development be expect strengthen bd foothold molecular diagnostic business globally notably check point be privately own diagnostic company base wageningen netherlands bd max system be fully integrate automate platform capable provide result sample multiple syndrome less hour bd max check point cpo test provide detection most common carbapenemase gene less hour compare traditional method take hour early detection presence such bacterium be crucial execute proper infection control measure assay replace older version test check point offer improve additional target becton dickinson company price consensus becton dickinson company price consensus becton dickinson company management estimate year antimicrobial resistance amr cause fatality annually precaution be take amr be ability microorganism survive be treat effective antimicrobial drug consequently patient such infection be prone develop lethal complication thus spread cpo be major challenge vigilance antimicrobial disease due organism ability produce enzyme carbapenemase abundant prospect global molecular diagnostic market be encourage accord research market be project reach cagr share shine brightbd have have favorable run bourse last year stock have return compare industry rally zack rank key picksbecton dickinson carry zack rank hold few better rank stock broader medical space be bio rad laboratory inc bio free report neogen corporation neog free report humana inc hum free report stock sport zack rank strong buy see complete list today zack rank stock here bio rad have massive project growth rate percent first quarter stock have outperformed industry return last month neogen have long term project growth rate last month stock have gain surpass industry humana have expect growth rate first quarter last month stock have gain industry return more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
183,BDX,ministry commerce person republic china have approve becton dickinson company bdx free report acquisition bard company be set complete cash stock deal favorable tiding regulatory front have accelerate deal progress recently federal trade commission give approval acquisition however acquisition be subject satisfaction customary close condition formation bd interventional new segmentafter completion deal becton dickinson establish third business segment bd interventional notably bard be integrate vertical becton dickinson be already lead player interventional specialty solution company promote positive clinical outcome used minimally invasive percutaneous technique obtain sample liver breast lung kidney biopsy further company provide facility peritoneal drainage home april becton dickinson sign agreement management company be track become biggest medical technology device company world buyout becton dickinson operate segment currently bd medical segment bd life science segment post deal closure company project growth adjust earning start fiscal strategic acquisition be expect generate benefit complementary business geographical expansion becton dickinson company price becton dickinson company price becton dickinson company quote moody not happymoody investor service rating service arm moody corporation mco free report downgrade becton dickinson senior unsecured note ba lgd baa commercial paper rating not prime prime lackluster rating reflect becton dickinson aggressive acquisition strategy regard company latest deal acquire bard have be sign just year carefusion buyout moody acquisition be likely almost double becton dickinson debt load include assume debt issue bard further company pro leverage debt ebitda increase almost time closure deal indicate loom concern stock becton dickinson expect reduce debt ebitda ratio time year close moody believe be unlikely happen positive note moody believe company cost save target be achievable regard becton dickinson expect cost saving fiscal moody also expect becton dickinson make use free cash flow debt reduction card post deal closure becton dickinson announce divest soft tissue core needle biopsy product bard aspira product line tunnele home drainage catheter accessory merit medical system inc mmsi free report contingent completion buyout come strategic advantage becton dickinson generate high single digit growth adjust earning share fiscal company be able expand new area bard currently operate fast grow vascular access segment peripherally insert central catheter piccs midline drug delivery port moreover acquisition be expect strengthen combine entity footprint home healthcare market unite state research report market market reveal home healthcare market be expect reach total cagr price performance zack rank last month becton dickinson have outperformed industry term price performance company share have return compare favorably industry rally stock have zack rank hold see complete list today zack rank strong buy stock here more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
184,BDX,gnc holding inc gnc free report have be dominate headline announcement plan strike couple deal china lead pharmaceutical company harbin pharmaceutical group hold co ltd hayao notably company intend enter strategic partnership china joint venture agreement hayao term equity investment agreement hayao invest cash kind gnc holding follow close transaction hayao own gnc holding converted basis investment be anticipate strengthen gnc holding capital position however subject certain customary close condition unite state china transaction be expect close second half same time gnc holding enter joint venture agreement hayao notably leverage latter expertise operational manufacturing area well broad pharmaceutical distribution network china gnc holding plan strengthen presence china boom supplement market however closure hayao transaction be dependent successful completion gnc holding plan amend extend term loan facility interestingly gnc holding aim extend maturity date term loan facility year march issue abl term loan part plan maturity extension international business key growth drivernotably gnc holding international business have be key growth driver company recent year late company have be see solid growth china furthermore recent past company have witness improvement trend mexico south korea hong kong believe successful completion execution agreement significantly drive top line contribution china market potentialper report grand view research global market dietary supplement be expect see cagr report further state usage supplement treat cardiovascular disease malnutrition continue boost demand thus view such datum believe gnc holding joint venture plan hayao be strategic share price performancegnc holding have be gain investor confidence consistently positive result past month company share price have outperformed industry stock have gain industry decline zack rank key picksgnc holding carry zack rank hold better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
185,BDX,share becton dickinson company bdx free report fall dec follow federal trade commission ftc nod much talk bard acquisition bard be however close becton dickinson company now await approval ministry commerce person republic china mofcom complete propose acquisition also need fulfill certain customary close conditionsdeal detailsin april becton dickinson sign agreement acquire bard management becton dickinson be track become biggest medical technology device company world buyout cash stock acquisition be value completion deal becton dickinson company create third business segment bd interventional notably bard be integrate vertical further becton dickinson company announce divest soft tissue core needle biopsy product bard aspira product line tunnele home drainage catheter accessory merit medical system inc mmsi free report order facilitate approval acquisition bard have announce back august majority shareholder approve merger becton dickinson holder approximately bard share participate vote favore merger benefit becton dickinson companycome strategic advantage post deal closure becton dickinson company generate high single digit growth adjust earning share fiscal transaction also lead pre tax annual saving fiscal becton dickinson company be able expand new area bard currently operate fast grow vascular access segment piccs peripherally insert central catheter midline drug delivery port moreover acquisition be expect strengthen combine entity footprint home healthcare market unite state research report market market reveal home healthcare market be expect reach total cagr conclusionwe view acquisition strategic fit generate benefit complementary business geographical expansion however combine entity be likely face challenge regard integration new business cost associate apart increase competition delay order renewal process constricted federal spending be other concern share price movementbecton dickinson company have outperformed broader industry year date stock have gain compare broader industry increase zack rank key picksbecton dickinson company carry zack rank hold better rank medical stock be bruker corporation brkr free report carry zack rank buy see complete list today zack rank stock here bruker have long term expect earning growth rate stock have rally roughly year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
186,BDX,merit medical system inc mmsi free report be name reckon current medtech space top perform stock improvement price performance strong fundamental reflect bullish run therefore clear message investor be haven yet take advantage stock share price appreciation time add portfolio good return company impressive performance account potential carry momentum forward imminent period long term expect earning growth rate also hold great promise stock regard attractive pick share price appreciationa glimpse company price trend reveal stock have have encourage trip bourse year date merit medical return whopping compare favorably index rally metric also better industry gain merit medical system inc price consensus merit medical system inc price consensus merit medical system inc quotenorthbound estimate stock have see zack consensus estimate current year earning be revise upward analyst past day thus absence single southbound revision highlight analyst optimism company well boost positive sentiment stock same time frame consensus mark adjust earning have remain stable share zack consensus estimate earning have be raise last couple month company sport zack rank strong buy indicate robust fundamental expectation outperformance term strong growth company earning estimate reflect year year growth moreover bottom line be expect register rise year year basis consensus mark revenue represent year year improvement moreover top line be anticipate witness increase next year company be likely gain decision purchase certain asset becton dickinson company bdx free report include soft tissue core needle biopsy product also acquire aspira pleural effusion drainage kit aspira peritoneal drainage system bard integration help expand footprint acquisition drive growthmerit medical have be leverage bolt buyout drive inorganic growth company recently acquire small base entity laurane medical manufacturing operation europe purchase company specialize bone biopsy business management merit medical expect accretive return deal laurane medical first quarter fact merit medical also buy australian custom pack business unit form part itl health group october takeover be project fortify company footprint other key pickanother top rank stock broader medical sector be petm express pet free report flaunt same bullish zack rank merit medical company have long term expect earning growth rate see complete list today zack rank stock here zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
187,BDX,feb issue update research report petm express inc pet free report stock carry zack rank strong buy company be strive implement several strategy revitalize top line include increase focus advertising efficiency boost new order sale shift sale higher margin item also expand product line several quarters drag new order sale be impressed petm improve performance last fiscal current year have demonstrated bullish momentum so far petm be also work improve effectiveness campaign have be quite successful drive sale internet petm offer wide range product dog cat horse believe improvement economic condition petm wide range product help drive growth come quarters however aim increase recognition brand name petm market product national advertising campaign procedure company have be incur huge expense related advertising campaign recent time hence escalate advertising expense exert pressure bottom line also tough competitive landscape be major concern stock performance estimate revisionover last year petm have outperformed industry company have gain compare industry also estimate revision trend current year be favorable estimate move north last month compare movement opposite direction earning estimate moved other key picksother top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company be zack rank player company have long term expect earning growth rate zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
188,BDX,gnc holding inc gnc free report report fourth quarter adjust earning share ep cent reflect massive year year increase adjust ep also surpass zack consensus estimate penny full year adjust ep compare adjust ep also surpass zack consensus estimate revenuesrevenue now exclude lucky vitamin period report quarter drop year year figure also miss zack consensus estimate gnc holding inc price consensus ep surprise gnc holding inc price consensus ep surprise gnc holding inc quote company report full year revenue compare year figure miss zack consensus estimateof same store sale increase domestic company own store include gnc com sale quarter review domestic franchise location same store sale decline segment detailsgnc holding report operation segment canada include company own store unite state puerto rico canada franchise store unite state commerce international include franchise location approximately country health store china operation manufacturing wholesale comprise manufacture product sell other segment third party contract manufacturing sale wholesale partner report quarter gnc holding revenue canada segment inched primarily drive increase same store sale company own store include gnc com partially offset decrease due discontinuation gold card program unite state introduction loyalty program domestic franchise location well revenue decline due lower wholesale sale include impact retail sale comp negative revenue international segment increase drive higher cross border commerce sale china revenue manufacturing wholesale segment exclude intersegment revenue decline segment third party contract manufacturing sale fall sale wholesale partner decrease year year quarter however intersegment sale increase year company increase focus proprietary product asset sale lucky vitamin sep lucky vitamin be now include other segment applicable prior period ensure comparability result drop fourth quarter revenue prior year quarter margingross profit increase report quarter result gross margin expand basis point bps selling general administrative expense contract accordingly adjust operate margin expand bps financial positiongnc holding exit cash cash equivalent end long term debt be end compare end net cash flow operate activity totale compare year further company generate free cash flow compare previous year new gnc plan updateearlier management have announce plan revamp exist business model dub new gnc company have be see change fourth quarter well transaction growth be fourth quarter more consumer have joined company loyalty program include approximately customer enrolled pro access membership takegnc holding exit fourth quarter mixed note however year year increase adjust earning be encourage also expansion gross adjust operate margin be encourage fourth quarter management witness positive response new gnc plan company have also be witness improvement transaction commerce business buoy optimism zack rank key picksgnc holding have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal adjust earning share cent prior year quarter revenue rise perkinelmer post fourth quarter adjust earning share cent adjust revenue be approximately year becton dickinson report first quarter adjust earning share constant currency revenue totale constant currency don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
189,BDX,davita inc dva free report report fourth quarter adjust operate earning cent share beating zack consensus estimate cent however earning decline year year basis total revenue increase year year miss zack consensus estimate davita carry zack rank hold davita healthcare partner inc price consensus davita healthcare partner inc price consensus davita healthcare partner inc quote segmental analysisas operate division davita davita kidney care focus set worldwide standard clinical social operational practice kidney care davita see impressive result kidney care business net consolidated revenue segment be year year adjust operate income segment be year year revenue dialysis lab business rise year year company patient care cost be approximately cent treatment compare last quarter third quarter davita patient care cost be favorably impact hurricane total dialysis treatment fourth quarter be treatment day indicate day increase year year basis fourth quarter davita acquire dialysis center open new center close unite state davita also acquire dialysis center open center close center outside unite state investor notice company major segment davita medical group dmg have be track divestment optum subsidiary unitedhealth group inc transaction be subject regulatory approval other customary close condition result dmg business operation have be report discontinue quarter financial updateon dec free cash flow continue operation be month end dec davita have operate cash flow be continue operation share repurchase updatedure quarter end dec davita repurchase total share common stock approximately average price share davita buy back almost share common stock average price share company project kidney care consolidated operate income range operate cash flow continue operation be estimate range effective tax rate be expect range key picksa few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal adjust earning share cent prior year quarter revenue rise perkinelmer post fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue totale constant currency don even think buy bitcoin read most popular cryptocurrency sky-rocket last year give investor chance bank return even more gain however come serious volatility risk bitcoin sank more time zack have just release new special report help reader capitalize explosive profit potential bitcoin other cryptocurrency significantly less volatility buy directly see crypto related stock now
190,BDX,myriad genetic inc mygn free report have be dominate headline favorable result large study myrisk hereditary cancer test notably result be featured poster presentation genitourinary cancer symposium san francisco result patient study confirm more man prostate cancer have inherited hereditary mutation cancer cause gene management go result study be important expand use genetic testing man diagnosed prostate cancer consistent exist professional medical guideline management further add study result prove percentage woman breast cancer carry hereditary cancer cause mutation be same percentage man prostate cancer carry mutation company prostate cancer be most commonly diagnosed second lead cause cancer death american man go cancer fact figure report american cancer society man be diagnosed prostate cancer report also state roughly american man be presently suffering prostate cancer myriad genetic also state global market myrisk hereditary cancer other type hereditary cancer test be worth roughly annually view such datum believe favorable result boost company customer base top line great extent furthermore company have be leave stone unturned strengthen hold same regard last december myriad genetic present favorable riskscore test datum san antonio breast cancer symposium sabcs texas september company introduce riskscore myrisk hereditary cancer testing portfolio also present encourage riskscore test datum also announce favorable study result myrisk hereditary cancer suite moreover recently report second quarter fiscal marked fourth consecutive quarter year year hereditary cancer volume growth lead encourage response latest riskscore test myrisk hereditary cancer testing portfolio thus believe encourage datum study drive uptake myrisk hereditary cancer test price genetic have be gain investor confidence consistently positive result past month company share price have outperformed industry stock have gain industry decline zack rank key picksmyriad genetic carry zack rank hold better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
191,BDX,luminex corporation lmnx free report report adjust earning cent share fourth quarter surpass zack consensus estimate cent adjust earning also increase year year gaap basis company report fourth quarter loss cent share consider necessary adjustment expect company tax obligation defer tax asset liability related passage tax cut job act revenue quarter increase almost year year outpace zack consensus estimate luminex corporation price consensus ep surprise luminex corporation price consensus ep surprise luminex corporation quote glancefull year earning share come cent share increase year number ahead zack consensus estimate cent full year revenue come increase year adjust number ahead zack consensus estimate system sale segment report total revenue assay revenue account total sale royalty revenue contribute total revenue year consumable sale contribute year other revenue segment also contribute service revenue contribute total revenue year segment analysissystem sale revenue increase year year basis notably company ship multiplexing analyzer quarter here note system include magpix lx flexmap also company place sample answer molecular system contract reach total number active customer more assay revenue assay revenue grow year year royalty revenue sale segment increase year year basis consumable sale revenue segment decline exit full year cash cash equivalent compare end marginsgross profit increase year quarter primarily drive higher revenue gross margin expand basis point bps increase volume verigene ary internal manufacturing process improvement result strong gross margin expansion adjust operate expense totale reflect decline year quarter selling general administrative expense increase research development expense contract year year meanwhile adjust operate margin expand massive bps revenue growth most segment gross profit expansion consistent effort control operate expense boost company operate margin quarter guidanceluminex provide annual revenue guidance range indicate growth midpoint year year company expect first quarter revenue band bottom lineluminex exit fourth quarter solid note company see strong top line solid cash flow well profit company also witness favorable tiding regulatory front regard company win fda nod ary group strep assay management be sixth assay fda have clear use ary system last year also be look forward company recently provide long term outlook be quite promising company expect achieve total revenue band increase cagr further expansion operate margin buoy optimism flip side low consumable revenue raise concern furthermore year year drop expense be discourage cutthroat competition niche space be headwind zack rank key picksluminex carry zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal adjust earning share cent prior year quarter revenue rise perkinelmer post fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue totale constant currency hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
192,BDX,feb issue update research report becton dickinson company bdx free report popularly know bd stock carry zack rank buy bd focus expand overseas emerge market product launch acquisition drive strategy be significant growth catalyst meanwhile company end first quarter fiscal impressive note beating zack consensus estimate count strong guidance fiscal instill confidence investor bd have be banking solid segmental growth late first quarter fiscal bd medical segment generate revenue constant currency cc year year basis bd life science segment generate revenue cc year quarter result company report net revenue prior year quarter cc strategic acquisition have also be key catalyst bd recently company acquire bard management bd be way become biggest medical technology device company world approximately annualize revenue include accretion bard acquisition bd expect fiscal revenue increase range report basis however revenue be expect grow range cc notably revenue be likely be affected change dispense business model becton dickinson company price becton dickinson company price becton dickinson company quote company expect adjust earning share range previous range current range indicate growth approximately report basis approximately cc bd collaborative move fresenius medical care fms free report provide sodium chloride saline customer be also noteworthy bd enjoy strong presence instrument market buyout boost competitive position sequence market company be expect continue pursue strategic acquisition boost long term growth prospect bd announce agreement italy base euroclone development global distribution molecular assay molecular assay be exclusively formulate detect sexually transmit pathogen bd euroclone plan launch molecular assay outside unite state favorable price performancein last year bd have outperformed broader industry term price company share have return compare favorably broader industry rally other key picksa few other top rank stock broader medical sector be bio rad laboratory bio free report perkinelmer pki free report bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
193,BDX,feb issue update research report amedisys inc am free report stock carry zack rank hold renown home health hospice service provider have be trading broader industry past month stock have rally broader industry decline late company have make number strategic acquisition recent be tenet healthcare home health hospice operation arizona deal value amedisys claim buyout be strategic fit be likely help company provide high quality post acute service key market consolidation allow amedisys improve delivery care patient management care continuum market amedisys personal care segment have be grow strong stable latest integrate tuck acquisition moreover company be upbeat bountiful prospect segment october amedisys announce subsidiary associate home care complete buyout intercity home care personal care provider headquarter malden also favorable home health final rule buoy optimism report healthcarefirst rule be finalize implement home health grouping model schedule rollout meanwhile amedisys be poise benefit age demographic population need higher acuity patient home nursing environment moreover company strong cash balance position bolster investor confidence stock flip side escalate operate expense decline gross margin continue raise concern also intensely competitive landscape regulatory concern weigh home health hospice industry key pickssome better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report perkinelmer have long term expect earning growth rate stock carry zack rank bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate becton dickinson company be zack rank player company have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
194,BDX,feb issue update research report haemonetic corporation hae free report stock carry zack rank buy lead provider hematology product solution have be trading industry last month stock have rally compare industry gain stock have also outperformed gain haemonetic exit third quarter fiscal promising note earning revenue beating zack consensus estimate continue momentum new business generation geographical expansion have help company deliver strong result quarter expansion gross operate margin buoy optimism be upbeat haemonetic growth plasma franchise strong end market demand plasma derive continue drive growth haemonetic be also confident maintain growth commercial plasma collection business further raise fiscal adjust earning guidance be encourage company strong cash position also boost investor confidence flip side haemonetic operate very competitive environment manual automate system include like mak system moreover company have be witness sluggish revenue growth blood center franchise significantly affect result past few quarters management also doesn expect early recovery blood center outcome add concern other key pickssome other top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
195,BDX,dec issue update research report becton dickinson company bdx free report popularly know bd stock carry zack rank hold see complete list today zack rank strong buy stock here lead medtech company be steadily progress acquisition bard post completion bd expect growth adjust earning start fiscal acquisition enable company generate profit complementary business geographical expansion nov bd announce divest soft tissue core needle biopsy product merit medical system inc mmsi free report product be currently sell bard aspira product line tunnele home drainage catheter accessory divestment be contingent completion bd acquisition bard year date bd have outperformed industry term stock price company have return compare favorably industry rally just notably current return be relatively higher increase becton dickinson company price consensus becton dickinson company price consensus becton dickinson company quote flip side lackluster performance bd medical unit be concern performance segment be affected sluggishness medication management solution pharmaceutical system unit unite state diabetes care unit bd temporarily have pause shipment insulin infusion set thank higher anticipate rate complaint associate insertion pilot launch product however management conduct clinical trial gather insight ensure patient ultimately realize full benefit bd flowsmart technology bd continue collaborate medtronic plc mdt free report full productad wo ongoing political conundrum pertain repeal obamacare republican have give rise uncertainty dental stock bd conm corporation thus lack favorable development regulatory front be concern medtech major zack editor chief go stock full disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
196,BDX,st paul mn base ecolab inc ecl free report lead provider water hygiene energy technology service be expect report second quarter result aug last quarter company report earning cent share miss zack consensus estimate cent meanwhile trail quarters company deliver average earning miss let see thing be shape prior release factor playecolab earning growth challenge business environment raise investor confidence additionally company large base recur revenue industry lead technology excellent field service be significant propeller quarter review ecolab project adjust diluted earning share range compare year period be also upbeat acquisition abednego environmental service notably abednego part ecolab nalco water business operation be expect boost performance quarter nalco be worldwide leader sustainability service integrate water treatment solution current quarter analyst moved south compare upward revision last month zack consensus estimate earning share be stable same time frame slightly unfavorable price trend stock have solid potential appreciation long term expect earning growth rate furthermore uncertainty associate possibility repeal affordable care act president trump add company concern ecolab inc price ep surprise ecolab inc price ep surprise ecolab inc quoteearning whispersour quantitative model doesn conclusively point earning beat quarter stock be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp ecolab be be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank ecolab carry zack rank increase odd earning beat earning esp keep prediction inconclusive please note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be company want consider proven model show have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp carry zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp sport zack rank stryker corporation syk free report have earning esp carry zack rank more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
197,BDX,cerner corporation cern free report be schedule report second quarter result jul market close base north kansa city mo company provide healthcare information technology hcit solution worldwide cerner have stellar quarter average earning surprise last quarter cerner report adjust earning cent share beating zack consensus estimate cent notably earning improve cent year quarter company report net revenue beating zack consensus estimate meanwhile revenue rise year period delve deeper fundamental stock let see thing be shape prior release likely positive surprise proven model show cerner be likely beat earning have right combination key ingredient zack esp earning esp cerner be most accurate estimate stand cent zack consensus estimate be peg cent favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank cerner currently carry zack rank hold note stock zack rank strong buy buy have significantly higher chance beating earning conversely sell rate stock never be consider go earning announcement combination cerner zack rank positive esp make reasonably confident positive earning surprise season cerner corporation price ep surprise cerner corporation price ep surprise cerner corporation quotefactor considerview upbeat believe cerner strong sale performance solid portfolio strategic initiative have position stellar growth second quarter company forecast revenue adjust earning be now expect band cent cent share full year management expect revenue cerner currently forecast adjust earning band share development electronic health record system cerner announce have be choose department veteran affair develop electronic health record ehr system department veteran affair use same system company be develop department defense begin operation first site february system facilitate exchange datum military care facility civilian health provider current former service member receive care stable estimate revision trend current quarter analyst moved south compare upward revision last month zack consensus estimate earning share be stable cent same time frame robust portfolio believe cerner strong product portfolio help boost customer base frequent contract win reflect grow traction furthermore company have strong growth opportunity revenue cycle management rcm ambulatory space solid global foothold cerner be largest pure play hcit company wide footprint large reference able client base composite array solution make ideal candidate investor seek exposure hcit industry cerner offer exposure worldwide healthcare automation international operation provide more diversify revenue stream past company have win contract well middle east company have also be work client organization globally focus population health management profile other stock warrant lookhere be few other company want consider proven model show also have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
198,BDX,henry schein inc hsic free report be expect report second quarter result aug last quarter renown healthcare product service distributor deliver positive earning surprise encouragingly henry schein earning surpass zack consensus estimate past quarters average let see thing be shape prior announcement factor playhenry schein first quarter result be quite impressive record growth segment dental animal health medical technology value add service geographically company gain traction north america overseas market expect similar trend second quarter well henry schein inc price ep surprise henry schein inc price ep surprise henry schein inc quotenotably be report second quarter henry schein animal health open new national distribution service center ndsc columbus brookhollow neighbourhood have enabled company be complete solution provider veterinary practice country expect boost top line yet be report quarter company strategy expand digital dentistry globally be also encourage regard note management expect least mid single digit growth north america dental equipment market second quarter company be currently banking digital dentistry be part strategic plan henry schein be thus busy promote digital workflow general dentistry well dental specialty flip side henry schein year year deterioration gross operate margin past few quarters due higher cost sale expense be matter concern meanwhile management solid sale second quarter be likely be partially offset timing good friday year notably international holiday have fall second quarter year compare last year timing be first quarter apart currency fluctuation tough competitive landscape add wo also advent group purchasing organization gpos add competitiveness market overall company reaffirm ep guidance reflect growth year period second quarter have be change estimate revision last day same have be observed magnitude estimate revision earning estimate remain same time frame earning whispersour proven model do not conclusively show earning beat henry schein quarter be stock need have positive earning esp zack rank strong buy buy hold happen however be not case here see zack esp henry schein have earning esp be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank henry schein zack rank increase predictive power esp however company esp make surprise prediction difficult meanwhile caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
199,BDX,illumina inc ilmn free report lead provider tool integrate system analysis genetic variation function be schedule report second quarter result aug close bell last quarter company earning be line zack consensus estimate however illumina earning outpaced zack consensus estimate past quarters average let take look thing be shape prior announcement factor playin last report first quarter illumina witness robust revenue growth account consistent improvement sequence consumable strong demand microarray management be still emphasize portfolio sequence platform fortify market position expect company maintain top line growth second quarter management top line growth first quarter also be attribute strong uptake novaseq platform more order place period moreover active hiseq customer base roughly customer company expect replacement older generation instrument novaseq trend continue yet be report quarter illumina inc price ep surprise illumina inc price ep surprise illumina inc quotefurther company recently launch veriseq nipt solution europe ce ivd marked next generation sequence base approach noninvasive prenatal testing notably outside rate nipt adoption be increase netherlands denmark begin cover test first quarter same be expect shortly france company continue see positive reimbursement trend europe well also illumina have be forge ahead nipt expansion plan china believe development boost company top line upcoming quarter flip side weak margin owing introduction novaseq higher array service revenue product mix sequence consumable continue act deterrent company also tough competitive landscape challenge company be also apprehensive issue pertain nih funding illumina have be face quite time now overall second quarter illumina project revenue growth approximately current zack consensus estimate second quarter revenue be peg company expect adjust ep range cent however zack consensus estimate be stable cent guide range earning whispersour proven model do not conclusively show illumina be likely beat estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen however be not case here see zack esp illumina have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank illumina zack rank increase predictive power esp however company earning esp make surprise prediction difficult meanwhile caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
200,BDX,stryker corporation syk free report lead player medical technology space be set report second quarter result jul bell last quarter company post earning share surpass zack consensus estimate cent notably average stryker beat zack consensus estimate almost last quarters let see thing be shape prior release likely positive surprise proven model show stryker be likely beat estimate have right combination key ingredient zack esp stryker earning esp be most accurate estimate be higher zack consensus estimate favorable esp serve meaningful indicator likely positive surprise uncover best stock buy sell re report earning esp filter zack rank stryker currently have zack rank buy note stock zack rank strong buy hold have significantly higher chance beating earning estimate conversely sell rate stock zack rank never be consider go earning announcement combination stryker favorable zack rank positive esp make reasonably confident beat stryker corporation price ep surprise stryker corporation price ep surprise stryker corporation quotefactor second quarter stryker expect adjust earning share range notably indicate rise year year basis believe grow adoption mako robot drive sale orthopedic reconstructive surgery market additionally stryker be well poise acquisition sage physio control past full year company expect adjust earning band stryker expect organic sale growth full year tie indo uk institute health medicity program be important factor well notably be year partnership aim offer primary joint replacement orthopedic area hip knee trauma product healthcare service india low cost company estimate revision trend be encourage current quarter stryker see upward estimate movement movement opposite direction last month current quarter estimate earning share be peg stock warrant lookhere be company want consider proven model show have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
201,BDX,resm inc rmd free report be slate report fourth quarter fiscal result market close aug last quarter company deliver positive earning surprise quarter average earning beat be let see thing be shape announcement factor playmanagement expect sg expense margin band yet be report quarter be third quarter also expense margin be project fourth quarter compare precede quarter hence expect bottom line drag continue yet be report quarter resm inc price ep surprise resm inc price ep surprise resm inc quotemeanwhile company generate significant portion revenue international market notably last report quarter currency impact resm combine emea asia pacific revenue be likely dent result fourth quarter well moreover overall macroeconomic uncertainty be major obstacle come company international operation also market sleep disordered breathe sdb product be highly competitive respect product price feature reliability other challenge competitive bidding reimbursement pressure continue hurt stock brighter side expand chronic obstructive pulmonary disease copd market be huge opportunity resm line company release positive datum pertain clinical trial related home oxygen therapy home mechanical ventilation hot hmv result demonstrated copd patient receive invasive ventilation niv home oxygen therapy have decrease risk re hospitalization death stay hospital more time longer compare receive oxygen alone company current endeavor gain traction copd market be expect boost revenue further major breakthrough treatment sleep apnea resm introduce airtouch full face mask ultrasoft memory foam keep patient cpap therapy comfortable night airtouch be available canada now be expect drive company top line yet be report quarter resm effort expand business internationally be encourage company revenue performance segment report third quarter be impressive expect company maintain similar trend quarter resm estimate revision trend be also encourage current year company see estimate move north movement opposite direction last month have take current year estimate same period earning whispersour proven model do not conclusively show earning beat resm quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp resm have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank resm have zack rank increase predictive power esp however company esp make surprise prediction difficult meanwhile caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
202,BDX,stock market continue winning streak fourth straight session major index end positive territory tuesday investor have pin high hope second quarter earning result evaporation trade war concern least time be robust economy also boost investor confidence equity boy positive record highest close more month dow jone industrial average dji close increase point index inx close nasdaq composite index ixic close gain point total share be trade tuesday lower last session average share advancer outnumber decliner nyse ratio nasdaq decliner have edge advancer ratio cboe vix decrease close do benchmark perform dow rise reflect first successive day positive territory jun notably stock blue chip index close green trade red remain unchanged advanced record highest close feb consumer staple select sector spdr xlp utility select sector spdr xlu gain respectively notably sector benchmark index end positive territory similarly tech laden nasdaq composite be marginally point due broad base market rally earning expectation mount upmarket participant be expect strong show american corporate second quarter earning season slowly gathering steam total earning index be expect be same period last year backed year year growth revenue big driver positive revision be obviously direct impact tax cut read more keep bank stock beverage soft drink behemoth pepsico inc pep free report report second quarter result earning top estimate sale lag adjust earning share beat zack consensus mark however net revenue increase year level lag zack consensus estimate read more pepsico stock earning beat revenue lag follow earning result share price pepsico soar strong earning pepsico also lift stock price other consumer staple major such coca cola co ko free report procter gamble co pg free report respectively notably banking giant jpmorgan chase co jpm free report citigroup inc free report well fargo co wfc free report report second quarter earning result week tuesday share price jpmorgan chase citigroup well fargo decline respectively financial select sector spdr xlf also decline banking stock carry zack rank hold see complete list today zack rank stock here economy remain robustwall street continue rally tuesday investor shrug trade war fear buoy strong economic datum friday job market datum reduce concern unite state be late stage economic expansion stock make headlinesbd buy tva medical provide minimally invasive procedurebecton dickinson co bdx free report recently complete acquisition texas base tva medical financial term deal have be keep wrapped read more qep resource sell uinta asset deepen focus permianqep resource inc qep free report recently inked deal offload oil gas asset uinta basin bid sharpen focus prolific permian play read more more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
203,BDX,mckesson corporation mck free report largest healthcare service provider be schedule report first quarter fiscal result jul last report quarter company earning surpass zack consensus estimate also last quarters mckesson earning beat zack consensus estimate average let see thing be shape prior announcement likely positive surprise proven model show mckesson be likely beat earning have perfect combination key ingredient zack esp mckesson have earning esp most accurate estimate be peg zack consensus estimate be favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank mckesson currently carry zack rank hold note stock zack rank strong buy buy have significantly higher chance beating earning estimate conversely caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision combination mckesson zack rank esp make reasonably confident earning beat drive better expect earning mckesson be major player pharmaceutical medical supply distribution market management expect gain gradually stabilize generic brand market company distribution solution segment perform favorably fiscal weak pricing trend customer consolidation also mckesson expect earning share range fiscal distribution solution business revenue growth be expect increase mid single digit year year keep mind last quarter performance promising guidance expect similar trend yet be report quarter mckesson corporation price ep surprise mckesson corporation price ep surprise mckesson corporation mckesson be likely benefit acquisition covermymed llc quarter be report regard note acquisition be complete fourth quarter fiscal international segment management expect percentage revenue growth mid single digit constant currency basis management international business be likely be impact additional reimbursement cut incremental cut impact fiscal be significantly smaller fiscal however continue volatility unfavorable pricing trend reimbursement generic drug significant fluctuation nature frequency magnitude generic pharmaceutical launch have adverse impact mckesson also competitive landscape add wo other stock considerhere be other company consider model show also have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here thermo fisher scientific inc tmo free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
204,BDX,feb issue update research report steris plc ste free report company have be actively try expand adjacent market strengthen core business acquisition dilution however company operate tough competitive landscape be concern stock carry zack rank hold developer manufacturer marketer infection prevention decontamination microbial reduction surgical support product service have outperformed industry past year stock have gain compare industry rally steris exit third quarter fiscal mixed note earning beating zack consensus estimate revenue miss same be encourage favorable underlie market trend new product service offering company organic growth be strong specialty service life science apply sterilization segment be particularly upbeat steris acquisition first month fiscal buyout company aim strengthen healthcare product healthcare specialty service apply sterilization technology business furthermore finance cash hand credit facility borrowing company have incur acquisition cost net cash acquire include potential contingent consideration believe steris pursue back back acquisition long run order expand business customer base courtesy strong financial position be also encourage company recent organizational change serve customer better way also expect move enhance company cost structure further growth free cash flow reserve be indicative company strong cash balance meanwhile steris compete pharmaceutical research industrial customer several large company have extensive product portfolio global reach well number small company limit product offering operation few country company expect face intense competition new infection prevention sterile process contamination control surgical support product service enter market hamper steris growth considerably moreover number steris customer be undergo consolidation partly due healthcare cost reduction measure initiate competitive pressure well legislator regulator third party payor believe company fail check rate customer consolidation now adversely affect business well financial condition key pickssome better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy becton dickinson company be zack rank player company have long term expect earning growth rate zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
205,BDX,laboratory corporation america holding lh free report labcorp have gain last year industry gain stock have market cap company year historical growth rate be also favorable compare index consider stable performance stock expect labcorp scale higher come quarters also company long term expect earning growth rate look promising company deliver positive earning surprise last quarters solid growth prospect zack rank buy stock be attractive pick present let find recent positive trend be sustainable company have impressive growth style score growth style score highlight vital metric company financial obtain clear picture quality sustainability growth research show stock style score combine zack rank strong buy hold offer best investment opportunity stock have vgm score northward revision current estimate revision trend be favorable current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year rise share company project annualize earning growth rate be strong earning market be upbeat company fourth quarter result year year increase adjust earning revenue be encourage labcorp diagnostic business be solid back increase acquisition organic volume expansion favorable foreign exchange scenario several quarters dull performance covance drug development have be deliver sturdy growth past couple term uptrend be attribute chiltern takeover robust organic growth positive foreign currency translation also guidance look promising believe integration newer acquisition labcorp be perfectly position drive long term profitable growth combination world class diagnostic drug development expertise knowledge service solid guidance full year revenue growth be estimate band include likely improvement basis point bps foreign currency translation zack consensus estimate current year revenue be peg adjust earning share ep guidance be project range consensus mark metric fall guidance free cash flow have be project growth be expect band year other key picksa few other top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson be zack rank player company have long term expect earning growth rate zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
206,BDX,medtronic plc mdt free report expand product portfolio introduction minime advance infusion set recent offer diabetes business be commercially available canada hong kong certain country europe fourth quarter fiscal however company plan extensive launch same notably minime advance infusion set witness limit launch country initial product introduction period third quarter fiscal customer be satisfied experience minime advance infusion set limit launch period company be optimistic effectiveness system be expect witness greater customer adoptability time drive top line progress minime have be forge ahead initiative boost performance minime portfolio recently company report positive datum home pediatric study patient age year datum be base minime system be demonstrated advanced technology treatment diabetes international conference vienna austria notably medtronic commercially launch minime system june be hybrid close loop insulin delivery system type diabetic patient age year older minime system feature medtronic latest guardian sensor glucose sensor increase accuracy enhance performance development diabetes witness rise constant exchange rate revenue diabetes business third quarter fiscal company benefit positive uptake new sensor augment insulin pump system unite state well international market enhance production capacity same notably medtronic expect double digit growth segment fourth quarter fiscal courtesy consistent performance minime system unite state enhance sensor supply capacity additionally medtronic have be gear international launch minime launch cgm system guardian connect sugar iq late new professional cgm ipro regard company also announce favorable result support use cgm patient type diabetes october market potentialan agee population unhealthy lifestyle rise awareness expenditure healthcare be likely drive growth diabetes market report mordor intelligence global market diabetes care device be project reach value cagr consider bullish market sentiment believe latest development have arrived opportune moment price have be underperform broader industry past month stock have decline versus industry rally however believe introduction minime advance infusion set help company regain investor optimism zack rank key picksmedtronic carry zack rank hold few better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy becton dickinson be zack rank player company have long term expect earning growth rate zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
207,BDX,abbott free report announce availability freestyle librelink app europe use smartphone iphone android notably diabetes patient used freestylelibre system europe longer need carry freestyle libre get glucose result diabetes patient now be able check glucose result directly smartphone company freestyle librelink app allow user hold smartphone freestyle libre sensor capture view real time glucose level also show hour glucose history glucose level be change freestyle librelink app customer have access several update new feature compare freestyle libre reader company also say app replace reader also be used combination other freestyle librelink customer have option share information physician libreview librelinkup be other digital health tool be part freestyle libre platform freestyle librelink app be free cost iphone android user initially be available european country also abbott be plan mobile app solution freestyle libre user outside europe base country regulatory approval development freestyle librefreestyle libre system be flagship sensor base continuous glucose monitoring cgm system company have be witness solid growth global diabetes care business notably diabetes care sale rise comparable operational basis last report fourth quarter buoy double digit international sale growth lead continue consumer uptake freestyle libre accordingly be leave stone unturned cash grow popularity system eliminate need daily finger stick follow fda approval september freestyle libre flash glucose monitoring system abbott recently achieve major milestone center medicare medicaid service cms grant freestyle libre approval medicare coverage meanwhile abbott have be steadily progress development diabetes care segment last september company announce receipt national reimbursement freestyle libre mark milestone company notably freestyle libre system be partially fully cover country include france germany japan moreover company announce receipt health canada license freestyle libre flash glucose monitoring system june drive diabetes care segment see revenue growth third quarter continue acceptance freestyle libre internationally market potentialaccord report mordor intelligence global market diabetes care device be expect reach value cagr consider huge potential market believe latest development help abbott gain traction space share price estimate revision trendabbott have be gain investor confidence consistently positive result last month stock have outperformed broader industry have gain comparison broader industry current estimate revision trend be favorable current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have rise share zack rank key picksabbott carry zack rank hold better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
208,BDX,qiagen qgen free report recently announce receipt japan ministry health labor welfare approval quantiferon tb gold qft diagnostic detect tuberculosis tb infection notably build quantiferon tb gold qft platform qft provide enhance analysis tb infection advanced kit make tb testing innovative antigen possible measure cell mediate immune response cd cd cell believe approval help qiagen expand customer base drive uptake qft test thereby boost top line quantiferon tb diagnostic test quantiferon tb diagnostic test kit fall qiagen molecular diagnostic segment be highest revenue grosser last report quarter notably segment contribute total revenue substantial growth quantiferon latent tb test qiasymphony automation system consumable portfolio solid performance companion diagnostic pharma collaboration regard post receipt fda approval june qiagen have announce complete launch fourth generation blood test tb infection quantiferon tb gold qft unite state furthermore continue slew development qiagen announce signing collaboration agreement diasorin january post collaboration qiagen quantiferon tb diagnostic test be available diasorin liaison portfolio fully automate analyzer be not first time qiagen be partner renown diagnostic ivd player june company have partner develop test base review selection process involve qiagen assay technology test diasorin liaison family analyzer latest announcement qft stand be first assay qiagen quantiferon portfolio be available use liaison family system moreover agreement company be work develop completely automate version quantiferon test read component use quantiferon tb test future quantiferon base test be adopt use liaison regard company plan launch ce marked quantiferon read component use liaison xl third quarter moreover launch unite state launch china be plan same market prospectsqiagen have be witness substantial demand thequantiferon tb diagnostic test kit notably company announce milestone conduct quantiferon tb test globally initial launch end accord research market datum publish business wire global tb diagnostic market be expect see cagr share price have be gain investor confidence consistently encourage result past month company share price have outperformed broader industry stock have gain contrast broader industry decline zack rank key picksqiagen carry zack rank hold better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
209,BDX,feb issue update research report qiagen qgen free report stock carry zack rank hold netherlands base molecular diagnostic provider offer innovative technology product pre analytical sample preparation molecular diagnostic solution stock have be trading broader industry past month latest share price have lose compare decline broader industry company end fourth quarter solid note earning revenue beating zack consensus estimate quarter qiagen molecular diagnostic sale increase significantly dynamic growth quantiferon latent tb test also double digit cer growth revenue company companion diagnostic partnership sustain double digit cer growth consumable related qiasymphony automation system contribute top line moreover report quarter company surpass goal qiasymphony placement reflect strong demand system management now aim surpass cumulative qiasymphony placement end also company focus drive growth sample insight offering buoy optimism be also upbeat qiagen solid progress test menu expansion strategy regard january company ipsogen jak rgq pcr kit ipsogen jak assay receive fda approval additional use diagnosis neoplasms mpns also look forward implementation recently draw strategy boost top line contribution ngs portfolio meanwhile qiagen be expose stiff competition company be face intensify competition firm provide competitive pre analytical solution other product used qiagen customer market company product be very competitive price sensitive add concern also strong reliance collaboration decline hpv sale unite state be other negative key pickssome better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
210,BDX,bruker corporation brkr free report report adjust earning share ep cent fourth quarter year figure also adjust ep beat zack consensus estimate couple cent revenue detailbruker report revenue fourth quarter year year top line surpass zack consensus estimate exclude positive effect acquisition favorable impact change foreign currency rate bruker report year year organic revenue growth bruker corporation price consensus ep surprise bruker corporation price consensus ep surprise bruker corporation currency adjust european revenue improve high single digit year year fourth quarter north america revenue decline mid single digit asia pacific organic revenue increase double digit china revenue rise mid single digit fourth quarter management company register organic revenue growth strength nano best bruker biospin group revenue decline low single digit organic basis due customer push out revenue nano group increase low teen organic basis significant growth semiconductor metrology business ray nano analysis product material research industrial academic research application calid revenue be low single digit organic basis strong performance mass spec optic product line be partially offset year year decline calid detection business best revenue rise organically margin trenda percentage revenue gross margin report quarter expand basis point bps selling general administrative expense increase research development expense rise year year overall adjust operate margin expand bps other charge rise year year financial positionbruker exit cash cash equivalent short term investment end precede year full year net cash used operate activity be compare year period glancein bruker revenue rise figure beat zack consensus estimate fiscal bruker year year organic revenue growth be growth acquisition be favorable effect change foreign currency rate be adjust ep be compare figure surpass zack consensus estimate guidancebruker issue guidance company expect revenue growth approximately include organic revenue growth approximately company expect year year increase adjust operate margin range bps fiscal bruker expect adjust ep range previous range zack consensus estimate be lower end company guidance takebruker exit fourth quarter solid note year year increase revenue earning expansion gross operate margin buoy optimism company strategic acquisition activity have be encourage be also upbeat company current focus product development higher flip side competitive landscape macroeconomic headwind continue challenge company zack rank key picksbruker carry zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue be constant currency hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
211,BDX,hologic inc holx free report report first quarter fiscal adjust earning share ep cent year year moreover adjust ep beat zack consensus estimate surpass company guidance cent report basis company record ep compare cent first quarter fiscal notably report figure include time tax provision net benefit courtesy tax reform revenue detailrevenue gross quarter year year constant exchange rate cer top line also exceed zack consensus estimate company guidance solid contribution hologic molecular diagnostic breast health international business drive top line geographically revenue unite state grow year year exclude blood screening medical aesthetic revenue decline international revenue be cer banking strong contribution cynosure exclude blood screening medical aesthetic international revenue increase constant currency hologic inc price consensus ep surprise hologic inc price consensus ep surprise hologic inc quotesegment detailrevenue diagnostic segment total revenue decline year year cer first quarter segment molecular diagnostic revenue increase cer global growth molecular diagnostic be primarily drive increase market share utilization fully automate panther system continue solid uptake aptima woman health product cytology perinatal revenue also show rise cer revenue breast health segment inched cer revenue unite state slip report quarter change product mix be partially offset increase service new product revenue international revenue however climb year year cer revenue gyn surgical business be cer medical aesthetic business quarter report revenue determine total revenue revenue skeletal health accounting rest decrease cer operational updatein fiscal first quarter hologic gross margin contract basis point bps adjust gross margin also decrease bps due divestiture blood screening business revenue low margin cynosure product hologic adjust operate expense amount year year adjust operate margin contract massive bps financial updatehologic exit first quarter fiscal cash cash equivalent report end first quarter fiscal total long term debt be end report quarter compare year quarter company generate operate cash flow compare year cash flow guidancehologic have update fiscal financial guidance company currently expect adjust revenue grow range compare previously provide range cer current zack consensus estimate be guide range adjust ep be expect grow previously state range current zack consensus estimate adjust ep be peg guide range second quarter fiscal hologic expect adjust revenue represent annualize growth cer current zack consensus estimate revenue be peg project range adjust ep be project cent reflect annualize growth current zack consensus estimate second quarter adjust ep be peg cent company guidance takehologic post better expect result first quarter fiscal term earning revenue growth geographical region buoy optimism however be disappoint decline revenue company diagnostic segment blood screening divestiture be also likely impede growth momentum company zack rank key pickshologic carry zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue be constant currency hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
212,BDX,surmodic inc srdx free report report adjust earning cent share first quarter fiscal lower year figure cent zack consensus estimate be loss cent revenue quarter fall miss zack consensus estimate stock have zack rank hold segment report revenue segment medical device diagnostic ivd medical devicein report quarter sale decline due lower hydrophilic royalty revenue royalty license fee revenue totale year year management decline royalty license fee revenue be cause lower royalty result expiration patent third generation hydrophilic coating unit generate operate loss report quarter compare unfavorably operate income year quarter operate income segment be affected plan increase investment related surmodic whole product solution strategy reduction royalty revenue well increase contingent consideration expense ivdin quarter review sale increase upside come back strong growth stabilization biofx microarray antigen product sale ivd operate income be current quarter compare first quarter fiscal surmodic inc price consensus ep surprise surmodic inc price consensus ep surprise surmodic inc quote margin detailsproduct gross margin contract basis point bps first quarter product sale compare year period margin quarter suffer expense irish facility infrastructure lower medical device product gross margin first quarter fiscal expense be net sale higher net sale year quarter company anticipate expense increase fiscal thank company whole product solution strategy investment advance transcend drug coater balloon human clinical trial preclinical work knee platform av fistula drug coat balloon project sg expense first quarter fiscal be revenue expand bps year year balance sheet cash flowat end first quarter company have cash investment surmodic generate cash operate activity company invest plant equipment continue expect fiscal year revenue range company expect fiscal earning share negative cent cent compare previous estimate adjust loss cent bottom linesurmodic end first quarter fiscal favorable note courtesy solid performance diagnostic segment segment have be gain ground back strong growth stabilization biofx microarray antigen product sale surmodic issue solid guidance fiscal company solid initiative strengthen research development program hold promise company witness significantly high operate loss specifically ireland product sale decline substantially owing shipment issue particularly medical device segment further foreign exchange wo related creagh medical buyout have be major dampener surmodic drug coat balloon face stiff competition niche space company margin be expect be pressure thank expense irish facility infrastructure lower medical device product gross margin key picksa few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm report third quarter fiscal result adjust earning share be cent prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue totale constant currency hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
213,BDX,cvs health corporation cvs free report fourth quarter adjust earning share ep be year year adjust ep also beat zack consensus estimate cent time adjustment exclude impact income tax benefit result latest tax reform report ep continue operation come share surge year period full year adjust ep come improvement year adjust number net revenue fourth quarter increase year year exceed zack consensus estimate cvs health corporation price consensus ep surprise cvs health corporation price consensus ep surprise cvs health corporation quoterevenue year be improvement revenue also beat zack consensus estimate quarter detailspharmacy service revenue increase report quarter drive growth specialty pharmacy volume higher pharmacy network volume well brand inflation be however partially offset increase generic dispense continue price compression pharmacy network claim processed quarter climb day equivalent basis backed net new business growth also mail choice processed claim count be day equivalent basis continue adoption maintenance choice offering rise specialty pharmacy claim revenue cvs health retail ltc be marginal year year accord company increase same store prescription day equivalent basis brand inflation be partially offset continue reimbursement pressure increase generic dispense rate front end same store sale be year year be positively impact basis point seasonal cough cold front store sale be adversely affected soft customer traffic effort rationalize promotional strategy be partially offset increase basket size pharmacy same store sale increase report quarter sale be adversely affected approximately basis point bps due recent generic drug introduction apart marketplace change restrict cvs pharmacy participate certain network have bps negative impact same store prescription volume report quarter generic dispense rate proportion generic prescription total number prescription dispense increase approximately bps pharmacy service segment bps retail ltc segment gross profit improve however gross margin contract bps total operate margin quarter decline bps cvs health exit year cash cash equivalent short term investment compare end full year net cash provide operate activity be year period fourth quarter cvs health open new retail store close relocate retail location dec cvs health operated retail store include pharmacy target store state well district columbia puerto rico brazil company have revise outlook revision reflect effect tax reform achieve tax cut job act tcja management note cash benefit tcja company be able make strategic investment stimulate greater growth longer term accordingly company have increase adjust operate profit growth guidance range earlier state range earlier provide initial outlook cvs health note expect deliver net revenue growth year current zack consensus estimate full year revenue be peg first quarter company expect register adjust operate profit growth range takecvs health end year solid note better expect fourth quarter performance year year growth top line be drive strong pharmacy service segment benefit upside specialty service however year year retail ltc comparison be dull zack rank key pickscvs health have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue be constant currency make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
214,BDX,integer holding corporation itgr free report report adjust earning cent share fourth quarter compare cent year quarter further earning beat zack consensus estimate cent revenue rise year year report basis exceed zack consensus estimate notably revenue improve organic basis sale grow report organic basis courtesy solid performance company cardio vascular business stock have zack rank sell integer holding corporation price consensus integer holding corporation price consensus integer holding corporation quote segmental analysisinteger holding operate segment medical sale medical sale medical salessale segment be year year revenue increase organic basis total medical sale have subsegment advanced surgical orthopedic portable medical cardio vascular cardiac neuromodulation advanced surgical orthopedic portable medicalrevenue amount prior year quarter report basis comparable organic constant currency basis advanced surgical orthopedic portable medical revenue rise year year be primarily drive stable performance portable medical space new launch orthopedic arthroscopic platform cardio vascularrevenue segment totale prior year quarter come back strong demand exist oem product line contract component comparable organic constant currency basis revenue improve prior year figure be primarily drive higher customer demand vascular access product cardiac segment totale rise prior year quarter comparable organic constant currency basis cardiac neuromodulation revenue increase relentless focus customer relationship numerous value add service opportunity economic efficiency be expect drive sale segment fact company be well position optimize total cost ownership supply chain control segment medical sale sale segment totale year year report organic basis margin analysisinteger holding generate gross profit fourth quarter year year percentage revenue gross margin fourth quarter expand basis point bps total operate income fourth quarter be year year percentage revenue operate margin fourth quarter expand bps glancein integer holding register revenue improve report basis organic basis year year total medical sale quarter be net revenue medical sale be almost net revenue guidanceinteger holding expect revenue range adjust comparable basis reflect year year growth zack consensus estimate revenue be currently peg adjust earning be project range share reflect year year growth zack consensus estimate adjust earning be currently peg bottom lineinteger holding end fourth quarter solid note strong performance medical medical unit however cardiac neuromodulation remain flat year year integer holding cardiac rhythm management unit have be sluggish also revenue headwind be concern thank private insurance rate reduction higher provision rental revenue adjustment lower net patient addition owing continue reimbursement decline company expect rental revenue patient fall upcoming quarters major positive company provide positive guidance full year company steadfast focus customer relationship focus cost reduction burgeon financial performance be key catalyst integer holding derive significant portion revenue medicare service reimbursement program key picksa few better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank buy becton dickinson have zack rank company have long term expect earning growth rate zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
215,BDX,omnicell inc omcl free report have be gain investor confidence consistently positive result past year stock have rally mountain view base developer marketer end end automation solution medication use process have market cap company year project growth rate be favorable compare broader industry however estimate revision trend zack rank hold company current year have be mixed last day analyst revise estimate upward movement opposite direction however estimate revision earning increase share same time frame factor playwe note stock be progress well legged strategy cover market expansion delivery differentiate innovative solution expansion new market primarily outside unite state expansion strategic partnership acquisition new technology last report quarter company gain new prominent customer well significant strategic deal exist customer thereby progressed first leg strategy apart xt series momentum company be witness market momentum value validate entire omnicell platform strategic solution omnicell xr automate central pharmacy system be likely be available mid be already gain significant momentum market number contractual booking fourth quarter second leg expand new market be drive growth acute care segment company continue focus middle east south africa also see greater adoption technology other part world latest be australia internationally company have sign contract hcl hca healthcare pharmacy supply solution hospital third leg acquisition partnership be also progress successfully company most recent buyout be inpharmic mississippi base technology service company help omnicell expand capability performance center omnicell strong position sweden germany singapore middle east south africa china also buoy optimism company have be witness strong pipeline development country addition omnicell witness strong business trend europe have observed healthy acceptance medication adherence product meanwhile remain sideline past month omnicell have be underperform broader industry stock have decline versus industry fall moreover omnicell continue expect higher cost upcoming quarters stem integration aesynt ateb expense related recently launch xt series thereby add concern moreover omnicell be expose resilient hospital capital expenditure environment adversely affect adoption solution furthermore reimbursement mix have also affected endowment income further affect hospital spending capability company have win new deal larger hospital market be still susceptible economy credit condition key picksa few better rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
216,BDX,becton dickinson company bdx free report popularly know bd be currently top perform stock medtech space improvement price performance strong fundamental indicate stock bullish run therefore haven take advantage share price appreciation yet time add stock portfolio stock have zack rank buy long term expect earning growth rate be positive bd arguably earning growth be utmost importance determine stock potential surge profit level indicate solid prospect long haul here take look other factor be likely provide bd competitive edge medtech quarters come factor worth price appreciation glimpse company price trend reveal share have return compare favorably index rally current return be also greater industry gain price surge be attribute strong investor optimism stock consider bd scale size commercial platform industry lead brand solid acquisition strategy be likely drive growth becton dickinson company price becton dickinson company price becton dickinson company quote recently company establish third business segment bd interventional notably recently acquire bard be integrate vertical regard management confirm bd be track become biggest medical technology device company world follow buyout acquisition be expect generate benefit complementary business geographical expansion also boost company share price upcoming day launch recently bd announce commercial availability ce ivd marked paxgene blood circulate cell free dna ccfdna tube european economic area switzerland western europe plastic tube used blood collection be develop preanalytix gmbh joint venture bd netherlands base provider sample insight solution qiagen qgen free report preanalytix be jointly form bd qiagen develop manufacture sell integrate standardized system sample collection stabilization purification rna dna human blood bone marrow study market market global molecular diagnostic market be project reach cagr northward estimate revision company zack consensus estimate earning fiscal reflect year year growth moreover earning be expect register growth fiscal fiscal zack consensus estimate revenue be peg reflect year year improvement moreover revenue be expect witness growth fiscal becton dickinson company price consensus becton dickinson company price consensus becton dickinson company quote guidance strong include accretion bard acquisition bd expect fiscal revenue increase range report basis however revenue be expect grow range notably revenue be likely be affected change dispense business model company expect adjust earning share range current range indicate growth approximately report basis approximately cc geographical expansion bd continue focus geographical expansion overseas market particular emerge market first quarter fiscal international revenue grow year year basis growth be drive kiestra installation strength core microbiology diagnostic system well strong sale clinical instrument bioscience unit strength pre filled flush device mps strong growth pharmaceutical system also contribute international growth develop market revenue grow first quarter include anticipate headwind dispense change basis point bps growth be drive strong performance europe pharmaceutical system diagnostic system combination bd bard augment company growth profile develop market fiscal bd estimate develop market growth report basis adjust basis market be expect grow year year exclude estimate bps impact dispense change hurricane puerto rico other key picksa few other top rank stock broader medical sector be bio rad laboratory bio free report perkinelmer pki free report bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
217,BDX,edward lifescience corporation ew free report have be healthy growth trajectory late positive tiding regulatory front strategic acquisition have be provide company competitive edge medtech solid prospect zack rank buy stock be attractive pick moment edward lifescience have outperformed broader industry last month stock have gain ahead gain broader industry stock have market cap company year historical growth rate be also favorable compare increase industry gain company have positive earning surprise last quarters also have long term expect earning growth rate headquarter irvine company estimate revision trend current year have be positive past couple month analyst moved north movement opposite direction earning estimate rise share same time frame let find recent positive trend be sustainable edward lifescience fourth quarter performance be quite promising company beating zack consensus estimate revenue earning also raise guidance hint brighter prospect fact raise outlook be backed strong performance company product line market be also upbeat edward lifescience recent ce mark self expand centera valve regulatory approval be likely boost company transcatheter heart valf thv segment edward lifescience recently acquire harpoon medical inc privately hold medical technology company focuse beating heart repair degenerative mitral regurgitation agreement harpoon medical flagship beating heart repair procedure mitral valve patient harpoon system be add edward lifescience surgical heart valve therapy portfolio treat structural heart disease other key picksother top rank stock broader medical sector be perkinelmer pki free report bio rad laboratory bio free report becton dickinson company bdx free report bio rad laboratory have zack rank see complete list today zack rank strong buy stock here company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank becton dickinson company have zack rank company have long term expect earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
218,BDX,becton dickinson company bdx free report popularly know bd have recently announce commercial availability ce ivd marked paxgene blood circulate cell free dna ccfdna tube european economic area switzerland western europe plastic tube used blood collection be develop preanalytix gmbh joint venture bd netherlands base provider sample insight solution qiagen qgen free report research use only ruo version paxgene blood ccfdna tube have be market preanalytix expand access product europe further consolidate bd foothold molecular diagnostic testing space management launch also heighten growth prospect company western europe offer ccfdna base test becton dickinson company price consensus becton dickinson company price consensus becton dickinson company quotepaxgene paxgene blood ccfdna tube provide solution clinical laboratory sample be processed same day be used collection whole blood sample stabilization ccfdna paxgene sample be store room temperature day stabilization be convenient clinical laboratory collection process occur day apart standard edta acid tube tube include proprietary sample stabilization additive bd vacutainer hemogard technology assure healthcare worker safety ascertain accurate consistent result molecular diagnostic testing application used ccfdna be used treat cancer also reduce potential error invasive prenatal test be jointly form becton dickinson qiagen view develop manufacture sell integrate standardized system sample collection stabilization purification rna dna human blood bone marrow offer broad array manual automate product addition serve healthcare institution academic researcher clinical laboratory gainful market prospectsper study market market global molecular diagnostic market be project reach cagr high prevalence infectious disease various type cancer be major factor drive market thus bd paxgene have solid market prospect be optimistic launch be perfectly strategic new development be also likely secure broader customer base europe price performancelast year becton dickinson have outperformed broader industry term price stock have return industry rally zack rank key picksbecton dickinson carry zack rank buy other top rank stock broader medical space be centene corp cnc free report haemonetic corp hae free report sporting zack rank strong buy see complete list today zack rank stock here centene have project positive long term growth rate last month stock have return haemonetic have expect long term growth rate last month stock have return today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
219,BDX,cardinal health inc cah free report report second quarter fiscal adjust earning share beat zack consensus estimate however exclude cent benefit legislate tax reform adjust earning be share meanwhile adjust earning year quarter be share revenue increase year year basis almost beat zack consensus estimate cardinal health inc price consensus ep surprise cardinal health inc price consensus ep surprise cardinal health inc stock have zack rank buy segmental revenue increase year year basis segment witness strong growth specialty business also gain large number pharmaceutical distribution customer however segment witness decline profit thank generic pharmaceutical pricing recent investment pharmaceutical platform lackluster generic program performance however solid performance specialty solution business partially offset negative impact segment medical segmentrevenue segment improve primarily higher contribution new exist customer medical segment profit increase courtesy higher contribution new exist customer acquisition patient recovery business share repurchase company board director approve new authorization repurchase company common share expire dec latest authorization cardinal health be authorize repurchase common share marginsas percentage revenue gross margin contract basis point bps net revenue however gross profit quarter be year year distribution selling general administrative sg expense increase year year basis benefit cent share lower federal rate due tax reform cardinal health raise fiscal outlook company expect adjust earning share continue operation range share higher previous range takecardinal health exit quarter solid note courtesy encourage performance medical segment pharmaceutical segment witness strong growth specialty business gain large number pharmaceutical distribution customer further company be banking strategic buyout joint venture supply agreement drive growth strong fiscal outlook buoy optimism flip side growth business profit pharmaceutical segment be hurt generic pharmaceutical pricing huge investment pharmaceutical platform lackluster generic performance be likely mar cardinal health operational efficiency upcoming quarter intense competition customer concentration be other bottleneck recently company recently close divestiture cardinal health china distribution other key picksa few other top rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank see complete list today zack rank stock here petm report third quarter fiscal result adjust earning share be cent prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue totale constant currency make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
220,BDX,feb issue update research report illumina inc ilmn free report zack rank hold stock last month san diego base company provide tool integrate system analysis genetic variation function have gain higher broader industry illumina exit fourth quarter solid note beating zack consensus estimate front additionally revenue earning improve year year basis apart improve margin scenario instilled investor confidence stock be also optimistic illumina expansion strategy enhancement portfolio sequence product development strategic partnership therapeutic diagnostic service provider regard january illumina sign commercial agreement distribute thermo fisher scientific ion ampliseq technology researcher conduct study illumina next generation sequence platform currently illumina be focuse product innovation research development well be evident recent launch iseq sequence system post promising fourth quarter expect illumina maintain growth momentum continue uptake sequence consumable instrument microarray portfolio meanwhile illumina face stiff competition sequence snp genotyp gene expression molecular diagnostic market several large player already enjoy significant market share intellectual property portfolio regulatory expertise also national institutes health nih funding issue raise concern key pickssome better rank stock broader medical sector be bio rad laboratory bio free report becton dickinson company bdx free report perkinelmer pki free report bio rad laboratory have zack rank buy see complete list today zack rank strong buy stock here company have long term expect earning growth rate becton dickinson company have zack rank company have long term expect earning growth rate perkinelmer have long term expect earning growth rate stock carry zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
221,BDX,cardiovascular system inc csii free report report adjust loss share penny second quarter fiscal year quarter adjust earning cent figure be narrower earlier guide range loss share cent figure also compare favorably zack consensus estimate loss cent net system record revenue fiscal second quarter mark year year increase also figure be guide range however revenue miss zack consensus estimate cardiovascular system inc price consensus ep surprise cardiovascular system inc price consensus ep surprise cardiovascular system inc quote segment detailscoronary device revenue increase year year date cardiovascular system have sell device lead institution unite statesmeanwhile peripheral device revenue rise year year basis company add new peripheral account coronary account fiscal second quarter margingross margin report quarter be basis point bps year year meanwhile selling administrative sg expense contract research development expense be resultantly adjust operate expense be management operate expense be lower earlier provide guidance due reduce incentive compensation payroll expense operate loss be operate income year quarter financial company exit second quarter fiscal cash cash equivalent compare end precede quarter company have long term debt system update fiscal revenue guidance range current zack consensus estimate fiscal revenue be peg company guide range company expect revenue range third quarter fiscal current zack consensus estimate be peg company guide range moreover company expect gross profit account revenue operate expense be estimate third quarter fiscal company expect incur net loss adjust earning share be expect be negative cent breakeven current zack consensus estimate be peg earning cent company guide range system exit second quarter fiscal solid year year increase coronary device peripheral device segment overall revenue increase year year basis strength company segment also expansion be gross margin buoy optimism company be putt effort product innovation investment flipside cardiovascular system face cutthroat competition niche space cardio vascular incur net loss recently report second quarter fact company have long history net loss inception zack rank key system have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share be cent prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue totale constant currency make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
222,BDX,steris plc ste free report report third quarter fiscal adjust earning share ep exclude net tax benefit cent result tax reform report ep come adjust ep figure be year year be zack consensus estimate revenue detailsteris generate revenue year year meanwhile top line miss zack consensus estimate organic revenue growth constant currency be year year mainly drive high single digit low double digit growth majority segment company operate segment healthcare product healthcare specialty service apply sterilization technology life science revenue healthcare product remain relatively flat year year be largely due decline capital equipment revenue offset rise consumable revenue increase service revenue revenue healthcare specialty service segment fall report basis due linen divestiture however organic revenue grow reflect growth im north america steris plc price consensus ep surprise steris plc price consensus ep surprise steris plc quote revenue apply sterilization technology rise organic revenue grow increase demand core medical device customer revenue life science segment grow growth service revenue increase consumable revenue rise capital equipment revenue organic basis revenue increase year year marginsadjusted gross margin improve basis point bps year year report quarter account synergy divest low margin business favorable product mix pricing steris witness year year rise selling general administrative expense research development expense rise accordingly adjust operate margin expand bps year year basis report quarter financial detailssteris exit third quarter fiscal cash cash equivalent compare end second quarter fiscal company have long term debt end third quarter fiscal compare end second quarter fiscal year date company generate cash flow operation year period free cash flow period be compare prior year period guidancesteris continue expect organic revenue growth fiscal constant currency basis prior fiscal zack consensus estimate fiscal revenue be peg company have raise adjust ep outlook fiscal adjust ep be now project range comparison previously provide range zack consensus estimate fiscal adjust ep be peg guide range takesteris exit third quarter fiscal mixed note be encourage favorable underlie market trend new product service offering further growth free cash flow reserve be indicative company strong cash balance company have also make certain divestment organizational change be expect better align operation zack rank key pickssteris have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share cent be prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue be constant currency make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
223,BDX,be thick fourth quarter earning season member have report number current earning season have see average proportion positive surprise favorable revision trend present upcoming quarter strong revenue momentum latest earning preview total earning company have report so far be year year higher revenue total beat earning surpass revenue estimate member line release quarterly result week be decidedly bullish equity market be gradually demonstrate sequential improvement medtech earning so farmedical zack sector be expect stand quarter sector benefit favorable consumer behavior grow prevalence minimally invasive surgery demand liquid biopsy test use ensure quick improve patient care shift payment system value base model be evident result medtech heavyweight laboratory corporation america holding lh free report labcorp becton dickinson company bdx free report company end fourth quarter solid note earning beating zack consensus estimate upbeat fy guidance also instill confidence regard labcorp adjust ep guidance be range further becton dickinson company expect adjust earning share band previous fourth quarter expect earning growth rate sector be revenue growth cah holx see stronger earning let take look major medtech stock cardinal health cah free report hologic inc holx free report slate release quarterly report feb cardinal health be schedule release result market open notably zack consensus estimate second quarter fiscal revenue be peg year year diverse product portfolio cardinal health be largest distributor pharmaceutical medical supply however zack consensus estimate second quarter earning be peg year year company face risk lose considerable business case loss major customer severely impair bottom line fact cardinal health announce loss large mail order customer prime therapeutic dent revenue company specialty pharmaceutical distribution segment last quarter cardinal health inc price ep surprise cardinal health inc price ep surprise cardinal health inc quotemoreover quantitative model do not conclusively show beat cardinal health be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate cardinal health have zack rank earning esp uncover best stock buy sell re report earning esp filter read more store cardinal health earning hologic be set report first quarter fiscal result market close notably zack consensus estimate earning be cent year year basis diagnostic segment be expect record revenue year quarter also zack consensus estimate show decline year year be blame estimate loss divest blood screening franchise also company have be see weak sale cytology perinatal product late bright side zack consensus estimate first quarter revenue be peg year year company be expect see stellar performance molecular diagnostic major sub segment diagnostic unite state company be expect gain expand market utilization fully automate panther system hologic inc price ep surprise hologic inc price ep surprise hologic inc quoteour quantitative model indicate earning beat hologic quarter have favorable combination earning esp zack rank see complete list today zack rank stock here zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
224,BDX,cerner corp cern free report report adjust fourth quarter earning cent share cent year quarter figure also miss zack consensus estimate cent revenue rise year year marginally miss zack consensus estimate last month cerner have have favorable run bourse stock have return compare industry gain cerner corporation price consensus ep surprise cerner corporation price consensus ep surprise cerner corporation quote segment detailssystem sale fourth quarter rise year year basis be drive primarily growth license software support maintenance service account revenue worth year year basis line management expectation reimbursement travel sale amount compare year quarter booking time upside revenue be primarily attribute increase booking fourth quarter booking be year year basis company report full year booking record compare level marginsgross margin fourth quarter be flat year year operate margin report quarter be contract basis point bps year year basis downside be cause surge operate expense rise year year growth be drive personnel expense related revenue generate associate cash item financial positionoperate cash flow fourth quarter be compare year quarter cerner exit fourth quarter cash cash equivalent long term debt include capital lease obligation be slightly sequential basis glancein domestic revenue grow revenue rise full year revenue be compare adjust earning share be compare gross margin be contract bps full year system sale account total revenue support maintenance service contribute whopping reimbursement travel segment represent mere total revenue guidancecerner expect first quarter revenue zack consensus estimate same fall project range revenue be project range zack consensus estimate same lag project range first quarter adjust earning share be project range cent figure lag zack consensus estimate cent full year adjust earning share be estimate range figure be higher zack consensus estimate further company expect first quarter new business booking range takecerner end fourth quarter mixed note company see significant surge booking grow revenue however dwindle earning be concern moreover sale margin be partially affected thank lower margin technology resale result higher mix device resale management large complex opportunity pipeline drive booking report quarter be likely drive booking quarters ahead zack rank other stock considercerner carry zack rank buy few other top rank stock report solid result be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share be cent prior year quarter revenue report quarter rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue be constant currency zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
225,BDX,myriad genetic inc mygn free report report adjust earning share ep cent second quarter fiscal year year moreover adjust ep beat zack consensus estimate solid margin exceed company guide range cent report earning come cent share quarter compare net cent year quarter revenuestotal revenue be year year quarter review figure however outpaced zack consensus estimate be company guidance year year decline be however cause fall hereditary cancer testing revenue owing price reduction long term contract myriad genetic inc price consensus ep surprise myriad genetic inc price consensus ep surprise myriad genetic inc quote however decline be partially offset grow new product volume expand reimbursement new product increase international rna kit revenue moreover be fourth consecutive quarter company witness year year hereditary cancer volume growth lead encourage response newly launch riskscore test myrisk hereditary cancer testing portfolio quarter detailssegment wise molecular diagnostic test total revenue record total revenue year year account decline hereditary cancer testing revenuesto endopredict testing revenue grow year year report quarter moreover vectra da testing revenue come year year other testing revenue decline prolaris testing space volume maintain double digit growth fiscal first quarter well increase average selling price benefit medicare favorable intermediate lcd be put effect sep prolaris test rake revenue quarter also hereditary cancer testing revenue decline due price reduction long term contract however volume growth exceed company growth target year year basis pharmaceutical clinical service revenue accounting rest quarter totale reflect year year increase margin trendsgross margin quarter review contract basis point bps accord management gross margin performance be affected hereditary cancer test pricing issue partially offset improve efficiency hereditary cancer production process result elevate initiative increase new product reimbursement operate expense decrease rise selling general administrative sg expense be offset slash research development expense report quarter financial positionmyriad genetic exit fiscal second quarter cash cash equivalent marketable security compare end precede quarter year date cash flow operation totale compare year period year date company register free cash flow compare year period guidancemyriad genetic have raise guidance fiscal revenue provide earlier zack consensus estimate lie guide range bottom line front company lift adjust ep range previous current zack consensus estimate be company guide range management have provide guidance third quarter fiscal company estimate adjust earning share cent total revenue zack consensus estimate adjust ep be cent revenue be viewmyriad genetic register better expect performance second quarter fiscal however year year decline revenue be disappointing positive note company observed strong growth genesight endopredict testing revenue recent fda approval encourage test result buoy optimism flip side unfavorable foreign currency translation continue threat considerable portion revenue come outside unite state company face risk exchange rate fluctuation zack rank key picksmyriad genetic have zack rank hold few better rank stock report solid result earning season be petm express pet free report perkinelmer pki free report becton dickinson company bdx free report petm sport zack rank strong buy perkinelmer becton dickinson carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share be cent prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter becton dickinson report first quarter adjust earning share constant currency revenue be constant currency zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
226,BDX,becton dickinson company bdx free report popularly know bd report first quarter fiscal earning share beat zack consensus estimate adjust earning increase constant currency cc year year basis company report revenue beating zack consensus estimate represent increase prior year quarter cc stock have zack rank buy segmental analysisbd medical bd medical segment generate revenue cc year year basis segment result reflect adverse impact change dispense business model however bd medical witness strong performance medication procedural solution well diabetes care pharmaceutical system unit becton dickinson company price consensus ep surprise becton dickinson company price consensus ep surprise becton dickinson company quote medication procedural solution register revenue bd medical segment year year cc diabetes care report revenue cc year year basis pharmaceutical system report revenue cc year year basis however medication management solution report revenue cc year year basis bd life bd life science segment generate revenue cc year quarter segment performance indicate strong number bioscience diagnostic system preanalytical system unit preanalytical system record revenue first quarter cc year year basis diagnostic system report revenue year year cc meanwhile bioscience unit register revenue cc geographic resultsunite statesu revenue be roughly year year basis bd medical segment growth medication procedural solution diabetes care unit be offset decline medication management solution pharmaceutical system unit bd life science segment result unite state be primarily drive diagnostic system preanalytical system unit report quarter international revenue rise cc bd medical bd life science segment register strong growth outside unite state bd medical segment growth be drive strength pharmaceutical system unit aid impressive result medication procedural solution diabetes care unit guidanceinclude accretion bard acquisition bd expect fiscal revenue increase range report basis however revenue be expect grow range notably revenue be likely be affected change dispense business model company expect adjust earning share range previous range current range indicate growth approximately report basis approximately cc bottom linebd end first quarter fiscal solid note beating zack consensus estimate count strong guidance fiscal instill investor optimism bd recently complete acquisition bard company now establish new segment bd interventional bard be integrate further collaboration check point health company obtain ce mark molecular screening test antibiotic resistant carbapenemase produce organism cpos bd max system flip side bd continue face headwind previously disclose change dispense business model further lackluster performance medication management solution unit be concern bd temporarily pause shipment insulin infusion set recent recall barricor blood collection tube quarter add wo other key picksa few other top rank stock report impressive earning season be petm express pet free report perkinelmer pki free report accuray aray free report petm sport zack rank strong buy perkinelmer accuray carry zack rank see complete list today zack rank stock here petm recently announce third quarter fiscal adjust earning share cent bottom line soar year year revenue report quarter rise year year perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter accuray report loss cent share second quarter fiscal result narrower cent year quarter figure top line improve year year more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
227,BDX,fda approval roche holding rhhby free report hemlibra coba cdiff nucleic acid test thermo fisher scientific tmo free report slew advancement next generation sequence latest be fda approve oncomine dx target test clearly point rapid emergence diagnostic ivd medtech space recent evaluatemedtech world preview indicate worldwide medtech sale be expect witness cagr steering ahead cardiology ivd rake annual sale cagr datum be just small indicator vast scope growth ivd market investor keen medtech most important fact be ivd benefit be not limit particular country geographic territory emergence complex transmittable disease worldwide part medtech space be currently spotlight ivd nutshellif go fda definition diagnostic be test detect disease condition infection test be used laboratory other health professional setting other test be consumer use home growth factorsrapid occurrence infectious disease worldwide increase burden killer bug cancer cardiovascular disease stroke other heart disease diabetes develop develop nation well grow cognizance early cancer screening detection prevention have make ivd indispensable healthcare space grow investment government private player form reimbursement coverage speedy patent approval be also drive demand apart report research market increase geriatric population rise capita gdp capita healthcare expenditure be act major growth catalyst report owing suitable demographical change rise disposable income couple improve basic infrastructure develop region be gradually become happy hunting ground business geographic distribution so far north america have lead diagnostic market coherent market insight datum be highest contribute region project market share cagr favorable demography regulatory policy increase healthcare spending have aid growth ivd business geography however increase instance lifestyle oriented disease improve government funding grow awareness new technology have fuel demand ivd emerge economy accord recent report research market china be fastest grow top ivd country market be likely expand more threefold other hand revenue indian ivd market have grow cagr have increase datum goldstein research segmental contribution medgadget report apart geographic distribution global diagnostic market have be segmented basis application type end user usability application wise diabetes infectious disease oncology nephrology autoimmune disease cardiology be generate huge revenue globe point view end user hospital laboratory point care testing be lead user term usability disposable ivd device re usable ivd device be widely used globe key player roche remain top player ivd market expect sale key ivd development roche include coba range test latest be coba first commercially available test detection virus rna sample human plasma other hand abbott free report recent acquisition alere establish company global leader point care testing fastest grow segment diagnostic market regard company note point care testing be segment diagnostic market be grow rapidly other bigwig becton dickinson company bdx free report deserve mention company be strive get approval innovative product fast grow infectious disease testing market bd diagnostic provide product safe collection transport diagnostic specimen well instrument reagent system detect broad range infectious disease healthcare associate infection cancer wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
228,BDX,asia pacific apac be home more half world population so demand healthcare be also exceptionally high region furthermore need cut edge medtech product service be significantly high world apac be exception fact research report mckinsey show apac be expect outpace european union world second largest medtech market pretty soon unite state almost person region be expect enter age group indicate emerge demand healthcare need also apac account third global disease burden further research report statista show medtech market asia pacific region be estimate reach nearly trump focus datum point huge unmet healthcare need apac market investor find president trump recent day long asia trip stop japan south korea china vietnam philippine be positive sign furthermore recent tweet great country be respect again asia see fruit long successful trip many year come be indicative favorable republican stance apac especially respect business trade here take sneak peek major postulate trump recent asia visit bilateral trade agreementtrump promise augment bilateral trade agreement indo pacific nation instill confidence apac policy however trump specifically mentioned agreement be bound follow principle fair reciprocal trade also voiced free open indo pacific trade emphasize increase focus nation japan australia india prospect china pacific be big enough accommodate china unite state say china president xi jinp trump visit china undoubtedly pose serious competitive threat unite state not just healthcare space also electronic semiconductor retail other area jinp statement clearly hint possibility country coexist peacefully political tension also be indicative strategic merger company nation order enhance trade practice medtech company eye apacconsider trump grow focus apac region seem be poise yield accretive return long term fact stakeholder medical universe have be eyee emerge market last couple year company be bullish grow medical awareness economic prosperity age population increase wealth government focus healthcare infrastructure expansion medical insurance coverage apac space meanwhile health policy debacle unite state deteriorate economic condition europe conclude growth emerge market china india japan other bolster global foothold medtech company take look lead medtech player be tap also gain bountiful opportunity apac market baxter international bax free report baxter solid presence asia precisely india be worth mention company have research hub japan china just report third quarter baxter complete acquisition india base claris injectable global generic injectable pharmaceutical company almost december baxter have initiate agreement management acquisition bolster baxter foothold generic pharmaceutical space second quarter baxter sign agreement india base dorizoe lifescience expansion generic injectable pipeline further baxter strong presence peritoneal dialysis nutrition iv fluid anesthesia gase fortify footprint china zack rank buy stock have have impressive run bourse last year stock have return significantly higher broader industry gain corporation bsx free report important part boston scientific growth strategy be continue pursue development opportunity outside unite state just report third quarter business emerge market register organic growth rate remain company target reach sale business china be also remarkable year year company be currently look forward improve performance china banking recent approval synergy boston scientific be also optimistic core cardiology segment be gradually stabilize growth bric nation cardiology capacity china be expect double end india business be project grow more annually zack rank hold stock have yielded stellar return last year way ahead broader industry same time frame see complete list today zack rank stock here intuitive surgical inc isrg free report intuitive surgical grow interest emerge market specifically apac region bode well last couple year company procedure performance asia show continue strength solid growth china japan korea just report third quarter intuitive surgical system placement include japan india new mexico china zack rank hold company have return last year much higher broader industry same period becton dickinson company bdx free report becton dickinson company bd be focuse geographical expansion overseas market particular emerge nation note company be especially focuse broader emerge market india china be see rapid growth economic healthcare sector believe significant emerge market exposure boost company top line turn lead accelerate ep growth bd revenue grow just report fourth quarter fiscal emerge market revenue grow strong year year quarter constant currency drive strong performance greater asia china revenue see double digit growth lead player medtech space be zack rank hold stock have return last year much higher broader industry growth paradoxhowever trump americafirst pitch asia pacific economic cooperation summit apec be hold vietnam november have be serious threat multilateral trade have be clearly portray trump primary focus be be be betterment unite state zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
229,BDX,expect idexx laboratory inc idxx free report beat expectation report second quarter result aug open bell last quarter company beat zack consensus estimate cent deliver positive earning surprise be worth note idexx have outperformed zack consensus estimate precede quarters average let take look thing be shape prior announcement likely positive surprise proven model show idexx be likely beat earning have perfect combination key ingredient zack esp idexx have earning esp most accurate estimate be cent zack consensus estimate be lower cent favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank idexx currently carry zack rank buy note stock zack rank strong buy hold have significantly higher chance beating earning estimate conversely caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision combination idexx zack rank esp make reasonably confident earning beat drive better expect earning idexx achieve strong organic growth international region last report first quarter drive strong global gain companion animal group cag diagnostic recur revenue include double digit organic revenue gain consumable reference lab rapid assay revenue well continue expansion idexx premium instrument install base company expect bullish trend continue upcoming quarters well overall idexx raise revenue outlook range reflect organic revenue growth expectation zack consensus estimate revenue be peg guide range idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc quoteon bottom line front company raise ep guidance share earlier range support continue operate margin expansion align long term goal update outlook represent ep growth report basis zack consensus estimate ep be peg be guide range be upbeat company innovation base global strategy be lead cag diagnostic growth june idexx announce addition rvetlink portfolio technology application notably rvetlink be advanced inclusive referral management solution design specialty care hospital simplify referral procedure primary care specialty care veterinarian apart idexx continue display solid growth respect international expansion company have be significantly benefitting companion animal market emerge nation demonstrate bountiful opportunity further management consistent share buyback reflect strong free cash flow reserve believe outcome endeavor be reflect second quarter performance flip side foreign currency fluctuation be major headwind company concern be company high reliance third party distributor purchasing dynamic distributor have significant impact company sale instrument consumable rapid assay product also company be expose higher operate expense pertain increase head count higher investment target growth acceleration geographical expansion internationally portfolio expansion also competitive landscape domestic overseas market weigh idexx performance struggle gain market share also prove be drag second quarter result other stock considerhere be other company consider model show also have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank thermo fisher scientific inc tmo free report have earning esp zack rank see complete list today zack rank stock here stryker corporation syk free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
230,BDX,pharmacy benefit manager express script hold company esrx free report be schedule report second quarter result jul market close st loui mo base company be largest pharmacy benefit manager pbm north america meanwhile company earning exceed zack consensus estimate almost last report quarter stock have deliver positive earning surprise past quarters average express script stock have underperform zack classify medical service industry last month specifically stock lose period compare industry gain moreover current rate be way lower same time frame indicate loom concern ahead express script hold company price ep surprise express script hold company price ep surprise express script hold company quotelet take look thing be shape prior second quarter earning announcement factor playsecond quarter outlook second quarter express script expect total adjust claim range adjust earning diluted share second quarter be estimate band represent growth year year basis furthermore company anticipate compound annual ebitda growth band core pbm business favorable macroeconomic scenario expect express script continue benefit increase generic utilization shift mail order strong specialty growth age population brand drug be become increasingly expensive due double digit brand inflation thus continue rise price specialty drug increase regulatory burden have be drive demand generic key catalyst company cutthroat competition niche space flipside express script face intense competition pbm industry company face competition independent pbms medimpact navitus health solution moreover niche space be dominate player cvs aetna cigna other expect intensify competition mar second quarter revenue estimate revision trend express script estimate revision trend lack luster moment current quarter analyst moved south compare upward revision last month fact last month current quarter estimate decline almost share probable loss biggest customer be too early gauge loss express script be verge lose biggest customer lead health insurer anthem inc antm follow series legal conundrum anthem be longer expect extend pharmacy benefit management agreement withexpress script be slate expiration end management express script lose almost revenue related anthem contract second quarter earning whispersbuoy factor proven model do not conclusively show express script be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate be not case here see zack esp earning esp express script be most accurate estimate be peg zack consensus estimate stand uncover best stock buy sell re report earning esp filter zack rank express script currently carry zack rank favorable zack rank increase predictive power esp company negative esp make surprise prediction difficult meanwhile caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock warrant lookhere be few company want consider proven model show have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank top pick ride hottest tech trend zack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
231,BDX,baxter international inc bax free report be schedule report second quarter earning jul open bell last report quarter company record positive earning surprise reach quarter average let see thing be shape prior release factor playwe be encourage company guidance second quarter full year second quarter baxter estimate sale growth constant currency adjust earning share be forecast range cent cent versus year figure cent also full year company project earning band share continue operation special item full year earning late baxter have accelerate pace acquisition strategic collaboration enhance product portfolio thereby open significant long term opportunity also several recent fda approval be likely boost growth yet be report second quarter baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc company estimate revision trend be also encourage current year baxter see upward estimate revision movement opposite direction last month however lower sale threat company integrate pharmacy solution franchise second quarter decline sale be expect impact top line low single digit also foray group purchasing organization gpos intensify competition company earning whispersour quantitative model doesn point earning beat quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp baxter international be be most accurate estimate zack consensus estimate stand cent uncover best stock buy sell re report earning esp filter zack rank baxter international carry zack rank increase predictive power esp however company esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here thermo fisher scientific inc tmo free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank top pick ride hottest tech trendzack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
232,BDX,varian medical system inc var free report be schedule report third quarter fiscal earning jul market close last quarter company report earning cent share beat zack consensus estimate penny however adjust earning decline year year basis factor playwe be particularly upbeat varian oncology business account company total revenue second quarter notably company have be address tier mid tier market edge truebeam vitalbeam product have also be winning international contract oncology space third quarter fiscal varian expect adjust earning share range cent cent revenue be expect increase year year basis further strengthen foothold oncology business company launch fda approve product halcyon also june company sign agreement vijametech upmc establish radiation oncology center vietnam be also upbeat varian prospect internationally primarily bank proton therapy advanced treatment option cancer patient regard note varian medical recently receive shonin approval japan market probeam system proton therapy varian medical system inc price ep surprise varian medical system inc price ep surprise varian medical system inc apart varian medical recently enter international agreement concern proton therapy platform bangkok base king chulalongkorn memorial hospital have select probeam compact single room proton therapy system cancer treatment thailand delray medical center florida believe western europe china africa present significant top line growth opportunity term company be open new office africa middle east show be aware opportunity region moreover varian strong product pipeline be key catalyst nevertheless increase local competition be primary headwind unfavorable foreign currency affect company revenue be report quarter also company be expose seasonal demand fluctuation higher operate expense pertain increase investment target growth acceleration geographical expansion portfolio expansion earning whispersour proven model do not conclusively show earning beat varian medical quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp varian medical currently have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank varian medical carry zack rank increase predictive power esp however company esp make surprise prediction difficult please note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here thermo fisher scientific inc tmo free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank top pick ride hottest tech trendzack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
233,BDX,expect align technology inc algn free report beat expectation report second quarter earning jul market close last quarter company have post positive earning surprise be worth note align technology have outperformed zack consensus estimate precede quarters average positive earning surprise let take look thing be shape prior announcement likely positive surprise proven model show align technology be likely beat earning have perfect combination key ingredient zack esp align technology have earning esp most accurate estimate be cent zack consensus estimate be peg lower cent favorable zack esp serve meaningful lead indicator likely positive earning surprise uncover best stock buy sell re report earning esp filter zack rank align technology currently carry zack rank buy note stock zack rank strong buy hold have significantly higher chance beating earning estimate conversely caution stock zack rank sell rate stock go earning announcement especially company be see negative estimate revision combination align technology zack rank esp make reasonably confident earning beat drive better expect earning be upbeat align technology execution strategic initiative international expansion thereby ensure invisalign treatment grow base patient context company strengthen foothold internationally acquire invisalign distributor highly lucrative europe middle east africa emea region well brazil feb be likely drive company result be report quarter company announce receipt patent align smarttrack aligner material be exclusively used invisalign aligner treatment moreover bid gain traction invisalign platform align collaborate digital design march post collaboration align invisalign clear aligner treatment be used dentist tooth alignment procedure design protocol align technology inc price ep surprise align technology inc price ep surprise align technology inc quotenotably expand invisalign brand offering align technology introduce patient friendly solution invisalign mandibular advancement teen march accord company advancement help offer more option treatment boost top line yet be report quarter recently company expand work flow option lead itero scanner context align collaborate exocad gmbh march integrate portfolio result high tech solution efficient scanning design manufacturing house dental prosthesis february company have announce addition digital nobel biocare implant itero intraoral scanner portfolio moreover company see increase adoption itero scanner invisalign case submission instead pvs impression especially north america thereby drive invisalign utilization management expect bullish trend likely continue yet be report quarter notably second quarter company project earning share cent revenue company also expect invisalign case shipment band year flip side unfavorable foreign currency affect company revenue be report quarter also company be expose seasonal demand fluctuation higher operate expense pertain increase head count higher investment target growth acceleration geographical expansion portfolio stock considerhere be other company consider model show also have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here thermo fisher scientific inc tmo free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank top pick ride hottest tech trendzack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
234,BDX,murray hill nj base cr bard inc be schedule report second quarter earning market close jul last quarter company report adjust earning exceed zack consensus estimate cent also company earning top zack consensus estimate last quarters average beat delve deeper fundamental stock let see thing be shape prior release factor playwe believe grow adoption company flagship lutonix drug coat balloon dcb continue be key growth catalyst be report quarter regard lutonix dcb be used treat patient suffering peripheral arterial disease pad endovascular business peripheral pta line sale be solely drive accelerate demand lutonix dcb expect see product significantly contribute company top line quarter furthermore company investment emerge market have strengthen position internationally be also upbeat solid contribution company vascular product line urology oncology segment be likely drive second quarter sale flip side challenge med tech environment especially hernia fixation peripheral stent business raise concern company continue witness significant pricing pressure well also unfavorable foreign currency continue hurt top bottom line growth furthermore uncertainty associate possibility repeal affordable care act president trump add company concern earning whispersour quantitative model doesn point earning beat quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp cr bard be be most accurate estimate zack consensus estimate stand uncover best stock buy sell re report earning esp filter zack rank cr bard carry zack rank increase predictive power esp however company esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision bard inc price ep surprise bard inc price ep surprise bard inc quotestock consider here be few company want consider proven model show have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp carry zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp hold zack rank stryker corporation syk free report have earning esp carry zack rank top pick ride hottest tech trend zack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
235,BDX,gnc holding inc gnc free report specialty retailer health nutrition related product be schedule report second quarter result jul open bell last quarter company post positive earning surprise however gnc holding trail quarter earning average lag zack consensus estimate let see thing be shape prior announcement factor playgnc holding last report first quarter adjust earning share ep reflect massive year year deterioration revenue quarter drop year year dismal performance be primarily due lower sale canada international manufacturing wholesale segment also first quarter gross margin adjust operate margin deteriorate hence expect similar trend second quarter well gnc holding inc price ep surprise gnc holding inc price ep surprise gnc holding inc quotemoreover gnc holding have number tough competitor market include large international pharmacy chain major international supermarket firm large base company global operation thus expect company slash product price face stiff competition turn hurt margin also currency headwind continue be grow concern gnc holding management also expect failure comply ftc regulation change consumer preference hamper business however bright side performance new gnc be quite encourage first quarter banking expect company continue gain yet be report quarter meanwhile launch pro access program have add member company customer base be expect drive growth earning whispersour proven model do not conclusively show earning beat gnc holding quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp gnc holding have earning esp be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank gnc holding have zack rank sell please note caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision stock considerhere be few company want consider proven model show have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
236,BDX,edward lifescience corporation ew free report be schedule report second quarter earning jul market close last quarter company have post positive earning surprise be worth note edward lifescience have outperformed zack consensus estimate precede quarters average positive earning surprise let take look thing be shape prior announcement factor playedward lifescience post strong global sale last report quarter primarily buoy strength transcatheter heart valve tavr banking continue therapy adoption geography notable strength company be expect maintain bullish trend second quarter well tavr space edward lifescience report highly encourage european post approval clinical trial result sapien transcatheter heart valve company also demonstrated successful result pertain centera valve transcatheter aortic valve replacement procedure much await europcr hold edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quotewe be also upbeat company initiative strategic investment research development receipt regulatory approval product move latest breakthrough achieve tavr segment be fda approval sapien valve early jun bullish company ongoing performance management raise growth expectation high end project full year guidance segment moreover note company project total sale adjust earning share cent cent second quarter apart management complete acquisition israel base valtech cardio developer cardioband system transcatheter repair mitral tricuspid valf end be expect boost top line quarter be report flip side tough competition cardiac device market reimbursement issue continue challenge company also believe unfavorable foreign currency affect company gross margin be report quarter earning whispersour proven model do not conclusively show earning beat edward lifescience quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp edward lifescience have earning esp be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank edward lifescience have zack rank increase predictive power esp however esp make surprise prediction difficult meanwhile caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be few company want consider proven model show have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
237,BDX,quest diagnostic inc dgx free report be schedule report second quarter earning result open bell jul last quarter company beat zack consensus estimate cent deliver positive earning surprise be worth note quest diagnostic outperformed zack consensus estimate precede quarters average let take look thing be shape prior announcement factor playpose threat quest diagnostic revenue requisition performance last report first quarter see basis point bps decrease same moreover remain apprehensive company professional lab service pls engagement wj barnabas health healthone system hca holding inc hca carry lower revenue requisition due nature work apart unit price headwind have less bps first quarter unit price headwind stay moderate range approximately last few year company continue expect same too quest diagnostic incorporate price ep surprise quest diagnostic incorporate price ep surprise quest diagnostic incorporate quotealso last year quest diagnostic face several reimbursement issue affected revenue company be concern cms center medicare medicaid service proposal related protect access medicare act pama however reimbursement pressure have likely act overhang performance be report quarter company expect beat pressure test business mix positive note observed report first quarter fiscal quest diagnostic seem be determine stimulate performance adhere point growth strategy accelerate growth drive operational excellence be also optimistic successful execution company strategy grow esoteric testing business drive profitable growth also recent past quest diagnostic witness significant growth infectious disease testing prescription drug monitoring industry lead wellness business expect growth driver remain active second quarter well drive same metric precede quarter believe recent development significantly contribute company top line second quarter company currently expect full year revenue range annualize growth current zack consensus estimate revenue be peg close low end company guide range addition company adjust earning share have be forecast zack consensus estimate be range earning whispersour proven model do not conclusively show quest diagnostic be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp quest diagnostic have earning esp be most accurate estimate zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank quest diagnostic have zack rank increase predictive power esp however esp make surprise prediction difficult meanwhile caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be few company want consider proven model show have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank trade profit big league trump policiesif stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
238,BDX,pacific bioscience california inc pacb free report report loss cent share third quarter penny narrower zack consensus estimate loss be line year quarter strength china asia boost company bottom line quarter company have zack rank hold revenue miss zack consensus estimate decline year year basis notably dna sequence market be highly competitive owing presence several establish player cutthroat competition niche space be primary reason year year decline revenue segment detailsproduct revenue rise almost service revenue decline year quarter almost year date pacific bioscience generate product service revenue generate first quarters consumable revenue report quarter be year year basis consumable revenue growth be drive higher install base instrument growth sequel instrument utilization instrument revenue third quarter be year year basis end quarter review pacific bioscience install base sequel instrument totale instrument company didn record contractual revenue quarter pacific bioscience california inc price consensus pacific bioscience california inc price consensus pacific bioscience california inc quotemargin detailsin third quarter pacific bioscience generate gross profit percentage revenue gross margin quarter be substantially year operate expense third quarter totale compare year year basis year date operate expense be expense quarter totale year sale general administrative expense third quarter be compare third quarter financial updatecash investment end third quarter be compare end second quarter expect full year revenue improvement gross margin performance fourth quarter pacific bioscience expect gross margin range net revenue viewpointsolid contribution instrument consumable revenue platform act significant positive pacific bioscience third quarter improvement margin sale sequel system be encourage factor company also witness significant strength china notably place numerous system order region new exist customer major concern dna sequence market be highly competitive owing presence several establish player cutthroat competition niche space be headwind however problem related limit availability smrt cell single molecule real time sequel system higher cash operate expense be expect mar prospect company report solid earning surgical inc isrg free report post adjust earning share third quarter beating zack consensus estimate stellar revenue growth stock have zack rank buy petm express inc pet free report adjust earning share cent second quarter fiscal be year quarter also earning surpass zack consensus estimate stock have zack rank strong buy see complete list today zack rank stock here becton dickinson company bdx free report popularly know bd report fourth quarter fiscal earning share beat zack consensus estimate increase year year basis stock have zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
239,BDX,base new jersey becton dickinson company bdx free report be medical technology company engage principally development manufacture sale medical device instrument system reagent product be used healthcare institution life science researcher clinical laboratory pharmaceutical industry general public currently becton dickinson have zack rank buy change follow third quarter fiscal earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning becton dickinson adjust earning share beat zack consensus estimate cent increase post year quarter comparable currency neutral basis earning soar year year revenue report revenue amount year year basis owing divestiture respiratory solution business however revenue be year quarter comparable currency neutral basis revenue miss zack consensus estimate becton dickinson company price ep surprise becton dickinson company price ep surprise becton dickinson company quotekey stat company expect fiscal revenue fall range owing divestiture respiratory solution business fiscal year adjust earning share be expect be represent growth band approximately major factor bd medical generate revenue year year basis impressive result company medical segment reflect strong performance medication procedural solution diabetes care pharmaceutical system unit bd life science generate revenue year quarter revenue growth bd life science segment reflect strong performance bioscience unit solid growth diagnostic system preanalytical system unit check back later full becton dickinson company earning report more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
240,BDX,becton dickinson company bdx free report be set report second quarter fiscal result aug becton dickinson have impressive track comfortably beating estimate trail quarters last report quarter deliver positive earning surprise bring quarter average let take look thing be shape prior second quarter earning announcement factor playbecton dickinson innovative product pipeline be key catalyst view plethora regulatory approval international market be help company rapidly expand product portfolio management becton dickinson expect strong demand pyxis es platform infusion pump be growth driver fiscal second quarter overall fiscal revenue be anticipate increase approximately additionally partnership collaboration be provide company competitive edge however unfavorable foreign exchange rate be anticipate remain headwind rest year furthermore uncertainty associate possibility repeal affordable care act president trump add company concern company estimate revision trend lack luster current quarter analyst moved south compare upward revision last month last month current quarter estimate decline share add concern overall fiscal adjust earning currency neutral basis be expect range reflect year year growth however include estimate unfavorable impact foreign currency company expect adjust diluted earning share represent increase approximately becton dickinson company price ep surprise becton dickinson company price ep surprise becton dickinson company quoteearning whisper proven model do not conclusively show becton dickinson be likely beat earning quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp becton dickinson currently have earning esp be most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank becton dickinson have zack rank increase predictive power esp however negative esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock warrant lookhere be few company want consider proven model show have right combination element post earning beat quarter genomic health inc ghdx free report have earning esp zack rank see complete list today zack rank stock here halyard health inc have earning esp zack rank pfizer inc pfe free report have earning esp zack rank make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
241,BDX,corp abc free report be set report third quarter fiscal result aug open bell track record have be quite impressive company comfortably beating estimate trail quarters last report quarter deliver positive earning surprise bring quarter average let see thing be shape prior release factor pharmaceutical distribution segment continue face headwind form contract renewal lower generic inflation drug corporation abdc business be also be hurt several factor include accelerate deflation generic drug lower contribution generic launch generic inflation have be nominal rate deflation be rise gradually factor combine anticipate shift product mix lower margin higher price specialty brand drug lack generic inflation adversely impact bottom line however company renew relationship largest health system customer have be make persistent effort address headwind abdc segment boost top line extent fiscal third quarter company estimate revision trend be mixed current quarter see upward downward estimate movement last month current quarter estimate earning share be peg also company be apprehensive earning revenue growth expectation fiscal due uncertainty surround drug pricing trend company currently expect revenue growth range company expect adjust diluted earning share range meanwhile expect brand drug inflation range corporation hold co price ep surprise corporation hold co price ep surprise corporation hold co quoteearning whispersour quantitative model doesn point earning beat quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp be be most accurate estimate be zack consensus estimate be peg uncover best stock buy sell re report earning esp filter zack rank carry zack rank sell caution stock zack rank strong sell go earning announcement especially company be see negative estimate revision stock considerhere be company want consider proven model show have right combination element post earning beat quarter becton dickinson company bdx free report have earning esp carry zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp carry zack rank thermo fisher scientific inc tmo free report have earning esp hold zack rank more stock news company verge apple run do miss apple stock explosion launch iphone now look be pivotal year get emerge technology expect rock market demand soar almost nothing report suggest save life decade turn save healthcare cost bonus zack special report name breakthrough best stock exploit apple company be already strong coil potential mega gain click see right now
242,BDX,becton dickinson company bdx free report be big mover last session company see share rise nearly day move come solid volume too far more share change hand normal session stock remain volatile trade range past month time frame witness sharp increase yesterday move come company post better expect third quarter result becton dickinson have see positive estimate revision versus negative estimate revision past month zack consensus estimate current quarter have also revise upward past day suggest more solid trading be ahead company so make sure keep eye stock go forward see recent jump turn more strength road becton dickinson currently have zack rank buy earning esp be positive becton dickinson company price consensus becton dickinson company price consensus becton dickinson company quotea better rank stock medical dental supply industry be align technology inc algn free report carry zack rank strong buy see complete list today zack rank stock here be bdx go predict see other think downlooking stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
243,BDX,becton dickinson company bdx free report popularly know bd report fourth quarter fiscal earning share beat zack consensus estimate increase year year basis company register revenue year period revenue however beat zack consensus estimate quarterly bd medical segment generate revenue decline prior year period segment result reflect adverse impact change dispense business model bd life science segment generate revenue year quarter segment performance reflect strong number bioscience diagnostic system preanalytical system unit revenue be roughly report basis comparable basis international revenue rise however comparable currency neutral basis revenue rise back solid growth company business becton dickinson company price consensus ep surprise becton dickinson company price consensus ep surprise becton dickinson company company expect fiscal revenue increase company expect adjust earning share stand alone basis represent growth approximately zack rank key picksbecton dickinson currently carry zack rank buy few other top rank stock broader medical sector be petm express inc pet free report luminex corporation lmnx free report intuitive surgical inc isrg free report notably petm luminex sport zack rank strong buy intuitive surgical carry zack rank buy see complete list today zack rank stock here petm report earning share cent second quarter fiscal year quarter cent also gross margin expand bps year year report quarter luminex report third quarter adjust earning share cent year year company revenue quarter increase almost year year intuitive surgical post adjust earning share year year third quarter also revenue increase year year zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
244,BDX,base new jersey becton dickinson company bdx free report be medical technology company engage principally development manufacture sale medical device instrument system reagent product be used healthcare institution life science researcher clinical laboratory pharmaceutical industry general public currently becton dickinson have zack rank buy change follow fourth quarter fiscal earning report have just release see complete list today zack strong buy rank stock here have highlighted key detail just release announcement earning becton dickinson adjust earning share beat zack consensus estimate cent increase post year quarter revenue report revenue amount year period revenue however come zack consensus estimate key stat company expect fiscal revenue increase company expect adjust diluted earning share be stand alone basis represent growth approximately becton dickinson company price ep surprise becton dickinson company price ep surprise becton dickinson company quotemajor factor bd medical generate revenue year year basis bd life science generate revenue year quarter check back later full becton dickinson company earning report zack best private investment idea be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
245,BDX,earning season have take center stage member account index total market capitalization have report number latest earning preview total earning company be same period last year higher revenue beating earning surpass revenue estimate member line release quarterly result week be decidedly bullish equity market be gradually demonstrate improvement sequentially needless say ongoing week be crucial season end have result more bigwig medical broader sector zack sector be expect put impressive show quarter third quarter expect earning growth rate sector be revenue growth comparison report earning growth rate second quarter be quite impressive revenue growth let take look major factor be likely influence earning result medtech company broader medical universe factor influence medtech hurricane wreak havoc various report suggest hurricane end third quarter be likely mar revenue earning several medtech company primarily florida texas puerto rico medtech major ecolab ecl free report expect impact hurricane full year sale cost be approximately cent share fact medtronic mdt free report acknowledge impact hurricane marium quarterly metric company expect almost impact revenue earning apart natural factor rise unemployment short live decline consumer income couple increase aggregate spending be likely deal heavy blow medtech number political conundrumwhile overall investment world have be gain prominence investor medtech industry be unfortunately see reverse trend stock tumble thing get riskier graham cassidy bill retract obamacare fail gain support again president trump latest executive order have already become serious threat healthcare community large regard let not forget tax reform pledge trump have take abolish infamous medical device sale tax investor confidence trend upwards hope enactment new tax reform believe market have not get whiff due lack favorable development regulatory front favorable consumer behavior political issue healthcare space change consumer demand market dynamic lead dramatic transformation entire healthcare system last couple year be evident grow prevalence minimally invasive surgery rise demand liquid biopsy test use ensure quick improve patient care shift payment system value base model let take look major medical product stock slate release quarterly report nov becton dickinson company bdx free report becton dickinson be schedule report fourth quarter fiscal result open bell fiscal revenue be anticipate increase look quarterly estimate zack consensus estimate bd medical segment be fourth quarter signify sequential growth meanwhile zack consensus estimate medical surgical system be peg last quarter report number company innovative product pipeline be key catalyst view plethora regulatory approval unite state international market be help company rapidly expand product portfolio read more be becton dickinson poise beat earning buoy solid prospect quantitative model show beat company give combination zack rank buy earning esp becton dickinson company price consensus becton dickinson company price consensus becton dickinson company corporation abc free report be schedule report fourth quarter fiscal result market open quarterly result be expect show steady growth pharmaceutical distribution segment significant contributor company revenue zack consensus estimate segment stand reflect improvement almost year quarter flipside generic inflation have be nominal rate deflation be rise gradually furthermore anticipate shift product mix lower margin higher price specialty brand drug affect company bottom line read more earning disappoint meanwhile zack consensus estimate earning stand share year year consensus estimate net revenue be peg signify growth year year basis proven model do not predict earning beat company season thank earning esp zack rank hold see complete list today zack rank strong buy stock here corporation hold co price consensus corporation hold co price consensus corporation hold co quoteteleflex incorporate tfx free report teleflex be expect announce third quarter result market open believe company medical surgical instrument device segment drive top line season zack consensus estimate segment revenue stand year report number company strong focus high flow nasal cannula therapy hfnct be likely lend competitive edge niche space solid growth preload microbial thrombogenic vps piccs platform be likely strengthen vascular platform surgical segment new product efx ae product fortify company foothold finally company flagship lma unique product strengthen anasthesia product line quantitative model predict earning beat teleflex third quarter stock currently have zack rank earning esp notably zack consensus estimate revenue be third quarter year year basis consensus estimate earning be peg signify growth year year teleflex incorporate price consensus teleflex incorporate price consensus teleflex incorporate quote more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
246,BDX,align technology inc algn free report report adjust earning share ep cent second quarter substantial year year earning be also higher company guide range cent figure handily beat zack consensus estimate cent revenuesrevenue grow year year quarter surpass zack consensus estimate management strong top line be drive robust invisalign case shipment year year doctor ship second quarter upside be backed growth north america international region year year increase teenage case board thereby reach new benchmark patient adopt invisalign treatment align technology inc price consensus ep surprise align technology inc price consensus ep surprise align technology inc quotesegment detailrevenue clear aligner segment total revenue increase year year report quarter primarily drive continue strong invisalign case volume growth customer channel geography second quarter invisalign case shipment amount year year aid growth region quarter align technology add invisalign doctor worldwide be north america be international region revenue scanner service improve substantially marginsgross margin second quarter be basis point bps year year rise cost net revenue quarter align technology witness year year increase selling general administrative expense hike research development expense operate margin however contract bps due higher operate expense financial detailsalign technology exit second quarter cash cash equivalent short term marketable security marked rise precede quarter report quarter align technology paid accelerate stock repurchase plan asr company receive initial delivery roughly share common stock management have available repurchase repurchase plan be announce last april third quarter company project ep cent revenue company also expect invisalign case shipment band same period year takealign technology end second quarter solid note earning revenue beating zack consensus estimate be upbeat continue strong invisalign volume turn drive top line additionally company announce receipt patent align smarttrack aligner material be exclusively used invisalign aligner treatment go forward management anticipate consistent growth asia pacific region bid grow region company also open new invisalign treatment plan facility china be also upbeat multus dollar marketing campaign initiate company invisalign brand order gain increase awareness be also optimistic company expand work flow option lead itero scanner context align technology recently launch software upgrade itero element intraoral scanner be capable compare patient scan time new timelapse technology additionally company have strong cash balance enable carry share repurchase program turn provide solid return investor flip side unfavorable foreign currency affect company revenue be report quarter also company be expose seasonal demand fluctuation higher operate expense pertain increase head count higher investment target growth acceleration geographical expansion portfolio expansion zack rank other key pickscurrently align technology sport zack rank buy other top rank medical stock be mesa laboratory inc mlab free report insys therapeutic inc insy free report becton dickinson company bdx free report notably insys therapeutic sport zack rank strong buy mesa laboratory becton dickinson company carry zack rank buy see complete list today zack rank stock here insys therapeutic have long term expect earning growth rate stock have gain last month mesa laboratory have positive earning surprise last quarters stock have add roughly last month becton dickinson company have positive earning surprise last quarters stock have gain last month hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
247,BDX,zimmer biomet holding inc zbh free report report second quarter adjust earning share ep year year adjust earning be also ahead zack consensus estimate cent reportedly net earning come cent share mark massive increase year loss cent share revenue detailszimmer biomet second quarter net revenue come mark rise constant exchange rate cer year year recently include ldr hold contribute basis point bps top line exclude contribution ldr hold quarter revenue decline year year revenue however remain line zack consensus estimate revenue generate americas quarter touch year year cer same emea europe middle east africa gross asia pacific figure be zimmer biomet holding inc price consensus ep surprise zimmer biomet holding inc price consensus ep surprise zimmer biomet holding inc derive knee be year year cer hip record sale prior year quarter revenue surgical sport medicine foot ankle extremity trauma be year year other segment spine cmf record improvement dental be quarter other revenue drop marginswith reduction cost product sell zimmer biomet gross margin expand bps second quarter selling general administrative expense be research development expense increase however adjust operate margin expand bps surge operate profit quarter cash positionzimmer biomet exit second quarter cash cash equivalent first quarter end total long term debt be compare end first quarter year date operate cash flow be compare year period company also paid dividend second quarter outlook base dull topline show zimmer biomet have lower full year guidance company currently expect register revenue growth cer range earlier prediction be include contribution approximately bps ldr transaction current zack consensus estimate revenue be peg adjust ep expectation have be forecast range lower earlier range year current zack consensus estimate ep be peg much ahead current guidance takezimmer biomet end quarter mixed note earning top zack consensus estimate revenue remain line same be disappoint company decline sale performance several core segment trimemd guidance also add concern indicate little chance recovery ahead nevertheless improve gross operate margin performance be encourage look forward expect synergy ldr hold acquisition broaden complement company musculoskeletal offer be also impressed strong strategic financial goal combine entity expect reach now deal have be close zack rank other key pickscurrently zimmer biomet carry zack rank hold better rank stock broader medical sector be petm express inc pet free report becton dickinson company bdx free report thermo fisher scientific inc tmo free report notably petm sport zack rank strong buy becton dickinson company thermo fisher scientific carry zack rank see complete list today zack rank stock here petm have long term expect earning growth rate stock have soar last month becton dickinson company have long term expect earning growth rate stock have rally last month thermo fisher scientific have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
248,BDX,boston scientific corporation bsx free report post adjust earning share ep consider certain time adjustment other amortization expense cent second quarter year quarter consider amortize expense adjustment quarter adjust ep come cent year adjust number figure remain penny ahead zack consensus estimate fall company adjust ep guidance range cent adjustment company report earning cent share comparison loss cent share year period boston scientific corporation price consensus ep surprise boston scientific corporation price consensus ep surprise boston scientific corporation quoterevenue detailrevenue second quarter be year year report basis operational basis constant exchange rate cer figure top company guidance also exceed zack consensus estimate organic revenue growth second quarter exclude impact change foreign currency exchange rate sale acquisition endochoice holding symetis sa be year year geographically second quarter company achieve operational growth organically europe asia middle east africa region emerge market segment analysisboston scientific currently have global reportable segment cardiovascular rhythm management medsurg company generate maximum revenue cardiovascular sale subsegment interventional cardiology peripheral intervention be year year cer respectively second quarter second largest contributor boston scientific top line be rhythm management include cardiac rhythm management crm crm reflect year year increase sale cer report quarter worldwide sale pacemaker crm increase defibrillator be sale go year year cer other segment endoscopy urology pelvic health neuromodulation medsurg broader group record sale cer respectively marginsgross margin expand basis point bps year year fall cost product sell adjust operate margin also expand bps report quarter quarter selling general administrative expense go research development expense increase royalty expense reduce quarter balance sheetboston scientific exit second quarter cash cash equivalent end sequential last quarter end second quarter company have total long term debt marginal increase end first quarter guidanceboston scientific have provide update full year guidance company raise revenue guidance range annualize growth report basis growth operational basis include contribution approximately bps endochoice symetis earlier band annualize growth report basis growth operational basis current zack consensus estimate revenue be guide range adjust ep guidance range have be slightly increase earlier range zack consensus estimate be guide range company also provide third quarter financial guidance adjust earning be expect band cent share revenue zack consensus estimate ep stand cent revenue be takeeven challenge economic condition competitive environment severe currency headwind boston scientific post better expect second quarter earning miss zack consensus estimate revenue ahead mark foreign exchange headwind continue challenge be concern company recent recall prime product lotus range heart device also unimpressive defibrillator performance company core crm segment continue remain drag overall growth nevertheless boston scientific be leave stone unturned strengthen core business invest new technology global market account higher sale geography second quarter be also encourage company gain number approval product domestic overseas market recent development worth mention be company recent acquisition switzerland base symetis sa bid fortify structural heart business europe apart company receive fda approval resonate family implantable cardioverter defibrillator icd cardiac therapy defibrillator crt system also receive ce mark vercise gevia deep brain stimulation dbs system first mr conditional directional dbs system treatment movement disorder symptom patient parkinson disease dystonia essential tremor zack rank other key pickscurrently boston scientific carry zack rank sell other better rank stock broader medical sector be petm express inc pet free report becton dickinson company bdx free report thermo fisher scientific inc tmo free report notably petm sport zack rank strong buy becton dickinson company thermo fisher scientific carry zack rank see complete list today zack rank stock here petm have long term expect earning growth rate stock have soar last month becton dickinson company have long term expect earning growth rate stock have rally last month thermo fisher scientific have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
249,BDX,becton dickinson company bdx free report be set report fourth quarter fiscal result nov becton dickinson have impressive track comfortably beating estimate trail quarters last report quarter deliver positive earning surprise take quarter average let take look thing be shape prior fourth quarter earning announcement likely positive surprise proven model indicate becton dickinson be likely beat earning estimate quarter be stock need have positive earning esp zack rank strong buy buy hold happen be case here zack esp earning esp represent difference most accurate estimate zack consensus estimate be uncover best stock buy sell re report earning esp filter zack rank becton dickinson have zack rank be favorable combination zack rank positive esp indicate likely positive surprise note caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision becton dickinson company price consensus becton dickinson company price consensus becton dickinson company quotefactor playbecton dickinson innovative product pipeline be key catalyst view plethora regulatory approval unite state international market be help company rapidly expand product portfolio management becton dickinson expect strong demand pyxis es platform infusion pump be growth driver fiscal fourth quarter overall fiscal revenue be anticipate increase approximately zack consensus estimate bd medical segment be fourth quarter signify sequential growth meanwhile zack consensus estimate medical surgical system be peg sequentially additionally partnership collaboration be provide company competitive edge however unfavorable foreign exchange rate be anticipate remain headwind rest year furthermore uncertainty associate possibility repeal affordable care act president trump add company concern company estimate revision trend be also encourage current quarter analyst moved north compare downward revision last month last month current quarter estimate improve share overall fiscal adjust earning currency neutral basis be expect range reflect year year growth stock considerhere be few medical stock worth consider have right combination element post earning beat quarter inc research holding inc have earning esp carry zack rank see complete list today zack rank stock here medpace holding inc medp free report have earning esp carry zack rank henry schein inc hsic free report have earning esp carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
250,BDX,earning season have kick start last week result participant total market cap have be report so far observed index have make pretty good open respect earning revenue growth latest earning preview oct total earning member go higher revenue member line release quarterly result week be decidedly bullish equity market scenario gradually demonstrate improvement sequentially last quarter look medtech space medical overall growth have be steadily accelerate precede few quarters performance investor be concern medical sector zack sector have see lot struggle past half year thank political power change ongoing policy restructure related battle lack visibility befuddle favorable trend sector be maintain past few quarters third quarter expect earning growth rate be standing revenue growth projection comparison report earning growth rate second quarter be quite impressive revenue growth needless say current crisis medtech industry integral part broader medical sector show sign abate medtech space be earlier hopeful change power white house however be currently fuss total failure republican obamacare repeal replacement consider prevailing uncertainty implementation health policy respite term seem unlikely political turmoil health policy related battle apart majority stock bottom line space be likely be hurt third quarter escalate cost induced consecutive hurricane mexico earthquake give gloomy backdrop investor interested medtech space keenly await earning report key medtech company namely edward lifescience corporation ew free report bard inc oct quantitative model stock solid zack rank strong buy buy hold be combine positive earning esp then chance beating estimate be always high uncover best stock buy sell re report earning esp filter sneak peek stockssimilar sequentially last quarter edward lifescience seem be gain strong transcatheter heart valve therapy thvt segment banking continue therapy adoption geographical region notable strength unite state company be expect maintain bullish trend third quarter well growth thvt be drive excellent clinical performance result sapien well continue strong therapy implementation region last quarter also receipt expand fda approval sapien valve early june top line thvt segment be expect get further boost yet be report quarter read edward lifescience gain thvt earning zack consensus estimate thvt net sale reflect increase year quarter zack consensus estimate transcatheter heart valf thv sale unite state show increase year quarter overall third quarter revenue be project also zack consensus estimate net sale unite state reflect increase year quarter notably company earning have outpaced zack consensus estimate average trail quarters edward lifescience have earning esp carry zack rank see complete list today zack rank stock here further stock have see zack consensus estimate third quarter earning cent share be revise penny downward last day however have show rally year report figure zack consensus estimate company revenue be peg yet be report quarter improvement year report number regard also anticipate company arch rival transcatheter heart valf space boston scientific corporation bsx free report fare well business third quarter boston scientific be slate report third quarter number oct market open edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quote look bard recent performance trend believe grow adoption company flagship lutonix drug coat balloon dcb continue be key growth catalyst soon be report quarter endovascular business peripheral pta line sale be solely drive accelerate demand lutonix dcb unite state expect product significantly contribute company top line quarter read cr bard spring surprise earning season notably company earning have outpaced zack consensus estimate average trail quarters bard have earning esp carry zack rank stock have see zack consensus estimate third quarter earning share be revise penny downward last day however have show improvement year report figure zack consensus estimate company revenue be peg yet be report quarter compare year report figure reflect gain regard note bard be slate be acquire becton dickinson company bdx free report fourth quarter acquisition be expect strengthen company footprint home healthcare market unite state bard inc price ep surprise bard inc price ep surprise bard inc quote comparative analysisanalyze revenue driver other fundamental factor edward lifescience bard respective zack consensus estimate conclude edward lifescience be expect perform better bard yet be report quarter make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
251,BDX,medtech space receive sudden jolt late night thursday white house pull plug obamacare subsidy reduce health care cost american low income come surprise lukewarm response replacement american health care act ahca have force republican continue seek new avenue bid save face trump administration attempt skinny repeal bill graham cassidy bill fail make headway senate believe impasse be slate continue president trump have always be outspoken critic aca apprehension come uncertainty regard outcome slew event include possibility rate hike fed stronger dollar stance healthcare insurance company aca be expect spark bout volatility now plenty speculation have be make regard extent interest rate hike fed end year federal reserve official remain largely divide raise interest rate majority banker vouch favor raise rate one debate increase rate state hike rate time inflation be lower target indication healthy economy cause major setback economy however investor also feel even fed decide increase rate hardly have impact long term nevertheless be foolish claim volatility have vanished market just global market have start recover yesterday doubt such market uncertainty have make investor increasingly cautious spending stock interestingly phase massive global sell off medtech sector have not only hold own also maintain stable uptrend be base powerful long term tailwind include merger acquisition emerge market expansion positive demographic trend innovation new product fact closer look sector history reveal company undaunting spirit expand business market scenario be political conundrum obamacare have witness big cross border merger recent time impending take bard inc becton dickinson company bdx free report reward strategy believe investor earn handsome profit extrapolate current bullish trend market future henceforth seek refuge momentum investment strategy be strategic investment gamble moment however pick right momentum stock baffle seasoned investor let alone new one be plan enter uncharted world jam packed trade here zack use style score system single stock aid beating market zack momentum style score indicate timing be best grab stock take advantage momentum highest probability success picksamid present volatility global economy have find handful top zack rank momentum stock medical device space be go gain share market turbulence style score better combine favorable zack rank strong buy buy stock be look especially impressive right now have cite stock be worth look invest steris plc ste free report company base ohio develop manufacture market infection prevention decontamination microbial reduction surgical support product service see complete list today zack rank stock here metric make lead scientific instrument provider more desirable be momentum score zack rank market cap corporation america holding lh free report labcorp be lead healthcare diagnostic company headquarter burlington nc provide comprehensive clinical laboratory service end end drug development support metric make company more attractive be momentum score zack rank market cap medical care corporation fms free report fresenius medical care fms free report base bad homburg germany be largest integrate provider product service individual undergo dialysis follow chronic kidney failure metric make company more desirable be momentum score zack rank market cap billionquidel corporation qdel free report quidel base san diego discover develop manufacture market point care rapid diagnostic test detection medical condition illness product provide accurate rapid cost effective diagnostic information acute chronic condition affect woman health phase life include reproductive status pregnancy management osteoporosis metric make quidel attractive choice be momentum score zack rank market cap inc cfms free report medical technology company base bedford develop manufacture sell joint replacement implant company ifit technology platform consist ifit design ifit printing ifit just time delivery company serve orthopedic surgeon hospital other medical facility patient metric make company more attractive be momentum score zack rank market cap millionbottom lineyou find stock good momentum score time year present market scenario make task little difficult aforementioned stock not be big certainly make impact medtech sector worldwide bullish market continue few more day stock have high chance perform well future stock watch massive equifax stock spiked recent news datum breach affect american stock be best buy candidate right now do future hold cybersecurity industry equifax be just most recent victim computer hacking identity theft be more common ever zack have just release cybersecurity investor guide inform zack com reader year space more importantly highlight cybersecurity pick strong profit potential get new investing guide now
252,BDX,becton dickinson company bdx free report commonly know bd recently announce agreement italy base euroclone development global distribution molecular assay molecular assay be exclusively formulate detect sexually transmit pathogen fact bd have be lead player provide solution woman health sexually transmit infection sti notably company latest development closely follow recent launch bd ultra fine micro pen needle mm use pen injection device needle offer comfortable injection experience enhance customer satisfaction device be slate distribution month come back news bd euroclone plan launch molecular assay outside unite state molecular assay leverage company flagship platform bd max system detect infectious genital mycoplasmas include mycoplasma ureaplasma species be generally unidentifiable conventional method however assay be currently not available sale unite state management addition assay exist bd max portfolio company other assay bd surepath bd onclarity hpv assay be likely fortify company foothold clinical laboratory testing sti impressive stock price bd inched close follow news release last year company have outperformed broader industry stock be broader industry gain just nonetheless current return be relatively lower addition same time frame also zack rank hold company focus expand overseas market particular emerge market follow new product launch acquisition drive strategy be significant growth catalyst takebd have diversify product portfolio reduce risk exposure specific product additionally diverse revenue base increase adoption company new exist product be expect drive top line growth meanwhile latest development be likely maintain company international footprint evidently bd witness increase revenue outside unite state comparable currency neutral basis last quarter accord report ally market research global sexually transmit disease testing market be anticipate reach cagr markedly consider huge potential market believe latest development be strategic fit stock consider few better rank stock broader medical sector include edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc edward lifescience sport zack rank strong buy idexx laboratory cogentix medical hold zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat last quarters company have long term expect earning growth rate idexx laboratory pull average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
253,BDX,becton dickinson company bdx free report commonly know bd recently launch bd ultra fine micro pen needle mm use pen injection device needle offer comfortable injection experience enhance customer satisfaction notably device be slate distribution month bd have widen needle length option diabetic person interestingly most insurance plan include medicare part cover bd ultra fine micro mm pen needle person diabetes require inject insulin subcutaneous fat abdomen thigh upper arm buttock bd latest needle diabetic person be less likely inject insulin dose muscle accidently accord company needle be rigorously test ensure performance maintain high quality standard medical technology company be consistently try improve performance diabetes care unit bd medical segment bd see diabetes care revenue growth last report third quarter expect bd see higher growth segment day ahead accord report bccresearch global diabetes market reach worth cagr also report market market global human insulin market be expect value grow cagr consider huge potential market believe latest development be strategic fit last year bd have outperformed broader industry term share price company have return compare favorably broader industry gain estimate revision estimate revision trend have be favorable company current year estimate moved north compare movement opposite direction last month result zack consensus estimate full year have increase share zack rank key picksbd carry zack rank hold few better rank medical stock be edward lifescience corporation ew free report amedisys inc am free report idexx laboratory inc idxx free report edward lifescience sport zack rank strong buy amedisys idexx carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month amedisys have long term expect earning growth rate stock have gain last month idexx have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
254,BDX,sep issue update research report franklin lake nj base becton dickinson company bdx free report company be medical technology firm engage principally development manufacture sale medical device instrument system reagent share becton dickinson have gain year date compare industry growth zack consensus estimate current year earning have remain stable last day stock carry zack rank hold market be upbeat company strategic acquisition collaboration becton dickinson sign agreement acquire bard inc march management company be poise become biggest medical technology device company world follow buyout cash stock acquisition be value completion deal fourth quarter fiscal company plan create third business segment bd interventional notably bard be integrate vertical come strategic advantage post closure deal becton dickinson generate high single digit growth adjust earning share fiscal transaction lead pre tax annual saving worth fiscal company be able expand new area bard currently operate include fast grow vascular access segment piccs peripherally insert central catheter midline drug delivery port regard note becton dickinson announce collaboration impress instrument management system cloud base solution provider uniteor surgical tray tracking vendor management solution system provide greater visibility surgical tray management health care worker operate room sterile process department integration uniteor allow becton dickinson offer truly integrate approach complex challenge hospital health system face regard surgical tracking also company complete buyout israeli base caesarea medical electronic global infusion pump system manufacturer apart acquisition merger other catalyst include company receipt clearance fda flow cytometer system leucocount reagent assay be used residual white blood cell enumeration becton dickinson also announce global distribution complete line product mass spectrometry provide high speed high confidence identification pathogen clinical laboratory be critical step fight antimicrobial resistance company mass spectrometry solution suite include mbt biotarget mbt sepsityper well standard reagent other product further becton dickinson focus geographical expansion overseas market india china brazil turkey be boost market sentiment key picksedward lifescience corporation ew free report lantheus holding inc lnth free report be better rank medical stock edward lifescience sport zack rank strong buy lantheus holding carry zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate stock have rally roughly last month lantheus holding have long term expect earning growth rate stock have gain last month more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
255,BDX,murray hill nj base bard inc announce majority shareholder have approve merger becton dickinson company bdx free report holder approximately bard share participate vote favore merger management expect complete merger fourth quarter dealon apr becton dickinson lead global medical technology company announce acquire bard agreement be expect close fourth quarter view acquisition strategic fit generate benefit complementary business geographical expansion believe development provide benefit medication management infection prevention bard customer bolster foothold global medical device market regard company have register more product internationally full year sum acquisition be expect strengthen combine entity footprint home healthcare market note research report market market reveal home healthcare market be expect reach total grow cagr however combine entity be likely face challenge regard integration new business cost associate apart increase competition delay order renewal process constricted federal spending be other concern key pickscurrently bard carry zack rank hold few better rank stock broader medical sector be edward lifescience corporation ew free report dextera surgical inc notably edward lifescience sport zack rank strong buy dextera have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock return last month dextera have project sale growth current year stock promise long term expect earning growth rate more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
256,BDX,becton dickinson company bdx free report popularly know bd report third quarter fiscal earning share beat zack consensus estimate increase year year basis interestingly bd post positive earning surprise past quarters average furthermore stock currently have zack rank buy signify probability outperformance term get back quarter bd register revenue year year basis primarily owing divestiture respiratory solution business however revenue be year quarter comparable currency neutral basis revenue miss zack consensus estimate segment detailsbd medical segment bd medical generate revenue year year basis however comparable currency neutral basis revenue increase year year impressive result company medical segment reflect strong performance medication procedural solution diabetes care pharmaceutical system unit bd life science segment bd life science generate revenue year quarter revenue growth bd life science segment reflect strong performance bioscience unit solid growth diagnostic system preanalytical system unit revenue report basis revenue decrease roughly increase comparable basis bd medical segment witness stellar performance medication procedural solution diabetes care unit however massive growth segment be partially negate sluggishness medication management solution pharmaceutical system unit bd solid performance preanalytical system bioscience unit buoy growth life science segment international revenue bd witness decline revenue outside however comparable currency neutral basis revenue rise back solid growth segment becton dickinson company price consensus ep surprise becton dickinson company price consensus ep surprise becton dickinson company fiscal comparable currency neutral basis revenue be anticipate increase approximately notably exclude respiratory solution other divestiture close fiscal revenue be likely decline range year year basis owing divestiture respiratory solution business fiscal adjust earning share be expect be previously issue range represent growth approximately key picksa few other top rank stock broader medical sector be edward lifescience corporation ew free report abiom inc abmd free report dextera surgical inc notably edward lifescience sport zack rank abiom dextera have zack rank buy see complete list today zack rank stock here edward lifescience have long term expect earning growth rate notably stock have return last month abiom yielded strong return last year stock have long term expect earning growth rate dextera have project sale growth current year stock promise long term expect earning growth rate more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
257,BDX,amedisys inc am free report report adjust earning continue operation cent share second quarter year year however earning miss zack consensus estimate cent exclude adjustment company report earning cent share reflect decline year quarter second quarter net service revenue gross year year top line however miss zack consensus estimate quarter company home health division net service revenue totale second quarter medicare revenue decline year year medicare revenue improve year year hospice division net service revenue gross year year include medicare revenue medicare revenue recently company integrate additional operate segment business personal care corporate personal care net service revenue totale reflect increase year number corporate other hand do not register revenue end second quarter amedisys inc price consensus ep surprise amedisys inc price consensus ep surprise amedisys inc company gross margin contract basis point bps second quarter gross profit rise expense salary benefit decline other expense also drop adjust operate income report quarter reflect increase year adjust operate income operate margin expand bps year figure amedisys exit second quarter cash cash equivalent compare end precede quarter company long term obligation exclude current portion be report quarter year quarter year date net cash provide operate activity be compare year period takeamedisys end second quarter dismal note earning revenue miss estimate home health division company witness decline medicare revenue be improvement medicare revenue hospice company register strong growth segment amedisys be currently explore opportunity home health hospice segment company favorable demographic trend strategic acquisition encourage well moreover company have be witness growth personal care segment synergy acquisition meanwhile expect synergy tenet healthcare acquisition boost operation escalate operate expense decline gross margin continue raise concern also intense competitive landscape regulatory concern continue challenge home health hospice industry zack rank other key pickscurrently amedisys carry zack rank buy other top rank stock worth consider broader medical sector include petm express inc pet free report becton dickinson company bdx free report quest diagnostic inc dgx free report notably petm sport zack rank strong buy becton dickinson company quest diagnostic carry zack rank see complete list today zack rank stock here petm have long term expect earning growth rate stock have gain last month becton dickinson company have long term expect earning growth rate stock have gain last month quest diagnostic have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
258,BDX,edward lifescience corporation ew free report report second quarter adjust earning share ep surpass zack consensus estimate cent wide margin adjust earning also improve stupendous year year primarily drive strong sale growth company transcatheter heart valf business exclude time item net income second quarter come cent share year year respectively sale detailsedward lifescience second quarter sale improve figure also beat zack consensus estimate underlie sale increase include impact germany stocking sale customer germany elect purchase additional inventory sapien valve anticipation potential supply interruption result recent intellectual property litigation revenue be primarily drive considerable growth transcatheter heart valve sale well strong performance other product line region edward lifescience corporation price consensus ep surprise edward lifescience corporation price consensus ep surprise edward lifescience corporation quotesegment second quarter company report transcatheter heart valve therapy thvt sale reflect growth prior year quarter thvt sale quarter be year year growth be drive excellent clinical performance result be deliver sapien well continue strong therapy implementation region surgical heart valve therapy sale quarter be prior year quarter be lead strong demand edward intuity elite valve system supply recovery mitral valve sale partially offset continue shift surgical aortic valf sapien valve critical care sale be report quarter represent increase second quarter solid growth product category be drive double digit growth company enhance surgical recovery program mainly asia pacific marginsin first quarter gross margin expand basis point bps owing more profitable product mix lead grow sale transcatheter valf be however partially offset adverse foreign exchange sg expense rise year year account sale personnel related expense primarily transcatheter valve thv segment other hand expenditure increase year year owing continue investment company transcatheter mitral valve mitral valve program include expenditure clinical trial adjust operate margin quarter expand bps rise revenue outweighed increase operate expense cash positionedward lifescience exit second quarter cash cash equivalent short term investment compare end first quarter long term debt quarter totale compare report previously cash flow operate activity be second quarter compare previous quarter exclude capital spending free cash flow be quarter management repurchase share offset dilution associate valtech cardio acquisition stock base incentive compensation update guidancebanking solid second quarter performance edward lifescience have raise full year sale expectation high end previously project range zack consensus estimate full year revenue be high end guide range adjust ep expectation have also be raise zack consensus estimate full year adjust ep stand company guide range third quarter company project sale exclude effect germany stocking sale zack consensus estimate revenue be project range company estimate adjust ep cent cent meanwhile zack consensus estimate adjust ep be cent be also company forecast range takeedward lifescience exit second quarter solid note earning revenue beating zack consensus estimate strong transcatheter valve sale be major positive company also perform well gross margin front raise optimism moreover edward lifescience raise revenue earning guidance hint better day ahead however tough competition cardiac device market reimbursement issue continue challenge company nevertheless management expect gain traction ever expand tavr market base increase preference favor transcatheter aortic valve replacement well compelling clinical evidence lead strong adoption thv therapy zack rank other key pickscurrently edward lifescience sport zack rank strong buy other top rank stock worth consider broader medical sector be petm express inc pet free report becton dickinson company bdx free report quest diagnostic inc dgx free report notably petm sport zack rank becton dickinson company quest diagnostic carry zack rank buy see complete list today zack rank stock here petm have long term expect earning growth rate stock have gain last month becton dickinson company have long term expect earning growth rate stock have gain last month quest diagnostic have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artificial intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
259,BDX,thermo fisher scientific inc tmo free report report better expect performance second quarter adjust ep come beating zack consensus estimate year quarter figure report basis second quarter ep marked year year rise revenue quarter come year year sale also exceed zack consensus estimate quarter detailorganic revenue second quarter grow year year back acquisition total revenue grow offset currency translation thermo fisher currently operate business segment life science solution analytical instrument specialty diagnostic laboratory product service revenue life science solution segment improve year year analytical instrument segment sale grow reflect acquisition fei company revenue laboratory product service segment grow specialty diagnostic segment record increase thermo fisher scientific inc price consensus ep surprise thermo fisher scientific inc price consensus ep surprise thermo fisher scientific inc quotegross margin second quarter be basis point bps year year rise gross profit adjust operate margin expand approximately bps rise selling general administrative expense increase research development expense company exit second quarter cash cash equivalent compare end previous quarter year date net cash provide operate activity be compare year period guidance raisedbacked solid second quarter performance less adverse foreign exchange environment forecast thermo fisher raise full year financial guidance revenue guidance have be raise range growth previous year earlier band current zack consensus estimate be close low end guide range company have also raise adjust ep guidance range reflect growth previous year earlier prediction be zack consensus estimate share be also low end band patheon acquisition dealin parallel announcement company inform enter definitive agreement acquire patheon thereby pave way contract development manufacturing organization cdmo market total transaction value be estimate be roughly include assumption approximately net debt apart strengthen offering management deal be also expect be immediately considerably accretive thermo fisher adjust ep first full year close bottom linethermo fisher end second quarter promising note adjust earning revenue beating zack consensus estimate be encourage company series product launch major progress precision medicine initiative thermo fisher acquisition fei company have already start boost analytical instrument portfolio company also open center excellence electron microscopy saudi arabia management be upbeat company gain entry cdmo market agreement acquire patheon raise guidance be more encourage indicate fact overall bullish trend continue zack rank other key pickscurrently thermo fisher carry zack rank buy other top rank stock worth consider broader medical sector be petm express inc pet free report becton dickinson company bdx free report quest diagnostic inc dgx free report notably petm sport zack rank strong buy becton dickinson company quest diagnostic carry zack rank see complete list today zack rank stock here petm have long term expect earning growth rate stock have gain last month becton dickinson company have long term expect earning growth rate stock have gain last month quest diagnostic have long term expect earning growth rate stock have gain last month hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
260,BDX,quest diagnostic inc dgx free report second quarter adjust earning share ep beat zack consensus estimate year number adjust ep report quarter exclude charge related restructure integration retirement debt well amortization expense report ep come line year figure report revenue second quarter inched year year however lag zack consensus estimate accord company year year improvement come back extend tie up hospital health system strength several company advanced diagnostic offering quest diagnostic incorporate price consensus ep surprise quest diagnostic incorporate price consensus ep surprise quest diagnostic incorporate quotevolume measure number requisition increase year year second quarter also revenue requisition increase diagnostic information service revenue quarter rise year year basis cost service report quarter be year year gross margin come reflect rise basis point bps year year operate expense selling general administrative expense increase report quarter adjust operate margin show improvement bps quest diagnostic exit second quarter cash cash equivalent marked fall precede quarter year date net cash provide operate activity be compare year period second quarter company repurchase share jun quest diagnostic be left authorization previous share repurchase plan outlookquest diagnostic raise full year revenue guidance company now expect full year revenue range annualize growth earlier state range annualize growth current zack consensus estimate revenue be peg par lower end company update guide range addition company adjust ep range have be raise earlier forecast zack consensus estimate be range operate cash flow be expect previous guidance current estimate capital expenditure be peg unchanged takequest diagnostic second quarter earning exceed zack consensus estimate revenue lag same positive note company be currently refocusing core diagnostic information service business work discipline capital deployment also raise guidance adjust earning revenue net cash operate activity buoy optimism company performance be also highly optimistic company focus new point strategy accord quest diagnostic plan divestiture focus diagnostic product business be part strategy refocu diagnostic information service addition several new collaboration hospital integrate delivery network be major growth driver regard be look forward company deal walmart particularly company be positive recent agreement peacehealth pacific northwest be expect bolster growth also management be upbeat latest acquisition med fusion clearpoint advance diagnostic space however past several quarters overall soft industry trend lead low volume environment act dampener company zack rank key pickscurrently quest diagnostic carry zack rank hold few better rank stock broader medical sector be petm express inc pet free report becton dickinson company bdx free report thermo fisher scientific inc tmo free report notably petm sport zack rank strong buy becton dickinson company thermo fisher scientific carry zack rank see complete list today zack rank stock here petm have long term expect earning growth rate stock have gain last month becton dickinson company have long term expect earning growth rate stock have gain last month thermo fisher scientific have long term expect earning growth rate stock have gain last month more stock news tech opportunity worth driverless car artifical intelligence ve see unsurpassed growth high tech product recent month yesterday science fiction be become today reality innovation be single component tech company survive demand critical device reach year alone likely grow even faster future zack have release brand new special report help take advantage exciting investment opportunity most importantly reveal stock massive profit potential see stock now
